Vitalibis, Inc. (Form: S-1, Received: 05/16/2019 17:29:34)

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM S-1

REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OF 1933

VITALIBIS, INC.

(Exact name of Registrant as specified in its charter)

Nevada

0001636509

30-0828224

(State or other jurisdiction of

incorporation or organization)

(Primary Standard Industrial

Classification Code Number)

(I.R.S. Employer

Identification Number)

3960 Howard Hughes Parkway, Suite 500

Las Vegas, NV 89169

702-944-9620

(Address, including zip code, and telephone number,

including area code, of Registrant’s principal executive offices)

Steven Raack

3960 Howard Hughes Parkway, Suite 500

Las Vegas, NV 89169

702-944-9620

(Name, address, including zip code, and telephone number,

including area code, of agent for service)

Copies to:

Michael J. Morrison, Esq.

Michael J. Morrison, Chtd.

1495 Ridgeview Dr., Ste. 220

Reno, NV 89519

(775) 827-6300

As soon as practicable after the effective date of this Registration Statement.

(Approximate date of commencement of proposed sale to the public)

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: [ ]

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act of 1933, please check the following box and list the Securities Act of 1933 registration statement number of the earlier effective registration statement for the same offering. [ ]

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act of 1933, check the following box and list the Securities Act of 1933 registration statement number of the earlier effective registration statement for the same offering. [ ]

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act of 1933, check the following box and list the Securities Act of 1933 registration statement number of the earlier effective registration statement for the same offering. [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non-accelerated filer	[ ]	Smaller reporting company	[X]
(Do not check if a smaller reporting company)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. [X]

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities to be Registered	Amount to be Registered	Proposed Maximum Offering Price Per Unit (1)(2)	Proposed Maximum Aggregate Offering Price		Amount of Registration Fee
Primary Offering:
Common stock, par value $0.001 per share (3)	5,000,000	$1.00	$5,000,000		$ 606.00(5)

Secondary Offering: (8)
Warrants (4)	3,500,000	1.00	$3,500,000		$424.20
Common Stock, par value $0.001 per share, underlying common stock purchase warrants	3,500,000	$1.00	$3,500,000		$424.20
Common stock, par value $0.001 per share (3)	4,161,371	$1.00	$4,161,371		$504.36
Common stock, par value $0.001 per share (7)	5,321,400	$1.00	$5,321,400		$644.95
Total secondary offering
Total (primary and secondary offerings)	21,482,771	$1.00	$21,482,771	(8)	$2,603.71	(9)

(1) To be determined.

(2) The registrant, or the selling stockholders, as applicable, will determine the proposed maximum offering price per share from time to time in connection with, and at the time of, the issuance of the securities registered hereby. Securities registered hereby may be offered for U.S. dollars or foreign currencies or currency units and may be sold separately or together in units with other securities registered hereby.

(3) Also includes such indeterminate principal amount, liquidation amount or number of securities as may be issued upon conversion or exchange of any securities that provide for conversion or exchange into other securities. Separate consideration may or may not be received by the registrant for securities that are issuable on exercise, conversion or exchange of other securities.

(4) The warrants registered hereby may be warrants to purchase common stock, preferred stock or debt securities.

(5) Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(o) under the Securities Act. The aggregate maximum offering price of all securities offered and sold by the registrant pursuant to this registration statement shall not have a maximum aggregate offering price that exceeds $5,000,000 in U.S. dollars or the equivalent at the time of offering in any other currency.

(6) Calculated in accordance with Rule 457(o) under the Securities Act.

(7) Up to 3,571,400 shares of common stock may from time to time be sold pursuant to this registration statement by the selling stockholders named herein. Includes shares of common stock issued to the selling stockholders and an additional 1,750,000 shares of common stock that may be earned by certain of the selling stockholders.

(8) Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities Act based on the average of the high and low prices per share of the registrant’s common stock on May 10 2019, as reported by the OTC Markets Group’s OTCQB.

(9) Calculated in accordance with Rule 457(c) under the Securities Act.

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act, or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

Subject to Completion, dated May 16, 2019

PROSPECTUS

Vitalibis, Inc.

5,000,000

SHARES OF COMMON STOCK

(Offered by the Company)

5,321,400

SHARES OF COMMON STOCK

(Offered by the Selling Stockholders)

3,500,000

COMMON STOCK PURCHASE WARRANTS

(Offered by the Selling Warrant Holder)

3,500,000

SHARES OF

Common Stock underlying common stock purchase warrants

The specific terms of any securities to be offered by us or the selling stockholders or the selling Warrant Holder, and the specific manner in which they may be offered, will be described in a supplement to this prospectus. You should read this prospectus and each applicable prospectus supplement carefully before you invest. This prospectus may not be used to sell securities unless accompanied by a prospectus supplement.

Our common stock is quoted by the OTC Markets Group’s OTCQB under the symbol “VCBD.” We have not yet determined whether any of the other securities that may be offered by this prospectus and a prospectus supplement will be listed on any exchange, inter-dealer quotation system or over-the-counter market. Our principal executive offices are located at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169, and our telephone number is 702-944-9620.

Investing in our securities involves risks. You should carefully read and consider the risk factors included in our periodic reports and other information that we file with the Securities and Exchange Commission and that are incorporated by reference into this prospectus or any prospectus supplement before you invest in our securities. See “Risk Factors” on page 4 of this prospectus and any risk factors contained in any applicable prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is , 2019.

ABOUT THIS PROSPECTUS

Unless otherwise indicated or the context otherwise requires, all references in this prospectus to “we,” “us,” the “Company” and “VCBD” mean Vitalibis, Inc. and, where appropriate, our consolidated subsidiaries.

This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”).

We, and the selling stockholders and selling warrant holder may offer and sell these securities to or through one or more underwriters, dealers and agents, or directly to purchasers, on a continuous or delayed basis.

This prospectus describes some of the general terms that may apply to the securities offered by us or the selling stockholders or the selling warrant holder, and the general manner in which they may be offered.

This Form S-1 and prospectus relating thereto includes:

(a)

the sale of up to 5,000,000 shares of the Company's common stock by the Company (the "Company’s Securities"),

(b)

the resale of 5,321,400 shares held by certain stockholders of the Company named in the registration statement (“Selling Stockholders”), previously purchased by the Selling Stockholders in a Private Placement at $1.00 per share,

(c)

the resale of 1,500,000 common stock purchase warrants held by one stockholder of the Company named in the registration statement (“Selling Warrant Holder”), previously acquired in conjunction with an agreement with the Company,

(d)

3,500,000 shares of our common stock issuable upon exercise of common stock purchase warrants held by the selling warrant holder, with 1,500,000 exercisable at $1.01 per share and 2,000,000 exercisable at $1.50.

(e)

4,161,371 shares of our common stock issuable upon conversion or exchange of any securities that provide for conversion or exchange into other securities.

The registration statement, while effective, allows the Selling Warrant older named in the registration statement to publicly sell the Warrants. The Company will not receive any proceeds from the sale of the Warrants by the selling warrant holder.

Upon the cash exercise of the warrants, the Company will receive the exercise price of the warrants. There can be no assurance any warrants will be exercised.

There are no underwriting commissions involved in this offering. We have agreed to pay all the costs and expenses of this offering. Selling shareholders will pay no offering expenses. As of the date of this prospectus, there is a limited trading market in our common stock. Our common stock is currently listed on OTCQB. There is no guarantee that our securities will ever trade on the NASDAQ or other exchange.

This offering is highly speculative and these securities involve a high degree of risk and should be considered only by persons who can afford the loss of their entire investment. Additionally, auditors have expressed substantial doubt as to our Company’s ability to continue as a going concern. See “Risk Factors” beginning on page ___, infra .

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

This prospectus provides you with a general description of the securities we or the selling stockholders may offer. Each time we or the selling stockholders sell securities, we will provide a prospectus supplement that will contain specific information about the terms and manner of that offering. The accompanying prospectus supplement or information incorporated by reference into this prospectus after the date of this prospectus may also add, update or change information contained in this prospectus. Any such information that is inconsistent with this prospectus will supersede the information in this prospectus. You should read both this prospectus and the accompanying prospectus supplement together with the additional information described under the heading “Where You Can Find More Information.”

You should rely only on the information we have provided or incorporated by reference into this prospectus, any applicable prospectus supplement and any related free writing prospectus. Neither we nor the selling stockholders have authorized anyone to provide you with different information. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus.

Neither the delivery of this prospectus nor any sale made under it implies that the information in this prospectus is correct as of any date after the date of this prospectus. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date thereof and that any information incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of a security.

This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under “Incorporation by Reference.”

TABLE OF CONTENTS

PROSPECTUS SUMMARY	1
THE OFFERING	3
SUMMARY FINANCIAL DATA	5
RISK FACTORS	6
NOTE ABOUT FORWARD-LOOKING STATEMENTS	6
TAX CONSIDERATIONS	7
USE OF PROCEEDS	7
DILUTION	7
PLAN OF DISTRIBUTION	8
DESCRIPTION OF SECURITIES	9
INTERESTS OF NAMED EXPERTS AND COUNSEL	10
DIVIDEND POLICY	10
DESCRIPTION OF BUSINESS	11
PROPERTIES	15
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION	15
USE OF PROCEEDS	20
RATIO OF EARNINGS TO FIXED CHARGES	19
DESCRIPTION OF CAPITAL STOCK	20
DESCRIPTION OF WARRANTS	23
SELLING STOCKHOLDERS	24
SELLING WARRANT HOLDER	27
PLAN OF DISTRIBUTION	28
DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS, AND CONTROL PERSONS	30
EXECUTIVE COMPENSATION	31
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS	32
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT	33
MARKET FOR COMMON STOCK / SHARES ELIGIBLE FOR FUTURE SALE	34
WHERE YOU CAN FIND MORE INFORMATION	34
LEGAL PROCEEDINGS	35
EXPERTS	35
CORPORATE GOVERNANCE	35
FINANCIAL STATEMENTS	F-1

You should rely only on the information contained in this prospectus and any free writing prospectus prepared by us or on our behalf. We have not authorized anyone to provide you with different or additional information. If anyone provides you with different or additional information, you should not rely on it. The information in this prospectus is accurate only as of the date on the front of this prospectus. Our business, financial condition, results of operations and prospects may have changed since the date of this prospectus. This prospectus is not an offer or solicitation relating to the securities in any jurisdiction in which such an offer or solicitation relating to the securities is not authorized. You should not consider this prospectus to be an offer or solicitation relating to the securities if the person making the offer or solicitation is not qualified to do so, or if it is unlawful for you to receive such an offer or solicitation.

WHERE YOU CAN FIND MORE INFORMATION

We file annual, quarterly and current reports, proxy statements, and other information with the SEC. Such reports, proxy statements, and other information concerning us can be read and copied at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 or on the Internet at http://www.sec.gov. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. The SEC also maintains a web site at http://www.sec.gov that contains reports, proxy statements and other information about issuers, such as us, who file electronically with the SEC.

This prospectus is part of a registration statement on Form S-1 under the Securities Act of 1933, as amended (the “Securities Act”) with respect to the securities covered by this prospectus. This prospectus, which is a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For further information with respect to us and the securities covered by this prospectus, please see the registration statement and the exhibits filed with the registration statement. A copy of the registration statement and the exhibits filed with the registration statement may be inspected without charge from the SEC as indicated above, or from us as indicated under “Incorporation by Reference.”

INCORPORATION BY REFERENCE

The SEC allows us to “incorporate by reference” into this prospectus the information that we file with the SEC. This permits us to disclose important information to you by referring to these filed documents. Any information referred to in this way is considered part of this prospectus, and any information filed with the SEC by us after the date of this prospectus will automatically be deemed to update and supersede this information. We incorporate by reference the following documents that have been filed with the SEC (other than, in each case, documents or information deemed furnished and not filed in accordance with SEC rules, including pursuant to Item 2.02 or Item 7.01 or any related exhibit furnished under Item 9.01(d) of Form 8-K, and no such information shall be deemed specifically incorporated by reference hereby):

Annual Reports on Form 10-K for the fiscal years ended December 31, 2017 and December 31, 2018;

Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2018, June 30, 2018, September 30, 2018 and March 31, 2019;

Current Report on Form 8-K filed with the SEC on November 15, 2018; and

The description of our common stock contained in our Registration Statement on Form S-1, filed with the SEC on March 25, 2015 (File No. 333-202970), and any amendment or reports filed for the purpose of updating such description.

We also incorporate by reference any future filings (other than information in such documents that is not deemed to be filed) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) until we file a post-effective amendment which indicates the termination of the offering of the securities made by this prospectus.

We will provide without charge upon written or oral request a copy of any or all of the documents that are incorporated by reference into this prospectus, other than exhibits which are specifically incorporated by reference into such documents. Requests should be directed to our Corporate Secretary at Vitalibis, Inc., 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169 , telephone number is 702-944-9620.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus and the documents incorporated by reference herein contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Some of these statements can be identified by use of forward-looking words such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans” or “estimates,” or the negative of these words, or other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, they may include, but are not limited to, the factors discussed under “Risk Factors” in our most recent Annual Report on Form 10-K, in our Quarterly Reports on Form 10-Q, in any prospectus supplement related hereto, and in other information contained in our publicly available SEC filings and press releases.

You should not consider this list to be a complete statement of all risks and uncertainties. You are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date such statements were first made. Except to the extent required by federal securities laws, we undertake no obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

iii

RISK FACTORS

As a “smaller reporting company”, we are not required to provide the information required by this Item.

However, investing in our securities involves significant risks. You should carefully consider the risks factors set forth in the documents and reports filed by us with the SEC and incorporated by reference into this prospectus, as well as any risks described or incorporated by reference in any applicable prospectus supplement before deciding whether to buy our securities. Additional risks and uncertainties not presently known to us or that we believe are immaterial may also significantly impair our business operations. If any of these risks actually occur, our business, financial condition and results of operations could be materially affected, and you could lose all or part of your investment in offered securities.

You should carefully consider the risks discussed under “Risk Factors” in our most recent Annual Report on Form 10-K, in our Quarterly Reports on Form 10-Q, in any prospectus supplement related hereto, and in other information contained in our publicly available SEC filings and press releases. See “Where You Can Find Additional Information.”

PROSPECTUS SUMMARY

This summary highlights certain information appearing elsewhere in this prospectus. This summary is not complete and does not contain all of the information you should consider prior to investing. After you read this summary, you should read and consider carefully the more detailed information and financial statements and related notes that we include in this prospectus, especially the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” If you invest in our securities, you are assuming a high degree of risk.

Unless we have indicated otherwise or the context otherwise requires, references in the prospectus to “Greater Cannabis Company” the “Company,” “we,” “us” and “our” or similar terms are to Vitalibis, Inc.

Going Concern

The Company intends to overcome the circumstances that impact its ability to remain a going concern through a combination of the expansion of revenues, with interim cash flow deficiencies being addressed through additional equity and debt financing. The Company anticipates raising additional funds through public or private financing, strategic relationships or other arrangements in the near future to support its business operations; however, the Company may not have commitments from third parties for a sufficient amount of additional capital. The Company cannot be certain that any such financing will be available on acceptable terms, or at all, and its failure to raise capital when needed could limit its ability to continue its operations. The Company’s ability to obtain additional funding will determine its ability to continue as a going concern. Failure to secure additional financing in a timely manner and on favorable terms would have a material adverse effect on the Company’s financial performance, results of operations and stock price and require it to curtail or cease operations, sell off its assets, seek protection from its creditors through bankruptcy proceedings, or otherwise. Furthermore, additional equity financing may be dilutive to the holders of the Company’s common stock, and debt financing, if available, may involve restrictive covenants, and strategic relationships, if necessary, to raise additional funds, and may require that the Company relinquish valuable rights. Please see NOTE 1- ORGANIZATION AND GOING CONCERN for further information.

There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing stockholders.

Company

We market and sell consumer products containing full Spectrum phytocannabinoid rich hemp oil with naturally occurring CBD under our Vitalibis™ brand in a range of market sectors including wellness, and beauty care. We currently distribute 3 products and we expect to continue to add new products to our Vitalibis™ portfolio to enhance our line of full spectrum phyto-cannabinoid rich hemp products with naturally occurring cannabidiol (CBD) and hemp-related consumer products. We also expect to develop and launch new brands under the Vitalibis™ product development umbrella to more effectively market and sell certain products. We also sell full spectrum phyto-cannabinoid rich hemp powder with naturally occurring cannabidiol (CBD) acquired through our supply relationships in the United States to various customers that produce products for resale into the market. We also began offering of our technology back-end which is being offered as a Software as a Service (SaaS) platform.

We seek to take advantage of an emerging worldwide trend to re-energize the production of industrial hemp and to foster its many uses for consumers. Historically cultivated for industrial and practical purposes, hemp is used today for textiles, paper, auto parts, biofuel, cosmetics, animal feed, nutritional supplements, and much more. The market for hemp-derived products is expected to increase substantially over the next five years, and we believe Vitalibis™ is well positioned to be a significant player in the hemp industry.

Hemp-derived CBD is one of at least 80 cannabinoids found in hemp, and is non-psychoactive. Our U.S. based supplier oversees our raw material supply chain and raw material processing. Our internal team manages product development and manufacturing, and sales and marketing. We will continue to scale-up our processing capability to accommodate new products in our pipeline.

Government Regulation

We are not yet aware of any direct government regulations relating to the marketing of CBD-related products containing less than 0.03 parts THC, which are the only products we currently sell and intend to sell.

Emerging Growth Company

We are an “emerging growth company,” as defined in the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies.

Section 107(b) of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

We could remain an “emerging growth company” for up to five years, or until the earliest of (i) the last day of the first fiscal year in which our annual gross revenues are $1 billion, as adjusted, or more, (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, and (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year period.

THE OFFERING

Securities offered		Up to 5,000,000 shares of our Common Stock by the Company

		Up to 5,321,400 shares of our Common Stock by the Selling Shareholders Up to 3,500,000 Common Stock Purchase Warrants by the Selling Warrant Holders Up to 3,500,000 shares of common stock underlying the Common Stock Purchase Warrants by the Selling Warrant Holders 4,161,371 shares of common stock issuable upon conversion or exchange of any securities that provide for conversion or exchange into other securities

Offering Amount		$ 21,482,771

Offering price		$ 1.00 per share of Common Stock offered by the Company Determined at the time of sale by the selling security holders

Common Stock Issued and Outstanding Before This Offering		30,781,400 (as of May 10, 2019)

Common Stock Issued and Outstanding After This Offering		30,781,4700 (1)(2)

Risk Factors		See “Risk Factors” beginning on page ____ and the other information set forth in this prospectus for a discussion of factors you should consider before deciding to invest in our securities.

Market for Common Stock		VCBD - OTCQB

Dividends		We have not declared or paid any dividends on our common stock since our inception, and we do not anticipate paying any such dividends for the foreseeable future.

(1) BLB was issued a warrant to purchase 1,500,000 shares of the Company’s common stock, and an additional 2,000,000 warrants were issued to a contractor. The shares to be issued under these warrants were not included in the offering nor in the calculation of the shares outstanding as of May10, 2019. In the event that BLB and the contractor were to fully exercise their warrants, the total number of shares outstanding would increase to 34,281,400. Please see NOTE 6- STOCKHOLDERS’ DEFICIT for further information. We will however, receive proceeds from the issuance of 3,500,000 shares of our common stock underlying the warrant issued to BLB pursuant to the Securities Purchase Agreement dated December 31, 2018 and the independent contact agreement dated March 29, 2019. The BLB warrants have an exercise price of $1.01 and are exercisable for a period of two (2) years. The contractor warrants have an exercise price of $1.50 per share and are excersiable for a period of three (3) years, with an additional one year term at the holders option.

(2) On January 10, 2019, the Company entered into a Securities Purchase Agreement with Power Up Lending, LLC (“PUL”). As per the terms of the Agreement, the Company is required to reserve One Million One Hundred Sixty Three Thousand and Seventy Six shares (1,163,076) of the Company’s common stock. Simultaneous with the entry into the Securities Purchase Agreement, the Company issued a Convertible Note to PUL in the amount of One Hundred Twenty Six Thousand NO/100 Dollars ($126,000.00). The shares reserved in the PUL transaction will not be issued until the Company receives a Notice of Conversion, and are not included in the shares calculated in the common stock issued and outstanding before this offering within “The Offering” table. Please see NOTE 5- CONVERTIBLE NOTES PAYABLE for further information.

On February 7, 2019, the Company entered into a Securities Purchase Agreement with Power Up Lending, LLC (“PUL”). As per the terms of the Agreement, the Company is required to reserve Seven Hundred Sixty Six Thousand One Hundred and Fifty Three shares (766,153) of the Company’s common stock. Simultaneous with the entry into the Securities Purchase Agreement, the Company issued a Convertible Note to PUL in the amount of Eighty Three Thousand NO/100 Dollars ($83,000.00). The shares reserved in the PUL transaction will not be issued until the Company receives a Notice of Conversion, and are not included in the shares calculated in the common stock issued and outstanding before this offering within “The Offering” table. Please see NOTE 5- CONVERTIBLE NOTES PAYABLE for further information.

On March 29, 2019, the Company entered into a Securities Purchase Agreement with Triton Funds LP (“Triton”). As per the terms of the Agreement, the Company is required to reserve Two Million Two Hundred and Thirty Two Thousand One Hundred and Forty Two shares (2,232,142) of the Company’s common stock. Simultaneous with the entry into the Securities Purchase Agreement, the Company issued a Convertible Note to PUL in the amount of Two Hundred and Fifty Thousand NO/100 Dollars ($250,000.00). The shares reserved in the PUL transaction will not be issued until the Company receives a Notice of Conversion, and are not included in the shares calculated in the common stock issued and outstanding before this offering within “The Offering” table. Please see NOTE 9- SUBSEQUENT EVENTS for further information.

SUMMARY FINANCIAL DATA

The following summary of our financial data should be read in conjunction with, and is qualified in its entirety by reference to, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements, appearing elsewhere in this prospectus.

Statements of Operations Data

	For the Three months Ended March 31, 2019			For the year-ended December 31, 2018			For the year-ended December 31, 2017
Revenue	$	139,585		$	51,331		$	–
Loss from operations	$	(2,445,159	)	$	(2,227,920	)	$	(102,865	)
Net loss	$	(2,448,499	)	$	(2,228,620	)	$	(102,904	)

Balance Sheets Data

	As of March 31, 2019		As of December 31, 2018		As of December 31, 2017
Cash	$	60,679	$	171,979	$	–
Total assets	$	408,682	$	570,407	$	–
Total liabilities	$	235,772	$	180,389	$	6,169
Total stockholders’ equity (deficit)	$	172,910	$	390,018	$	(6,169	)

RISK FACTORS

NOTE ABOUT FORWARD-LOOKING STATEMENTS

Statements under “Prospectus Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Description of Business” and elsewhere in this prospectus may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements include, among other things, statements regarding:

the growth of our business and revenues and our expectations about the factors that influence our success;

our plans to continue to invest in systems, facilities, and infrastructure, increase our hiring and grow our business;

our plans for the build out and expansion of our online store and portal, GCC Superstore, and the strategy and timing of any plans to monetize our network;

our user growth expectations;

our ability to attain funding and the sufficiency of our sources of funding;

our expectation that our cost of revenues, development expenses, sales and marketing expenses, and general and administrative expenses will increase;

fluctuations in our capital expenditures; and

our plans for potential business partners and any acquisition plans;

as well as other statements regarding our future operations, financial condition and prospects, and business strategies. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in this registration statement, of which this prospectus is a part, including the risks described under “Risk Factors.” Any forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances that occur in the future.

If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we may have projected. Any forward-looking statements you read in this prospectus reflect our current views with respect to future events and are subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, financial condition, growth strategy and liquidity. You should specifically consider the factors identified in this prospectus that could cause actual results to differ before making an investment decision. In addition, as discussed in “Risk Factors,” our shares may be considered a “penny stock” and, as a result, the safe harbors provided for forward-looking statements made by a public company that files reports under the federal securities laws may not be available to us.

TAX CONSIDERATIONS

We are not providing any tax advice as to the acquisition, holding or disposition of the securities offered herein. In making an investment decision, investors are strongly encouraged to consult their own tax advisor to determine the U.S. Federal, state and any applicable foreign tax consequences relating to their investment in our securities.

USE OF PROCEEDS

This prospectus relates to the sale of 5 million shares of our common stock by the company. The proceeds of our offering will be used for general working capital, including marketing, product development and corporate compliance expenses.

This prospectus also relates to shares of our common stock and warrants that may be offered and sold from time to time by the selling stockholders/warrant holders. We will not receive any proceeds from the sale of shares of common stock or warrants in this offering.

DETERMINATION OF OFFERING PRICE

The pricing of the Shares has been arbitrarily determined and established by the Company. No independent accountant or appraiser has been retained to protect the interest of the investors. No assurance can be made that the offering price is in fact reflective of the underlying value of the Shares. Each prospective investor is urged to consult with his or her counsel and/or accountant as to offering price and the terms and conditions of the Shares. Factors to be considered in determining the price include the amount of capital expected to be required, the market for securities of entities in a new business venture, projected rates of return expected by prospective investors of speculative investments, the Company’s prospects for success and prices of similar entities.

DILUTION

The Company does not have adequate revenue to fund all of its operational needs and may require additional financing to continue its operations if it is unable to generate substantial revenue growth. There can be no assurance that such financing will be available at all or on favorable terms. Failure to generate substantial revenue growth could result in delay or indefinite postponement of the Company’s deployment of its products, and may result in the Company looking to obtain such additional financing, resulting in possible dilution. Any such financing will dilute the ownership interest of the Company’s shareholders at the time of the financing, and may dilute the value of their shareholdings.

PLAN OF DISTRIBUTION

The selling stockholders and any of their respective pledgees, donees, assignees and other successors-in-interest may, from time to time, sell any or all of their shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling stockholders may use any one or more of the following methods when selling shares:

ordinary brokerage transactions and transactions in which the broker-dealer solicits the purchaser;

block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal

facilitate the transaction;

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

an exchange distribution in accordance with the rules of the applicable exchange;

privately-negotiated transactions;

broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;

through the writing of options on the shares;

a combination of any such methods of sale; and

any other method permitted pursuant to applicable law.

The selling stockholders may also sell shares under Rule 144 of the Securities Act, if available, rather than under this prospectus. The selling stockholders shall have the sole and absolute discretion not to accept any purchase offer or make any sale of shares if it deems the purchase price to be unsatisfactory at any particular time.

The selling stockholders or their respective pledgees, donees, transferees or other successors in interest, may also sell the shares directly to market makers acting as principals and/or broker-dealers acting as agents for themselves or their customers. Such broker-dealers may receive compensation in the form of discounts, concessions or commissions from the selling stockholders and/or the purchasers of shares for whom such broker-dealers may act as agents or to whom they sell as principal or both, which compensation as to a particular broker-dealer might be in excess of customary commissions. Market makers and block purchasers purchasing the shares will do so for their own account and at their own risk. It is possible that a selling stockholder will attempt to sell shares of common stock in block transactions to market makers or other purchasers at a price per share which may be below the then existing market price. We cannot assure that all or any of the shares offered in this prospectus will be issued to, or sold by, the selling stockholders. The selling stockholders and any brokers, dealers or agents, upon effecting the sale of any of the shares offered in this prospectus, may be deemed to be “underwriters” as that term is defined under the Securities Exchange Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the rules and regulations of such acts. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

We are required to pay all fees and expenses incident to the registration of the shares, including fees and disbursements of counsel to the selling stockholders, but excluding brokerage commissions or underwriter discounts.

The selling stockholders, alternatively, may sell all or any part of the shares offered in this prospectus through an underwriter. The selling stockholders have not entered into any agreement with a prospective underwriter and there is no assurance that any such agreement will be entered into.

The selling stockholders may pledge their shares to their brokers under the margin provisions of customer agreements. If a selling stockholder defaults on a margin loan, the broker may, from time to time, offer and sell the pledged shares. The selling stockholders and any other persons participating in the sale or distribution of the shares will be subject to applicable provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations under such Act, including, without limitation, Regulation M. These provisions may restrict certain activities of, and limit the timing of purchases and sales of any of the shares by, the selling stockholders or any other such person. In the event that any of the selling stockholders are deemed an affiliated purchaser or distribution participant within the meaning of Regulation M, then the selling stockholders will not be permitted to engage in short sales of common stock. Furthermore, under Regulation M, persons engaged in a distribution of securities are prohibited from simultaneously engaging in market making and certain other activities with respect to such securities for a specified period of time prior to the commencement of such distributions, subject to specified exceptions or exemptions. In addition, if a short sale is deemed to be a stabilizing activity, then the selling stockholders will not be permitted to engage in a short sale of our common stock. All of these limitations may affect the marketability of the shares.

If a selling stockholder notifies us that it has a material arrangement with a broker-dealer for the resale of the common stock, then we would be required to amend the registration statement of which this prospectus is a part, and file a prospectus supplement to describe the agreements between the selling stockholder and the broker-dealer.

DESCRIPTION OF SECURITIES

Common Stock

Our authorized capital consists of 112,500,000 shares of common stock, par value $.001 per share (the “Common Stock”) and 5,000,000 shares of preferred stock, par value $.001 per share (the “Preferred Stock”). As of December 31, 2018, the Company had 29,638,900 shares of Common Stock issued and outstanding and no shares of Preferred stock issued and outstanding. As of May 10, 2019, the Company had 30,781,400 shares of Common Stock issued and outstanding and no shares of Preferred stock issued and outstanding.

Holders of the Company’s common stock are entitled to one vote for each share on all matters submitted to a stockholder vote. Holders of common stock do not have cumulative voting rights. Therefore, holders of a majority of the shares of common stock voting for the election of directors can elect all of the directors. Holders of the Company’s common stock representing a majority of the voting power of the Company’s capital stock issued, outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a quorum at any meeting of stockholders. A vote by the holders of a majority of the Company’s outstanding shares is required to effectuate certain fundamental corporate changes such as liquidation, merger or an amendment to the Company’s articles of incorporation.

Holders of the Company’s common stock are entitled to share in all dividends that the board of directors, in its discretion, declares from legally available funds. In the event of a liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock. The Company’s common stock has no pre-emptive rights, no conversion rights and there are no redemption provisions applicable to the Company’s common stock.

Preferred Stock

Our Articles of Incorporation authorizes the issuance of up to 5,000,000 shares of preferred stock with designations, rights and preferences determined from time to time by its Board of Directors. Accordingly, our Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting, or other rights which could adversely affect the voting power or other rights of the holders of the common stock. In the event of issuance, the preferred stock could be utilized, under certain circumstances, as a method of discouraging, delaying or preventing a change in control of the Company. Although we have no present intention to issue any shares of its authorized preferred stock, there can be no assurance that the Company will not do so in the future.

Options and Warrants

On January 16, 2019, the Company issued a warrant to Bruce Lee Beverage, LLC (“BLB”) granting BLB the right to purchase 1,500,000 shares of the Company’s common stock at an exercise price of $1.01 per share. The warrant has a term of 2 years and expires on January 16, 2021. Please see NOTE 5- STOCKHOLDERS’ DEFICIT for further information.

In March 2019, the Company entered into an agreement with a contractor for services. This contractor may earn a total of 1,000,000 shares of common stock and 2,000,000 warrants to purchase common stock. The contractor can elect to extend the term for an additional year with 90 days’ notice. Of the total awards, 250,000 shares and 334,000 warrants were earned upon execution of the agreement, with the 250,000 shares being issued in April 2019. The warrants were issued March 29, 2019 and have an exercise price of $1.50 per share, and an initial term of 3 years from the date of issuance. The remaining shares and warrants vest upon completion of certain performance-related milestones. Please see NOTE 6- STOCKHOLDERS’ DEFICIT for further information.

Convertible Notes

On January 10, 2019, the Company entered into a Securities Purchase Agreement with Power Up Lending, LLC (“PUL”). As per the terms of the Agreement, the Company is required to reserve One Million One Hundred Sixty Three Thousand and Seventy Six shares (1,163,076) of the Company’s common stock. Simultaneous with the entry into the Securities Purchase Agreement, the Company issued a Convertible Note to PUL in the amount of One Hundred Twenty Six Thousand NO/100 Dollars ($126,000.00). The shares reserved in the PUL transaction will not be issued until the Company receives a Notice of Conversion, and are not included in the shares calculated in the common stock issued and outstanding before this offering within “The Offering” table. Please see NOTE 5- CONVERTIBLE NOTES PAYABLE for further information.

INTERESTS OF NAMED EXPERTS AND COUNSEL

The validity of the shares of common stock offered by the Company hereby will be passed upon for the Registrant by Michael J. Morrison, Chtd., Reno, NV.

DIVIDEND POLICY

We have never paid any cash dividends on our common stock and anticipate that, for the foreseeable future, no cash dividends will be paid on our common stock.

DESCRIPTION OF BUSINESS

Organization

Vitalibis, Inc. (the “Company”) was formed on April 11, 2014 as a Nevada corporation, under the name of Crowd 4 Seeds, Inc. On January 9, 2017, the Company filed a certificate of amendment to its Certificate of Incorporation with the Secretary of State of the State of Nevada in order to change its name to "Sheng Ying Entertainment Corp." On December 16, 2017, new management took over control of the Company and, on February 5, 2018, the Company filed a certificate of amendment to its Certificate of Incorporation with the Secretary of State of the State of Nevada in order to change its name to “Vitalibis, Inc”.

Emerging Growth Company

We are an “emerging growth company,” as defined in the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies.

We could remain an “emerging growth company” for up to five years, or until the earliest of (i) the last day of the first fiscal year in which our annual gross revenues are $1 billion, as adjusted, or more, (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, and (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year period.

VITALIBIS, INC.

Our principal executive offices are at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169, telephone number is 702-944-9620.

Our website is http://ir.vitalibis.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus.

Vitalibis is a socially conscious brand focused on people, profit, products and the planet. We are a multi-channel marketer and seller of premium, full spectrum phyto-cannabinoid rich (PCR) hemp products, along with personal care and certified organic nutritional products. We leverage our proprietary technology platform to maximize our innovative micro-influencer sales model. In addition to selling high-quality products and building long-term customer relationships, Vitalibis supports non-profits with environmental, health / wellness and neuro-emotional missions.

The Company was incorporated in Nevada on April 11, 2014, as Crowd 4 Seeds Inc. Most of our activity through March 31, 2018, involved incorporation efforts, registration to become a reporting company, planning our business and developing our website.

After change in ownership October 2017, the Company had a new management team on board and the Company’s business plan was changed substantially by the new management team to focus on the marketing of hemp-based products.

We commenced business operations with respect to our hemp-based products in May 2018, and such operations are continuing. We are now marketing and selling two (2) of our proprietary products, Signature 300 Hemp Oil and Daily Wellness Super-food Blend, through our website and Pro-Program.

For additional information visit: https://www.vitalibis.com/

Fundraising and Previous Offerings

BLB was issued a warrant to purchase 1,500,000 shares of the Company’s common stock, and an additional 2,000,000 warrants were issued to a contractor. The shares to be issued under these warrants were not included in the offering nor in the calculation of the shares outstanding as of May10, 2019. In the event that BLB and the contractor were to fully exercise their warrants, the total number of shares outstanding would increase to 34,281,400. Please see NOTE 6- STOCKHOLDERS’ DEFICIT for further information. We will however, receive proceeds from the issuance of 3,500,000 shares of our common stock underlying the warrant issued to BLB pursuant to the Securities Purchase Agreement dated December 31, 2018 and the independent contact agreement dated March 29, 2019. The BLB warrants have an exercise price of $1.01 and are exercisable for a period of two (2) years. The contractor warrants have an exercise price of $1.50 per share and are excersiable for a period of three (3) years, with an additional one year term at the holders option.

On January 10, 2019, the Company entered into a Securities Purchase Agreement with Power Up Lending, LLC (“PUL”). As per the terms of the Agreement, the Company is required to reserve One Million One Hundred Sixty Three Thousand and Seventy Six shares (1,163,076) of the Company’s common stock. Simultaneous with the entry into the Securities Purchase Agreement, the Company issued a Convertible Note to PUL in the amount of One Hundred Twenty Six Thousand NO/100 Dollars ($126,000.00). The shares reserved in the PUL transaction will not be issued until the Company receives a Notice of Conversion, and are not included in the shares calculated in the common stock issued and outstanding before this offering within “The Offering” table. Please see NOTE 5- CONVERTIBLE NOTES PAYABLE for further information.

Employees and Consultants

We have two full-time employees: Steven Raack and Thomas Raack. We utilize consultants on an as-needed basis.

Insurance

The company has insurance for errors in missions by its officers and directors in the amount of $2 million. The company also maintains a general umbrella policy for the company in the amount of $5 million.

Cole Memo

On August 29, 2013, United States Deputy Attorney General James Cole issued the Cole Memo to United States Attorneys guiding them to prioritize enforcement of Federal law away from the cannabis industry operating as permitted under certain state laws, so long as:

cannabis is not being distributed to minors and dispensaries are not located around schools and public buildings;

the proceeds from sales are not going to gangs, cartels or criminal enterprises;

cannabis grown in states where it is legal is not being diverted to other states;

cannabis-related businesses are not being used as a cover for sales of other illegal drugs or illegal activity;

there is not any violence or use of fire-arms in the cultivation and sale of marijuana;

there is strict enforcement of drugged-driving laws and adequate prevention of adverse health consequences; and

cannabis is not grown, used, or possessed on Federal properties.

Trademarks

The success of our business depends on our continued ability to use our existing trade name in order to increase our brand awareness. In that regard, we believe that our trade name is valuable asset that is critical to our success. As of the date of this prospectus, we have submitted a trademark application for “Vitalibis”. There is no guarantee that the U.S. Patent and Trademark Office will grant us a trademark. The unauthorized use or other misappropriation of our trade name could diminish the value of our business concept and may cause a decline in our revenue.

Competitors, Methods of Completion, Competitive Business Conditions

We believe that we face significant direct competition in the retail sector for CBD products. There are several direct competitors and some sell directly to consumers. The Company believes the density of CBD consumers and the wide product selection we seek to offer are what we believe will make our products attractive to CBD consumers and may help to serve as a competitive advantage.

Legal Proceedings

From time to time we may be a defendant and plaintiff in various legal proceedings arising in the normal course of our business. We are currently not a party to any material pending legal proceedings or government actions, including any bankruptcy, receivership, or similar proceedings. In addition, management is not aware of any known litigation or liabilities involving the operators of our properties that could affect our operations. Should any liabilities be incurred in the future, they will be accrued based on management’s best estimate of the potential loss. As such, there is no adverse effect on our consolidated financial position, results of operations or cash flow at this time. Furthermore, Management of the Company does not believe that there are any proceedings to which any director, officer, or affiliate of the Company, any owner of record of the beneficially or more than five percent of the common stock of the Company, or any associate of any such director, officer, affiliate of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company.

Sources and Availability of Raw Materials

We utilize various different sources of raw materials in an effort to help ensure the availability of such materials. However, there is no assurance that the raw materials be available when we require such materials, or that the price of such materials will be within our budget for such materials.

Seasonal Aspect of our Business

None of our products are affected by seasonal factors.

Reports to Security Holders

We are required to file reports and other information with the SEC. You may read and copy any document that we file at the SEC’s public reference facilities at 100 F. Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-732-0330 for more information about its public reference facilities. Our SEC filings are available to you free of charge at the SEC’s web site at www.sec.gov. We are an electronic filer with the SEC and, as such, our information is available through the Internet site maintained by the SEC that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. This information may be found at www.sec.gov and posted on our website for investors at http://greatercannabiscompany.com/sec-filings/.

PROPERTIES

Since our inception, we have shared space with our founders/management, but have now established our business offices in shared leased office space at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169.

We do not own any real property.

We believe that our facilities are adequate for our current needs and that, if required, we will be able to expand our current space or locate suitable new office space and obtain a suitable replacement for our executive and administrative headquarters.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATION

Please read the following discussion of our financial condition and results of operations in conjunction with financial statements and notes thereto, as well as the “Risk Factors” and “Description of Business” sections included elsewhere in this prospectus. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly in “Risk Factors”.

Overview

We expect to realize revenue to fund our working capital needs through the sale of finished products and raw materials to third parties. However, in order to fund our product development efforts, we will need to raise additional capital either through the issuance of equity and/or the issuance of debt. In the event we are unable to raise sufficient additional capital to fund our product development efforts, we may need to curtail or delay such activity.

Critical Accounting Policies

The preparation of these financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis management evaluates its critical accounting policies and estimates.

A “critical accounting policy” is one which is both important to the understanding of the financial condition and results of operations of the Company and requires management’s most difficult, subjective, or complex judgments, and often requires management to make estimates about the effect of matters that are inherently uncertain. Management believes the following accounting policies fit this definition:

Revenue Recognition - The Company recognizes revenue in accordance with ASC Topic 606, Revenue From Contracts With Customers, which was adopted on January 1, 2018 using the modified retrospective method, with no impact to the Company’s comparative financial statements. Revenues are recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods or services. Revenue is recognized based on the following five step model:

Identification of the contract with a customer

Identification of the performance obligations in the contract

Determination of the transaction price

Allocation of the transaction price to the performance obligations in the contract

Recognition of revenue when, or as, the Company satisfies a performance obligation

Product sales are recognized all of the following criteria are satisfied: (i) a contract with an end user exists which has commercial substance; (ii) it is probable the Company will collect the amount charged to the end user; and (iii) the Company has completed its performance obligation whereby the end user has obtained control of the product. A contract with commercial substance exists once the Company receives and accepts a purchase order or once it enters into a contract with an end user. If collectibility is not probable, the sale is deferred and not recognized until collection is probable or payment is received. Control of products typically transfers when title and risk of ownership of the product has transferred to the customer. Payment is received before shipment of the product. Net revenues comprise gross revenues less customer discounts and allowances, actual and expected returns. Shipping charges billed to customers are included in net sales. Various taxes on the sale of products and enrollment packages to customers are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority. The Company allows for customers to return unopened products within 45 days. During the year ended December 31, 2018, there were a trivial amount of refunds processed for returned product.

Inventory – Inventory is manufactured at third party facilities. Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.

Website Development Cost – The Company capitalizes certain development costs associated with internal use software incurred during the application development stage. The Company expenses costs associated with preliminary project phase activities, training, maintenance and any post-implementation period costs as incurred. Capitalization of qualifying application development cost begins when management authorized and commits to funding the project and it is probable that the project will be completed for the function intended. Capitalized internal use software costs are normally amortized over estimated useful lives ranging from 2 to 5 years once the related project has been completed and deployed for customer use. At time the software is considered to have be an indefinite lived asset in which case it is evaluated for impairment at least annually. For the year ending December 31, 2018, the Company capitalized $176,177 related to software under the criteria discussed in this paragraph. These costs are related to the development of our website and customer portal. The Company amortizes capitalized costs over an estimated useful life of three years.

Stock-Based Compensation – The Company measures the total amount of employee stock-based compensation expense for a grant based on the grant date fair value of each award and recognizes the stock-based compensation expense on a straight-line basis over the requisite service period for each separately vesting tranche of an award. Stock-based compensation is based on unvested outstanding awards. The Company has elected to recognize forfeitures when realized.

Recent Developments

Results of Operations

Three months ended March 31, 2019 compared to three months ended March 31, 2018

Revenue and Gross Profit

In the second half of fiscal year 2018, the Company began selling its products.

During the three months ended March 31, 2019, the Company generated $139,585 in revenue and $51,088 in gross profit. There were no sales during the three months ended March 31, 2018.

Selling, General and Administrative Expenses

Selling, general and administrative expenses amounted to $2,448,406 and $726,968, respectively for the three months ended March 31, 2019 and 2018, an increase of $1,721,438. The increase was primarily due to higher stock-based compensation associated with the Bruce Lee agreement and other contractors receiving stock in exchange for services provided, services rendered by our executive officers and expenses related to our independent contractors.

Professional fees

Professional fees amounted to $47,841 and $18,909, respectively for the three months ended March 31, 2019 and 2018. The increase of $28,932 was due to increased legal, accounting and audit fees associated with the increased operations of the Company.

Interest expense

Interest expense was $3,340 for the three months ended March 31, 2019 compared to $0 for the three months ended March 31, 2018. The interest expense primarily relates to the Company’s recently issued convertible notes.

For the years ended December 31, 2018 and 2017

Revenue and Gross Profit

During the year ended December 31, 2018, the Company began selling its products, and generated $51,331 in revenue and $28,330 in gross profit. There were no sales during the year ended December 31, 2017.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the period ending December 31, 2018, were $2,095,787 compared to $32,328 for the year ending December 31, 2017. The expenses consisted primarily of stock-based compensation, and services rendered by our executive officers.

Professional fees

Professional fees for the year ending December 31, 2018, were $160,463 compared to $70,537 for the year ending December 31, 2017. The increase was due to increased legal, accounting and audit fees associated with the increased operations of the Company.

Liquidity and Capital Resources

The following is a summary of the Company's cash flows provided by (used in) operating, investing, and financing activities for the three months ended March 31, 2019 and the years ended December 31, 2018 and 2017:

	Three Months Ended March 31, 2019			Year ended December 31, 2018			Year ended December 31, 2017
Operating Activities	$	(285,848	)	$	(543,204	)	$	(1,130	)
Investing Activities	$	–		$	(176,177	)	$	–
Financing Activities	$	174,548		$	891,360		$	–
Net Effect on Cash	$	(111,300	)	$	171,979		$	(1,130	)

Operating Activities

The cash used in operating activities of $285,848 for the three months ended March 31, 2019, was primarily due to increased selling, general and administrative costs as the Company increased its operations during the current period. These outflows were partially offset by the cash inflows from sales activity during the current period.

The cash used in operating activities of $543,204 for the year ended December 31, 2018 was primarily due to increased selling, general and administrative costs as the Company increased its operations during the year.

Investing Activities

The cash used in investing activities of $176,177 during the year ended December 31, 2018 was due to costs incurred to build our website.

Financing Activities

The cash provided by financing activities of $174,548 during the three months ended March 31, 2019, was primarily from two convertible debt issuances, which provided proceeds of $188,000, offset by payments of debt issuance costs of $6,000 and payments on unsecured notes payable of $7,452.

The cash provided by financing activities of $891,360 during the year ended December 31, 2018 was primarily from sales of common stock for cash of $912,400.

Financing Needs

In order to fund our operations, including the further build-out of business and marketing plans, we rely upon direct investments, partnerships and joint ventures with accredited investors. Once the Company becomes profitable, we intend to fund our operations from free cash flow.

At present, the Company only has sufficient funds to conduct its operations for three to six months. There can be no assurance that additional financing will be available in amounts or on terms acceptable to the Company, if at all.

If we are not successful in generating sufficient liquidity from Company operations or in raising sufficient capital resources, on terms acceptable to us, this could have a material adverse effect on the Company’s business, results of operations liquidity and financial condition.

The Company presently does not have any available credit, bank financing or other external sources of liquidity. Due to its brief history and historical operating losses, the Company’s operations have not been a source of liquidity. The Company will need to obtain additional capital in order to expand operations and become profitable. In order to obtain capital, the Company may need to sell additional shares of its common stock or borrow funds from private lenders. There can be no assurance that the Company will be successful in obtaining additional funding.

The Company will need additional investments in order to continue operations. Additional investments are being sought, but the Company cannot guarantee that it will be able to obtain such investments. Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. In the event there is a downturn in the U.S. stock and debt markets, this could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if the Company is able to raise the funds required, it is possible that it could incur unexpected costs and expenses, fail to collect significant amounts owed to it, or experience unexpected cash requirements that would force it to seek alternative financing. Further, if the Company issues additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders.

USE OF PROCEEDS

Unless otherwise set forth in a prospectus supplement with respect to the proceeds from the sale of the particular securities to which such prospectus supplement relates, we intend to use the net proceeds from the sale of the offered securities for general corporate purposes, including repayment or redemption of outstanding debt or preferred stock (if any), the possible acquisition of related businesses or assets thereof, and working capital needs. We will not receive any of the proceeds from the sale of common stock being offered by the selling stockholders.

RATIO OF EARNINGS TO FIXED CHARGES

No shares of our preferred stock were outstanding during the fiscal years ended December 31, 2018, 2017 and 2016. Therefore, the ratios of earnings to fixed charges and preferred dividends are not separately stated from the ratios of earnings to fixed charges for the periods listed above. The table below reflects our ratio of earnings to fixed charges for each of the fiscal years ended December 31, 2018, 2017, 2016 and 2015, and for period from April 11, 2014 to December 31, 2014.

	For the Fiscal Years Ended December 31,				For the Period from April 11, 2014 to December 31,
	2018	2017	2016	2015	2014
Ratio of earnings to fixed charges	3,184	(1)	(2)	(3)	(4)

______________________

(1)

The ratio was less than 1:1 for the year ended December 31, 2018 as earnings were inadequate to cover fixed charges by approximately $2,228,620.

(2)

The ratio was less than 1:1 for the year ended December 31, 2017 as earnings were inadequate to cover fixed charges by approximately $102,865.

(3)

The ratio was less than 1:1 for the year ended December 31, 2016 as earnings were inadequate to cover fixed charges by approximately $61,000.

(4)

The ratio was less than 1:1 for the year ended December 31, 2015 as earnings were inadequate to cover fixed charges by approximately $63,000.

(5)

The ratio was less than 1:1 for the period from April 11, 2014 (inception) to December 31, 2014 as earnings were inadequate to cover fixed charges by approximately $98,000.

DESCRIPTION OF CAPITAL STOCK

The following description of our capital stock is only a summary and is qualified in its entirety by reference to our articles of incorporation and bylaws, each as amended, which have been filed as exhibits to the registration statement of which this prospectus forms a part.

General

We are authorized to issue 112,500,000 shares of common stock, with a par value of $0.001 per share, and 5,000,000 shares of preferred stock. Our articles of incorporation also authorize us to issue options, rights, warrants and appreciation rights relating to our common stock for the consideration and on the terms and conditions established by our board of directors in its sole discretion, whether in connection with acquisitions or otherwise. As of December 31, 2018, 29,638,900 shares of common stock were issued and outstanding and no shares of preferred stock were issued and outstanding. As of May 10, 2019, 30,781,400 shares of common stock were issued and outstanding and no shares of preferred stock were issued and outstanding.

Common Stock

Holders of common stock are each entitled to cast one vote for each share held of record on all matters presented to stockholders. Cumulative voting is not allowed; hence, the holders of a majority of our outstanding shares of common stock can elect all directors.

Holders of shares of our common stock are entitled to receive such dividends as may be declared by our board of directors out of funds legally available and, in the event of liquidation, to a pro rata portion of any distribution of our assets after payment of liabilities. Our directors are not obligated to declare dividends, and it is anticipated that no dividend will be paid in the foreseeable future.

Holders of shares of our common stock do not have preemptive rights to subscribe for any additional shares which may be issued in the future. There are no conversion, redemption, sinking fund or similar provisions regarding the common stock. All outstanding shares of common stock are fully paid and non-assessable.

Pursuant to an Amendment to the Articles of Incorporation, effected under NRS 78.207 and .209, the Company effected a 2.5 for 1 forward stock split of our number of authorized shares of the Common Stock and a corresponding increase in the number of issued and outstanding shares of Common Stock held by each stockholder of record as of February 8, 2018, the “Effective Date” of the forward split, as set by FINRA .

All shares referenced in this Prospectus have been retroactively adjusted to reflect this stock split.

Authorized but Unissued Capital Stock

Nevada law does not require stockholder approval for any issuance of authorized shares. These additional shares may be used for a variety of corporate purposes, including future public offerings to raise additional capital or to facilitate corporate acquisitions.

One of the effects of the existence of unissued and unreserved common stock (and/or preferred stock) may be to enable our board of directors to issue shares to persons friendly to current management, which issuance could render more difficult or discourage an attempt to obtain control of our board by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of our management and possibly deprive the stockholders of opportunities to sell their shares of our common stock at prices higher than prevailing market prices.

The description of certain matters relating to the securities of the Company is a summary and is qualified in its entirety by the provisions of the Company's Certificate of Incorporation and By-Laws.

Preferred Stock

Our articles of incorporation authorize our board of directors, without further stockholder action, to provide for the issuance of up to 5,000,000 shares of preferred stock, in one or more series, and to fix the number of shares of such series, and the preferences, rights and restrictions thereof. All shares of any one series of preferred stock shall be alike in every particular except as otherwise provided by our articles of incorporation or the Nevada Business Corporations Act. We may amend from time to time our articles of incorporation to increase the number of authorized shares of preferred stock in accordance with the Nevada Business Corporations Act.

The particular terms of any series of preferred stock that we offer under this prospectus will be described in the applicable prospectus supplement relating to that series of preferred stock. Those terms may include:

the title and liquidation preference per share of the preferred stock and the number of shares offered;

the purchase price of the preferred stock;

the dividend rate (or method of calculation), the dates on which dividends will be payable, whether dividends shall be cumulative and, if so, the date from which dividends will begin to accumulate;

any redemption or sinking fund provisions of the preferred stock;

any conversion, redemption or exchange provisions of the preferred stock;

the voting rights, if any, of the preferred stock; and

any additional dividend, liquidation, redemption, sinking fund and other rights, preferences, privileges, limitations and restrictions of the preferred stock.

If the terms of any series of preferred stock being offered differ from the terms set forth in this prospectus, those terms will also be disclosed in the applicable prospectus supplement relating to that series of preferred stock. The summary in this prospectus is not complete. You should refer to the certificate of designations establishing a particular series of preferred stock which will be filed with the Colorado Secretary and the SEC in connection with the offering of the preferred stock.

Each prospectus supplement may describe certain U.S. federal income tax considerations applicable to the purchase, holding and disposition of the preferred stock that prospectus supplement covers.

Options and Warrants

On January 16, 2019, pursuant to the Securities Purchase Agreement dated December 31, 2018, the Company issued a warrant to Bruce Lee Beverages, LLC (“BLB”) granting BLB the right to purchase 1,500,000 shares of the Company’s common stock at an exercise price of $1.01 per share. The warrant has a term of 2 years and expires on January 16, 2021.

In March 2019, the Company entered into an agreement with a contractor for services. This contractor may earn a total of 1,000,000 shares of common stock and 2,000,000 warrants to purchase common stock. The contractor can elect to extend the term for an additional year with 90 days’ notice. Of the total awards, 250,000 shares and 334,000 warrants were earned upon execution of the agreement, with the 250,000 shares being issued in April 2019. The warrants were issued March 29, 2019 and have an exercise price of $1.50 per share, and an initial term of 3 years from the date of issuance. The remaining shares and warrants vest upon completion of certain performance-related milestones.

Please see NOTE 6 - STOCKHOLDERS’ DEFICIT for further information.

Anti-Takeover Effects of our Articles of Incorporation and Bylaws

Certain provisions of our articles of incorporation and bylaws may have the effect of delaying, deferring or preventing a change in control of the Company. Such provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. In particular, our articles of incorporation and bylaws, among other things, provide the board of directors with the ability to alter the bylaws without stockholder approval; provide that vacancies on the board of directors may be filled by a majority of directors in office, although less than a quorum; and, as discussed above, authorize our board of directors, without further stockholder action, to provide for the issuance of up to 5,000,000 shares of preferred stock , and to fix the number of shares of such series, and the preferences, rights and restrictions thereof. The existence of authorized but unissued preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of the Company by means of a merger, tender offer, proxy contest or otherwise.

Quotation on OTCQB

Our common stock is quoted by the OTC Markets Group’s OTCQB under the symbol “VCBD”.

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is VStock Transfer, 18 Lafayette Place, Woodmere,NY 11598. Tel: 212-828-8436.

DESCRIPTION OF WARRANTS

We may issue warrants, in one or more series, for the purchase of common stock, preferred stock or debt securities. Warrants may be issued independently or together with our common stock, preferred stock or debt securities and may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement. In addition to this summary, you should refer to the relevant prospectus supplement and the detailed provisions of the relevant warrant agreement for complete terms of the warrants and the warrant agreement. Unless otherwise specified in a prospectus supplement accompanying this prospectus, each warrant agreement will be between us and a banking institution organized under the laws of the United States or a state thereof as warrant agent. In connection with an offering of our warrants, a form of warrant agreement will be filed with the SEC as an exhibit to the registration statement by post-effective amendment or to a Current Report on Form 8-K.

Warrants will be evidenced by warrant certificates. Unless otherwise specified in the applicable prospectus supplement, the warrant certificates may be traded separately from the debt securities, preferred stock or common stock, if any, with which the warrant certificates were issued. Warrant certificates may be exchanged for new warrant certificates of different denominations at the office of an agent that we will appoint. Until a warrant is exercised, the holder of a warrant will not have any of the rights of a holder of our debt securities, preferred stock or common stock and will not be entitled to any payments on any debt securities, preferred stock or common stock issuable upon exercise of the warrants.

The prospectus supplement relating to a particular series of warrants to issue debt securities, preferred stock or common stock will describe the terms of those warrants, including the following, where applicable:

the title and the aggregate number of warrants;

the offering price for the warrants (if any);

the designation and terms of the securities purchasable upon exercise of the warrants;

the dates on which the right to exercise such warrants commence and expire;

the price or prices at which such warrants are exercisable;

the currency or currencies in which the offering price (if any) and the exercise price for such warrants are payable;

the periods during which and the places at which such warrants are exercisable;

the date (if any) on and after which such warrants and the securities purchasable upon exercise of such warrants will be separately transferable;

the redemption or call provisions (if any) applicable to the warrants;

the identity of the warrant agent;

the exchanges (if any) on which such warrants may be listed;

information with respect to book-entry procedures, if any;

a discussion of material U.S. federal income tax considerations; and

any other terms of or material information about such warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.

SELLING STOCKHOLDERS

This prospectus also relates to the possible resale by certain of our stockholders, who we refer to in this prospectus as the “selling stockholders,” from time to time of up to an aggregate of 3,571,400 shares of our common stock. When we refer to “selling stockholders” in this prospectus, we mean the stockholders listed in the table below, and any pledgees, donees, permitted transferees, assignees, successors and others who later come to hold any of the selling stockholders’ interest in our securities other than through a public sale.

The following table sets forth, as of the date of this prospectus:

Name of Shareholder	Total Shares	Percent Owned
RACHEL T GOLDBERG	5,000	0.02%
KARTHIK CHIDAMBARAM	10,000	0.03%
CURTIS SLATER	5,000	0.02%
DAVID W. ROCK	20,000	0.06%
TED MCCANN	5,000	0.02%
CLEAN CULTURE LABORATORIES LLC	100,000	0.32%
JAMES P. MEYERS	50,000	0.16%
DAN HOLLAND	15,000	0.05%
PHILIP B. DEMBO	10,000	0.03%
NICHOLAS T. CULLEN JR.	10,000	0.03%
STACY BROVITZ	40,000	0.13%
CHRISTOPHER MOBLEY	6,000	0.02%
COHN FAMILY TRUST	300,000	0.97%
DONALD F. ERNST	5,000	0.02%
AARON OLIVER	5,000	0.02%
COAST BRANDS GROUP, LLC	40,000	0.13%
ANTOINE KUNSCH	2,500	0.01%
STEPHEN R. BLASS	5,000	0.02%
ELIZABETH R DEMBO	5,000	0.02%
SEAN CHAWLA	7,500	0.02%
MICHAEL MILLER	5,000	0.02%
JONATHAN GOODMAN	20,000	0.06%
THE 2003 THOMAS EDWARD NOLAN	5,000	0.02%
EUGENE TSAI	5,000	0.02%
JERRY DAUDERMAN	40,000	0.13%
JUSTIN M DEMBO	5,000	0.02%
THOMAS ANDREW KUSTRA	5,000	0.02%
ANDREW PARK	5,000	0.02%
KEVIN LUCIER	300,000	0.97%
NORMAN MARK INGEBRIGTSEN	20,000	0.06%
ADAM D GOLDBERG	5,000	0.02%
THOMAS E. NOLAN	20,000	0.06%
SKYE BREILING	25,000	0.08%
STEPHANIE MARTIN	30,000	0.10%
FISCHLER FAMILY TRUST	25,000	0.08%
MANOJ CHAWLA AND NIKITA S. CHAWLA	7,500	0.02%

STEVE C. ROBERTS	1,400	0.00%
LIFE STRATEGIES LLC	10,000	0.03%
GREGORY CHAMBERS	200,000	0.65%
ORAN ARAZI-GAMLIEL	40,000	0.13%
KATHARINE GARDNER	2,000	0.01%
KINGDOM BUILDING, INC.	125,000	0.41%
JONATHAN SACKS	5,000	0.02%
DAVID HARPER	10,000	0.03%
TRITON FUNDS LLC	35,000	0.11%
WILLIAM K. YATES	15,000	0.05%
JEFF HARDEN	5,000	0.02%
CHARLES J. GROUX	25,000	0.08%
THE DAVE WENTZ FAMILY TRUST	160,000	0.52%
HELGA ARMINAK	250,000	0.81%
BRIAN LOWES	20,000	0.06%
CHRISTOPHER BLASS	5,000	0.02%
MICHELE MCDONOUGH	2,000	0.01%
MICHELE L. GROUX	20,000	0.06%
JOHNNIE B BAKER JR. AND MELISSA G BAKER REVOCABLE TRUST	250,000	0.81%
GERRY WONG	150,000	0.49%
JOHN MICHAEL ANDERSON	50,000	0.16%
ROBERT J. MCLEOD	20,000	0.06%
BRUCE LEE BEVERAGE, LLC	500,000	1.62%
NANCY WILCOX	2,500	0.01%
UGLY SOAP COMPANY LLC	500,000	1.62%

Total shares of selling stockholders	3,571,400	11.60%
Total outstanding shares as of May 10, 2019	30,781,400	100%

the name of the selling stockholders for whom we are registering shares of our common stock for resale to the public;

the number of shares of our common stock that the selling stockholders beneficially owned prior to the offering for resale of such shares of common stock under this prospectus;

the number of shares of common stock that may be offered for resale for the account of the selling stockholders pursuant to this prospectus; and

the number and percentage of shares of common stock to be beneficially owned by the selling stockholders after completion of the offering of such shares of common stock (assuming that all shares of common stock being registered under the registration statement of which this prospectus forms a part that are held by the selling stockholders are resold to third parties).

On March 29, 2019, the Company entered into an agreement with a contractor for services. This contractor may earn a total of 1,000,000 shares of common stock and 2,000,000 warrants to purchase common stock. The contractor can elect to extend the term for an additional year with 90 days’ notice. Of the total awards, 250,000 shares and 334,000 warrants were earned upon execution of the agreement, with the 250,000 shares being issued in April 2019. The warrants were issued March 29, 2019 and have an exercise price of $1.50 per share, and an initial term of 3 years from the date of issuance. The remaining shares and warrants vest upon completion of certain performance-related milestones.

Shares Beneficially
owned Prior
to this Offering

Number of Shares Being

Beneficial Ownership
After the Offering (3)

Name of Selling Stockholder

Number(1)

Percentage

Offered (2)

Number

Percentage

Bruce Lee Beverage, LLC

500,000

1.62%

500,000

1.62%

Johnnie B. Baker Jr. and Melissa G. Baker Revocable Trust

250,000

__________________________

Represents beneficial ownership of less than one percent of our outstanding common stock.

(1)

Includes warrants to acquire shares of our common stock that are being registered pursuant to the registration statement of which this prospectus forms a part. Except as otherwise indicated in these footnotes, each of the beneficial owners listed has, to our knowledge, sole voting and investment power with respect to the indicated shares of common stock.

(2)

Assumes exercise of all of the holder’s warrants to acquire shares of our common stock that are being registered pursuant to the registration statement of which this prospectus forms a part.

(3)

Assumes all offered shares are sold. The registration of the shares subject to the registration statement of which this prospectus forms a party does not mean that the selling stockholders will sell all or any portion of the shares covered by this prospectus.

The information set forth above is based upon information obtained from the selling stockholders and upon information in our possession regarding the issuance of shares of common stock and warrants to the selling stockholders in connection with private placement transactions. The percentages of shares beneficially owned after completion of the offering are based on 30,781,400 shares of our common stock outstanding as of May 10, 2019. None of the selling stockholders has within the past three years had any position, office or other material relationship with us or any of our subsidiaries other than as a holder of shares of our common stock or warrants.

SELLING WARRANT HOLDERS

This prospectus also relates to the possible resale by our Warrant Holder, who we refer to in this prospectus as the “selling warrant holder,” from time to time of up to an aggregate of up to 1,500,000 common stock purchase warrants. When we refer to “selling warrant holder” in this prospectus, we mean the stockholders listed in the table below, and any pledgees, donees, permitted transferees, assignees, successors and others who later come to hold any of the selling stockholders’ interest in our securities other than through a public sale.

The following table sets forth, as of the date of this prospectus:

the name of the selling stockholders for whom we are registering shares of our common stock for resale to the public;

the number of shares of our common stock that the selling stockholders beneficially owned prior to the offering for resale of such shares of common stock under this prospectus;

the number of shares of common stock that may be offered for resale for the account of the selling stockholders pursuant to this prospectus; and

On December 31, 2018, the Company entered into an Agreement with Bruce Lee Beverage LLC (“BLB”). As per the terms of the Agreement, the Company issued Five Hundred Thousand shares (500,000) of the Company’s common stock, with 350,000 shares issued on December 31, 2018 and 150,000 issued on January 16, 2019. On March 29, 2019, the Company entered into an agreement with a contractor for services. This contractor may earn a total of 1,000,000 shares of common stock and 2,000,000 warrants to purchase common stock. The contractor can elect to extend the term for an additional year with 90 days’ notice. Of the total awards, 250,000 shares and 334,000 warrants were earned upon execution of the agreement, with the 250,000 shares being issued in April 2019. The warrants were issued March 29, 2019 and have an exercise price of $1.50 per share, and an initial term of 3 years from the date of issuance. The remaining shares and warrants vest upon completion of certain performance-related milestones.

	Warrants Beneficially owned Prior to this Offering		Number of Warrants Being	Beneficial Ownership After the Offering (3)
Name of Selling Warrantholder	Number(1)	Percentage	Offered (2)	Number	Percentage
Bruce Lee Beverage, LLC	1,500,000	42.9%	1,500,000	1,500,000	42.9%
Johnnie B. Baker Jr. and Melissa G. Baker Revocable Trust	2,000,000	57.1%	2.000,000	2.000,000	57.1%

___________________

(1)

Includes warrants to acquire shares of our common stock that are being registered pursuant to the registration statement of which this prospectus forms a part.

(2)

Assumes exercise of all of the holder’s warrants to acquire shares of our common stock that are being registered pursuant to the registration statement of which this prospectus forms a part.

(3)

Assumes all offered Warrants are sold. The registration of the warrants subject to the registration statement of which this prospectus forms a party does not mean that the selling ant holder will sell all or any portion of the Warrants. covered by this prospectus.

PLAN OF DISTRIBUTION

We or the selling stockholders may sell the securities in one or more of the following ways from time to time:

to or through underwriters or dealers;

directly to one or more purchasers;

through agents;

through a combination of any of these methods of sale; or

any other method permitted pursuant to applicable law.

We or the selling stockholders may also sell securities, including shares of our common stock, in one or more of the following transactions: (i) block transactions (which may involve crosses) in which a broker-dealer may sell all or a portion of such shares as agent, but may position and resell all or a portion of the block as principal to facilitate the transaction; (ii) purchases by any such broker-dealer as principal, and resale by such broker-dealer for its own account pursuant to an accompanying prospectus supplement; (iii) a special offering, an exchange distribution or a secondary distribution in accordance with applicable OTCQB or other stock exchange, quotation system or over-the-counter market rules; (iv) ordinary brokerage transactions and transactions in which any such broker-dealer solicits purchasers; (v) sales “at the market” to or through a market maker or into an existing trading market, on an exchange or otherwise, for such shares; and (vi) sales in other ways not involving market makers or established trading markets.

For each offering of securities, the applicable prospectus supplement or other offering materials relating to the offering will set forth the terms of such offering, including:

the name or names of any underwriters, dealers or agents;

the purchase price of the offered securities and the net proceeds to VCBD from the sale;

any underwriting discounts and commissions or agency fees and other items constituting underwriters’ or agents’ compensation; and

any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers; and

any securities exchanges on which such offered securities may be listed.

Any initial public offering prices, discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time.

If underwriters are used in the sale, the underwriters will acquire the offered securities for their own account and may resell them from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. The offered securities may be offered either to the public through underwriting syndicates represented by one or more managing underwriters or by one or more underwriters without a syndicate. Unless otherwise set forth in a prospectus supplement, the obligations of the underwriters to purchase any series of securities will be subject to certain conditions precedent, and the underwriters will be obligated to purchase all of such series of securities, if any are purchased.

In connection with underwritten offerings of the offered securities and in accordance with applicable law and industry practice, underwriters may over-allot or effect transactions that stabilize, maintain or otherwise affect the market price of the offered securities at levels above those that might otherwise prevail in the open market, including by entering stabilizing bids, effecting syndicate covering transactions or imposing penalty bids, each of which is described below:

a stabilizing bid means the placing of any bid, or the effecting of any purchase, for the purpose of pegging, fixing or maintaining the price of a security;

a syndicate covering transaction means the placing of any bid on behalf of the underwriting syndicate or the effecting of any purchase to reduce a short position created in connection with the offering; and

a penalty bid means an arrangement that permits the managing underwriter to reclaim a selling concession from a syndicate member in connection with the offering when offered securities originally sold by the syndicate member are purchased in syndicate covering transactions.

These transactions may be effected on the OTC Markets Group’s OTCQB or otherwise. Underwriters are not required to engage in any of these activities, or to continue such activities if commenced.

If a dealer is used in the sale, VCBD will sell such offered securities to the dealer, as principal. The dealer may then resell the offered securities to the public at varying prices to be determined by that dealer at the time for resale. The names of the dealers and the terms of the transaction will be set forth in the prospectus supplement relating to that transaction.

Offered securities may be sold directly by VCBD or the selling stockholders to one or more institutional purchasers, or through agents designated by VCBD or the selling stockholders from time to time, at a fixed price or prices, which may be changed, or at varying prices determined at the time of sale. Any agent involved in the offer or sale of the offered securities in respect of which this prospectus is delivered will be named, and any commissions payable by VCBD or the selling stockholders to such agent will be set forth, in the prospectus supplement relating to that offering. Unless otherwise indicated in such prospectus supplement, any such agent will be acting on a best -efforts basis for the period of its appointment.

In compliance with the guidelines of the Financial Industry Regulatory Authority, Inc. (“FINRA”), the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate proceeds of the offering.

Underwriters, dealers and agents may be entitled under agreements entered into with us or the selling stockholders to indemnification by us or the selling stockholders against certain civil liabilities, including liabilities under the Securities Act, or to contribution with respect to payments that the underwriters, dealers or agents may be required to make in respect thereof. Underwriters, dealers and agents may be customers of, engage in transactions with, or perform services for us and our affiliates, or for the selling stockholders, in the ordinary course of business.

The selling stockholders may also sell all or a portion of their shares in reliance upon Rule 144 under the Securities Act or Section 4(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of those provisions. The selling stockholders may also transfer, devise or gift such shares by other means not described in this prospectus. The selling stockholders are not obligated to, and there is no assurance that the selling stockholders will, sell all or any of the shares of common stock we are registering.

Other than our common stock, which is quoted on the OTC Markets Group’s OTCQB, each of the securities issued hereunder will be a new issue of securities, will have no prior trading market, and may or may not be listed on a national securities exchange. Any common stock sold pursuant to a prospectus supplement will be quoted on the OTC Markets Group’s OTCQB, subject to official notice of issuance. Any underwriters to whom VCBD or the selling stockholders sell securities for public offering and sale may make a market in the securities, but such underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot assure you that there will be a market for the offered securities.

LEGAL MATTERS

Unless otherwise stated in an accompanying prospectus supplement, Michael J. Morrison, Chtd., Reno, NV , will provide us with an opinion as to the legality of the securities offered under this prospectus. Counsel representing any underwriters, dealers or agents will be named in the applicable prospectus supplement.

EXPERTS

The financial statements of Vitalibis, Inc. as of and for the year ended December 31, 2017, and as of and for the year ended December 31, 2018, have been incorporated herein in reliance upon the report (which contain an explanatory paragraph relating to our ability to continuing as a going concern) of MaloneBailey, LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as expert in accounting and auditing.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Critical Accounting Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows. See the Notes to the Financial Statements for more information.

DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS, AND CONTROL PERSONS

Directors and Executive Officers

Name and Address of Beneficial Owner of Shares of Common Stock	Amount and Nature of Beneficial Ownership (1)(3)(4)		Percentage of Outstanding Shares of Common Stock (2)
Steve Raack , , **, 3960 Howard Hughes Parkway, Suite 500 Las Vegas, NV 89169		7,500,000		24.4%

Thomas Raack , , **, 3960 Howard Hughes Parkway, Suite 500 Las Vegas, NV 89169		7,500,000		24.4%

B.L.U.E. Stone Ltd. * B1-214 AJMAN FREE ZONE BOX 16881 HMTFZC UNITED ARAB EMIRATES		7,500,000		24.4%

_____________________________

(1)

Unless otherwise indicated, all shares are owned directly by the beneficial owner.

(2)

Based on 30,781,400 shares of common stock issued and outstanding as of May 10, 2019

(3)

Unless otherwise indicated, none of these shares are known to be shares with respect to which such listed beneficial owner has the right to acquire beneficial ownership.

(4)

Unless otherwise indicated, none of these shares are known to be shares that are (a) pledged as security or (b) with respect to which such persons have the right to acquire beneficial ownership.

each person known to the Company to be the record or beneficial owner of 5% or more of the Company's common stock

each director of the Company

***

each of the named executive officers

****

all executive officers and directors of the Company as a group

Changes in Control

As of December 31, 2018, there are no existing arrangements, known to the Company, i ncluding any pledge by any person of securities of the Company or any of its parents, the operation of which may at a subsequent date result in a change in control of our Company.

Family Relationships

Steven Raack and Thomas Raack are brothers.

EXECUTIVE COMPENSATION

The following summary compensation table sets forth the total annual compensation paid or accrued by us to or for the account of our principal executive officer during the last completed fiscal year and each other executive officer whose total compensation exceeded $100,000 in either of the last two fiscal years:

Summary Compensation Table

Name and Principal				Stock	Option	Non-Equity Incentive Plan	Change in Pension Value & Non-Qualified Deferred Compensation	All Other
Position	Year	Salary($)	Bonus($)	Awards($)	Awards($)	Compensation($)	Earnings($)	Compensation($)	Total($)
		(a)	(b)	(c)	(d)(2)			(e)
Steve Raack President, CEO and Director(1)	2018	90,000	0	0	0	0	0	0	90,000

Thomas Raack
Director, Secretary, Treasurer and Chief Financial Officer (1)	2018	115,000	0	0	0	0	0	0	115,000

__________________________

(1)

Steve Raack and Thomas Raack each own 7,500,000 shares of the Company’s restricted Common Stock.

Equity Compensation, Pension or Retirement Plans

No retirement, pension, profit sharing, stock option or insurance programs or other similar programs have been adopted by the Company for the benefit of its employees.

Audit Committee

Presently, our Board of Directors is performing the duties that would normally be performed by an audit committee. We intend to form a separate audit committee, and plan to seek potential independent directors. In connection with our search, we plan to appoint an individual qualified as an audit committee financial expert.

Options/SARS Grants During Last Fiscal Year

None.

Directors’ Compensation

During our fiscal year ended December 31, 2018, we did not provide compensation to any of our directors for serving as a director. We currently have no formal plan for compensating our directors for their services in their capacity as directors, although we may elect to issue stock options to such persons from time to time. Directors are entitled to reimbursement for reasonable travel and other out-of-pocket expenses incurred in connection with attendance at meetings of our board of directors. Our board of directors may award special remuneration to any director undertaking any special services on our behalf other than services ordinarily required of a director.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

In March 2018, the Company issued 200,000 shares of common stock valued at $200,000 to acquire a license from VOTOCAST, INC. as discussed in Note 8 to our financial statements. It was determined to be a transaction with an entity under common control and the share issuance was determined to be a deemed distribution to the related party for the value of the shares in excess of the historical carry over basis of the asset.

During the year ended December 31, 2018, $200 of cash was contributed to the Company by the Chief Financial Officer to open the Company’s bank account.

During the year ended December 31, 2017, $2,754 of services were paid for and contributed to the Company by the current officers.

During the year ended December 31, 2017, the Company incurred operating expenses in the amount of $102,865, $92,851 of which was directly paid by Mr. Kok Chee LEE, the Chief Executive Officer of the Company at the time. On October 25, 2017 Mr. Kok Chee Lee forgave amounts owed to him which were recorded as a contribution to capital. As of December 31, 2018 and 2017, the Company owed $0 to Mr. Kok Chee LEE, respectively.

Corporate Governance and Director Independence.

The Company has not:

Established its own definition for determining whether its directors and nominees for directors are "independent". We currently use NASDAQ's general definition for determining director independence, which states that "independent director" means a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship, that, in the opinion of the company's board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of the director.

Nor:

Established any committee of the board of directors.

Given the nature of the Company's business, its limited stockholder base and the current composition of management, the board of directors does not believe that the Company requires any corporate governance committees at this time.

As of the date hereof, the entire board serves as the Company's audit committee.

We have not entered into any transactions in which any of our directors, executive officers, or affiliates, including any member of an immediate family, had or are to have a direct or indirect material interest.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information, as of December 31, 2018, with respect to any person (including any “group”, as that term is used in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) who is known to us to be the beneficial owner of more than five percent (5%) of any class of our voting securities, and as to those shares of our equity securities beneficially owned by each of our directors and executive officers and all of our directors and executive officers as a group. Unless otherwise specified in the table below, such information, other than information with respect to our directors and executive officers, is based on a review of statements filed with the Securities and Exchange commission (the “Commission”) pursuant to Sections 13 (d), 13 (f), and 13 (g) of the Exchange Act with respect to our common stock. As of December 31, 2018, there were 29,638,900 shares of common stock outstanding. The number of common shares outstanding used in computing the percentages is 29,638,900.

The number of shares of common stock beneficially owned by each person is determined under the rules of the Commission and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares as to which such person has sole or shared voting power or investment power and also any shares which the individual has the right to acquire within sixty (60) days after the date hereof, through the exercise of any stock option, warrant or other right. Unless otherwise indicated, each person has sole investment and voting power (or shares such power with his or her spouse) with respect to the shares set forth in the following table. The inclusion herein of any shares deemed beneficially owned does not constitute an admission of beneficial ownership of those shares.

The table below shows the number of shares beneficially owned as of December 31, 2018 by each of our individual directors and executive officers, by other holders of 5% or more of the outstanding stock and by all our current directors and executive officers as a group.

	Common Stock
	Beneficially		Percentage of
Name of Beneficial Owner (1)	Owned		Common Stock (3)
Steve Raack (6)		7,500,000		25.3%

Thomas Raack (7)		7,500,000		25.3%

Larry McNabb (2, 4, 5)		7,500,000		25.3%
Officers and Directors as a Group		15,000,000		50.6%

______________________

(1)

Beneficial Ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. Shares of common stock subject to options, warrants, or convertible debt currently exercisable or convertible, or exercisable or convertible within 60 days of March 31, 2019 are deemed outstanding for computing percentage of the person holding such option or warrant but are not deemed outstanding for computing the percentage of any person. Percentages are based on a total of 29,638,900 shares of common stock outstanding on December 31, 2018, and the shares issuable upon exercise of options, warrants exercisable, and debt convertible on or within 60 days of March 31, 2019.

(2)

The 7,500,000 shares issued to Larry D. McNabb by the Company and the shares held in the name of B.L.U.E. Stone Ltd. *are not included within this Registration Statement.

(3)

The number of common shares outstanding used in computing the percentages is 29,638,900.

(4)

Larry McNabb is the beneficial owner of these shares, held in the name of B.L.U.E. Stone, Ltd.

(5)

The address for Larry McNabb B1-214 AJMAN FREE ZONE BOX 16881 HMTFZC UNITED ARAB EMIRATES

(6)

The address for Steve Raack is 3960 Howard Hughes Parkway, Suite 500, Las Vegas NV, 89169.

(7)

The address for Tom Raack is 3960 Howard Hughes Parkway, Suite 500, Las Vegas NV, 89169.

Options and Warrants

The Company has issued warrants to the persons and upon the terms below:

Name	Date of Issuance	Shares upon Issuance of warrants or options	Exercise Price	Expiration Date
Bruce Lee Beverages, LLC	January 16, 2019	1,500,000	$1.01	January 16, 2021
Johnnie B. Baker Jr. and Melissa G. Baker Revocable Trust	March 29, 2019	2,000,000	$1.50	March 29, 2022

________________________________

To date, no options have been issued by the Company, and no warrants or options have been issued under shareholder approved plans and no shareholder approved plans currently exist.

MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

OTC Bulletin Board Considerations

As discussed elsewhere in this registration statement, the Company’s common stock is currently traded on the OTCQB, under the symbol “VCBD”.

Holders

As of December 31, 2018, the approximate number of stockholders of record of the Common Stock of the Company was 1,083.

Dividend Policy

The Company has never declared or paid any cash dividends on its common stock. We currently intend to retain future earnings, if any, to finance the expansion of our business. As a result, we do not anticipate paying any cash dividends in the foreseeable future.

Indemnification for Securities Act Liabilities

Our Certificate of Incorporation provides to the fullest extent permitted by Florida Law that our directors or officers shall not be personally liable to us or our shareholders for damages for breach of such director’s or officer’s fiduciary duty. The effect of this provision of our Articles of Incorporation is to eliminate our rights and our shareholders (through shareholders’ derivative suits on behalf of our company) to recover damages against a director or officer for breach of the fiduciary duty of care as a director or officer (including breaches resulting from negligent or grossly negligent behavior), except under certain situations defined by statute. We believe that the indemnification provisions in our Articles of Incorporation, as amended, are necessary to attract and retain qualified persons as directors and officers.

Our By-Laws also provide that the Board of Directors may also authorize us to indemnify our employees or agents, and to advance the reasonable expenses of such persons, to the same extent, following the same determinations and upon the same conditions as are required for the indemnification of and advancement of expenses to our directors and officers. As of the date of this Registration Statement, the Board of Directors has not extended indemnification rights to persons other than directors and officers.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.

WHERE YOU CAN FIND MORE INFORMATION

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock we and the selling stockholders are offering by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our common stock, you should refer to the registration statement and to its exhibits. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document.

We are subject to the informational requirements of the Securities Exchange Act of 1934 and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC’s website at www.sec.gov. You may also read and copy any document we file with the SEC at its public reference facility at 100 F Street, N.E., Room 1580, Washington, D.C. 20549.

You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities.

LEGAL PROCEEDINGS

We know of no pending proceedings to which any director, member of senior management, or affiliate is either a party adverse to us or has a material interest adverse to us.

EXPERTS

The financial statements for the years ended December 31, 2018 and 2017 for Vitalibis, Inc. financial statements included in this prospectus and elsewhere in the registration statement have been audited by MaloneBailey, LLP., as indicated in its report with respect thereto, and are included herein in reliance upon the authority of said firm as experts in auditing and accounting in giving said reports.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

CORPORATE GOVERNANCE

Governance of Our Company

We seek to maintain high standards of business conduct and corporate governance, which we believe are fundamental to the overall success of our business, serving our shareholders well and maintaining our integrity in the marketplace. Our corporate governance guidelines and code of business conduct, together with our Articles of Incorporation, Bylaws and the charters for each of our Board committees, form the basis for our corporate governance framework. We also are subject to certain provisions of the Sarbanes-Oxley Act and the rules and regulations of the SEC. The full text of the Code of Conduct is available on our website at http://greatercannabiscompany.com/corporate-governance/.

Our Board of Directors

Our Board currently consists of one member. The number of directors on our Board can be determined from time to time by action of our Board.

Our Board believes its members collectively have the experience, qualifications, attributes and skills to effectively oversee the management of our Company, including a high degree of personal and professional integrity, an ability to exercise sound business judgment on a broad range of issues, sufficient experience and background to have an appreciation of the issues facing our Company, a willingness to devote the necessary time to their Board and committee duties, a commitment to representing the best interests of the Company and our stockholders and a dedication to enhancing stockholder value.

Risk Oversight. Our Board oversees the management of risks inherent in the operation of our business and the implementation of our business strategies. Our Board performs this oversight role by using several different levels of review. In connection with its reviews of the operations and corporate functions of our Company, our Board of Directors addresses the primary risks associated with those operations and corporate functions. In addition, our Board of Directors reviews the risks associated with our Company’s business strategies periodically throughout the year as part of its consideration of undertaking any such business strategies. Each of our Board committees also coordinates oversight of the management of our risk that falls within the committee’s areas of responsibility. In performing this function, each committee has full access to management, as well as the ability to engage advisors. The Board also is provided updated by the CEO and other executive officers of the Company on a regular basis.

Shareholder Communications. Although we do not have a formal policy regarding communications with the Board, shareholders may communicate with the Board by writing to us at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169 , Attention: Investor Relations or via e-mail communication at info@vitalibis.com. Shareholders who would like their submission directed to a member of the Board may so specify, and the communication will be forwarded, as appropriate. Please note that the foregoing communication procedure does not apply to (i) shareholder proposals pursuant to Exchange Act Rule 14a-8 and communications made in connection with such proposals or (ii) service of process or any other notice in a legal proceeding.

Board Committees

None.

VITALIBIS, INC.

FINANCIAL STATEMENTS

MARCH 31, 2019 AND DECEMBER 31, 2018

INDEX TO FINANCIAL STATEMENTS

Balance Sheets at March 31, 2019 and December 31, 2018 (unaudited)	F-2

Statements of Operations for the three months ended March 31, 2019 and 2018 (unaudited)	F-3

Statements of Changes in Shareholders' Equity (Deficit) for the three months ended March 31, 2019 and 2018 (unaudited)	F-4

Statements of Cash Flows for the three months ended March 31, 2019 and 2018 (unaudited)	F-5

Notes to Financial Statements (unaudited)	F-6

Report of Independent Registered Public Accounting Firm	F-13

Balance Sheets at December 31, 2018 and 2017	F-14

Statements of Operations for the years ended December 31, 2018 and 2017	F-15

Statements of Change in Shareholders' Equity (Deficit) for the years ended December 31, 2018 and 2017	F-16

Statements of Cash Flows for the years ended December 31, 2018 and 2017	F-17

Notes to Financial Statements	F-18

F- 1

VITALIBIS, INC.

BALANCE SHEETS

(UNAUDITED)

	March 31,			December 31,
	2019			2018

ASSETS
Current assets:
Cash	$	60,679		$	171,979
Accounts receivable, net		90			–
Prepaid expenses		59,374			60,608
Inventory		154,117			188,717

Total current assets		274,260			421,304

Long term assets
Website development, net		134,422			149,103

Total assets	$	408,682		$	570,407

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable and accrued liabilities	$	44,147		$	63,841
Deferred revenue		–			105,159
Unsecured notes payable		3,937			11,389
Convertible notes payable, net		187,688			–
Total current liabilities		235,772			180,389

Total liabilities		235,772			180,389

COMMITMENTS AND CONTINGENCIES

Stockholders' equity:
Preferred stock; $.001 par value, 5,000,000 shares authorized, none issued and outstanding		–			–
Common stock; $.001 par value, 112,500,000 shares authorized, 30,496,400 shares issued and outstanding and 29,638,900 shares issued outstanding as of March 31, 2019 and 2018, respectively		30,496			29,639
Additional paid-in capital		5,144,437			2,913,903
Accumulated deficit		(5,002,023	)		(2,553,524	)
Total stockholders’ equity		172,910			390,018

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	408,682		$	570,407

The accompanying notes are an integral part of these unaudited financial statements.

F- 2

VITALIBIS, INC.

STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED MARCH 31, 2019 AND 2018

(UNAUDITED)

	For the Three Months Ended
	March 31,
	2019			2018
Revenue	$	139,585		$	–
Cost of Goods Sold		(88,497	)		–

Gross Profit		51,088			–

Operating expenses:
Selling, general and administrative expenses		2,448,406			726,968
Professional fees		47,841			18,909

Loss from operations		(2,445,159	)		(745,877	)

Interest expense		(3,340	)		–

Loss before provision for income taxes		(2,448,499	)		(745,877	)
Provision for income taxes		–			–

Net loss	$	(2,448,499	)	$	(745,877	)

Net loss per common share – basic and diluted	$	(0.08	)	$	(0.03	)

Weighted average common shares outstanding – basic and diluted		30,165,622			27,314,589

The accompanying notes are an integral part of these unaudited financial statements.

F- 3

VITALIBIS, INC.

STATEMENTS OF CHANGE IN SHAREHOLDERS' EQUITY (DEFICIT)

FOR THE THREE MONTHS ENDED MARCH 31, 2019 AND 2018

(UNAUDITED)

	Share Capital				Additional
	Number of				paid-in		Accumulated
	Shares		Amount		capital		deficit			Total

Balance at December 31, 2018		29,638,900	$	29,639	$	2,913,903	$	(2,553,524	)	$	390,018

Shares and warrants issued for services		857,500		857		2,230,534		–			2,231,391
Net loss		–		–		–		(2,448,499	)		(2,448,499	)
Balance at March 31, 2019		30,496,400	$	30,496	$	5,144,437	$	(5,002,023	)	$	172,910

	Share Capital				Additional
	Number of				paid-in			Accumulated
	Shares		Amount		capital			deficit			Total

Balance at December 31, 2017		27,010,000	$	27,010	$	291,725		$	(324,904	)	$	(6,169	)

Shares issued for cash		301,000		301		300,699			–			301,000
Shares issued for services		600,000		600		712,394			–			712,994
Deemed distribution		200,000		200		(200	)		–			–
Contribution from shareholders		–		–		200			–			200
Net loss		–		–		–			(745,877	)		(745,877	)
Balance at March 31, 2018		28,111,000	$	28,111	$	1,304,818		$	(1,070,781	)	$	262,148

The accompanying notes are an integral part of the unaudited financial statements.

F- 4

VITALIBIS, INC.

STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2019 AND 2018

(UNAUDITED)

	For the Three Months Ended
	March 31,
	2019			2018
Cash flow from operating activities:
Net loss	$	(2,448,499	)	$	(745,877	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization expense		14,681			–
Amortization of debt discount		5,688			–
Stock based compensation		2,231,391			712,994
Changes in operating assets and liabilities:
Accounts receivable		(90	)		–
Prepaid expenses		1,234			–
Inventory		34,600			–
Deferred revenue		(105,159	)		–
Accounts payable and accrued liabilities		(19,694	)		15,296
Net cash used in operating activities		(285,848	)		(17,587	)

Cash flow from investing activities:
Purchase of assets		–			–
Net cash used by investing activities		–			–

Cash flow from financing activities:
Contribution of cash by officer		–			200
Proceeds from convertible debt issuance		188,000			–
Payment of deferred financing costs		(6,000	)		–
Repayments on unsecured notes payable		(7,452	)		–
Proceeds from equity issuance		–			301,000
Net cash provided by financing activities		174,548			301,200

NET CHANGE IN CASH		(111,300	)		283,613
CASH AT BEGINNING OF PERIOD		171,979			–
CASH AT END OF PERIOD	$	60,679		$	283,613

Supplemental disclosure of cash flow information:
Cash paid for interest	$	184		$	–
Cash paid for income taxes	$	–		$	–

Non-cash transactions
Common stock issued to officer for VOTOCAST license	$	–		$	200
Discount on convertible notes payable	$	21,000		$	–

The accompanying notes are an integral part of these financial statements.

F- 5

VITALIBIS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 – ORGANIZATION AND GOING CONCERN

Vitalibis, Inc. (the “Company”) was formed on April 11, 2014 as a Nevada corporation, under the name of Crowd 4 Seeds, Inc. We plan to focus on the development, sale and distribution of hemp oil-based products that contain naturally occurring cannabinoids, including cannabidiol ("CBD") and other products containing CBD-rich hemp oil (“Legal Hemp”). We leverage our proprietary technology platform to maximize our innovative micro-influencer sales model, which fosters engaged customer connections.

On January 18, 2018, our Board of Directors approved an agreement and plan of merger to merge with and into our wholly-owned subsidiary, Vitalibis, Inc., a Nevada corporation, and our name changed from Sheng Ying Entertainment Corp. to Vitalibis, Inc. Vitalibis, Inc. was formed solely to effect the change of name and conducted no operations.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has suffered recurring losses and generated negative cash flows from operations since inception. Due to these conditions, it raised substantial doubt about its ability to continue as a going concern. Management intends to finance operating costs over the next twelve months with existing cash on hand, loans, loans from directors and, or, the sale of common stock. The financial statements do not include any adjustments that may result should the Company be unable to continue as a going concern.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies followed in the preparation of the financial statements are as follows:

Basis of Presentation

The unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited financial statements contain all the adjustments necessary (consisting only of normal recurring adjustments) to present the financial position of the Company as of March 31, 2019 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2019 are not necessarily indicative of the operating results for the full fiscal year. These financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Notes to the financial statements which would substantially duplicate the disclosure contained in the audited financial statements for the most recent year ended December 31, 2018 have been omitted.

Inventories

Inventory is manufactured at third party facilities. Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.

F- 6

As of March 31, 2019 and December 31, 2018, inventory consists of the following components:

	March 31, 2019		December 31, 2018
Raw materials and supplies	$	9,108	$	1,836
Finished products		145,009		186,881

Total inventory	$	154,117	$	188,717

The Company recognized a prepaid expense of $21,917 and $30,431 related to purchases of inventory that had not yet transferred into the control of the Company as of March 31, 2019 and December 31, 2018, respectively.

Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606, Revenue From Contracts With Customers, which was adopted on January 1, 2018 using the modified retrospective method, with no impact to the Company’s comparative financial statements. Revenues are recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods or services. Revenue is recognized based on the following five step model:

•	Identification of the contract with a customer

•	Identification of the performance obligations in the contract

•	Determination of the transaction price

•	Allocation of the transaction price to the performance obligations in the contract

•	Recognition of revenue when, or as, the Company satisfies a performance obligation

All of the Company’s revenue is currently generated from the sales of similar products. As such no further disaggregation of revenue information is provided.

During the three months ended March 31, 2019, approximately $105,159, or 75%, of the Company’s sales were to a single customer.

Performance Obligations

Product sales are recognized all of the following criteria are satisfied: (i) a contract with an end user exists which has commercial substance; (ii) it is probable the Company will collect the amount charged to the end user; and (iii) the Company has completed its performance obligation whereby the end user has obtained control of the product. A contract with commercial substance exists once the Company receives and accepts a purchase order or once it enters into a contract with an end user. If collectibility is not probable, the sale is deferred and not recognized until collection is probable or payment is received. Control of products typically transfers when title and risk of ownership of the product has transferred to the customer. Payment is received before shipment of the product. Net revenues comprise gross revenues less customer discounts and allowances, actual and expected returns. Shipping charges billed to customers are included in net sales. Various taxes on the sale of products and enrollment packages to customers are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority. The Company allows for customers to return unopened products within 45 days. During the three months ended March 31, 2019, there were a trivial amount of refunds processed for returned product.

Contract Costs

Costs incurred to obtain a customer contract are not material to the Company. The Company elected to apply the practical expedient to not capitalize contract costs to obtain contracts with a duration of one year or less, which are expensed and included within cost of goods and services.

F- 7

Contract Liabilities

The Company may at times receive payment by credit card at the time customer places an order. Amounts received for undelivered product are considered a contract liability and are recorded as deferred revenue. As of March 31, 2019 and December 31, 2018, the Company had deferred revenue of $0 and $105,159, respectively, related to unsatisfied performance obligations.

Cost of Sales

Cost of sales includes all of the costs to purchase and assemble the Company’s products. Products are manufactured for the Company by third-party contractors, such costs represent the amounts invoiced by the contractors. Additionally, shipping costs are included in Cost of Sales in the Statements of Operations.

Selling, General and Administrative Expenses

Selling, general and administrative expenses include advertising and promotional costs and research and development costs. Also included in Selling, general and administrative expenses are stock-based compensation, certain warehousing fees, non-manufacturing overhead, personnel and related expenses, rent on operating leases, and professional fees.

Advertising and promotional costs are expensed as incurred and totaled $3,848 and $8,000 in the three months ended March 31, 2019 and 2018, respectively. Research and development costs are expensed as incurred. There were no research and development costs during the three months ended March 31, 2019 and 2018.

Website Development Cost

The Company capitalizes certain development costs associated with internal use software incurred during the application development stage. The Company expenses costs associated with preliminary project phase activities, training, maintenance and any post-implementation period costs as incurred. Capitalization of qualifying application development cost begins when management authorized and commits to funding the project and it is probable that the project will be completed for the function intended. Capitalized internal use software costs are normally amortized over estimated useful lives ranging from 2 to 5 years once the related project has been completed and deployed for customer use. At time the software is considered to have be an indefinite lived asset in which case it is evaluated for impairment at least annually. During the year ending December 31, 2018, the Company capitalized $176,177 related to software under the criteria discussed in this paragraph. These costs are related to the development of our website and customer portal. The Company amortizes capitalized costs over an estimated useful life of three years. Amortization expense for the three months ended March 31, 2019 was $14,681. There were no such costs related to the software during the three months ended March 31, 2018.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings and financial position.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company adopted this standard on January 1, 2019 using the modified retrospective method, and adopted the package of practical expedients that allows it to (i) not reassess whether an arrangement contains a lease, (ii) carry forward its lease classification as operating or capital leases and (iii) not reassess its previously recorded initial direct costs.. The Company made an accounting policy election to treat leases with a minimum term of 12 months or less as short-term leases. The adoption of ASC 842 had no impact to the Company’s consolidated financial statements, due to the Company’s current rental agreements for office space having minimum terms of less than 12 months. The Company currently has no right of use assets or liabilities recognized on its balance sheet related to lease agreements.

F- 8

The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

NOTE 3 – UNSECURED NOTE PAYABLE

During the year ended December 31, 2018, the Company entered into two insurance financing arrangements. The first agreement was for a value of $6,676, bearing an interest rate of 12.6%. The Company made a down payment of $1,988 and makes monthly payments of $549 through March 2019. There was no outstanding balance for this agreement as of March 31, 2019. The second agreement was for a value of $25,954, bearing an interest rate of 7.75%. The Company made a down payment of $6,676 and makes monthly payments of $1,997 through May 2019. The Company has a balance of $3,937 for this agreement as of March 31, 2019.

NOTE 4 – COMMITMENTS AND CONTINGENCIES

Our principal office is part of a group of executive suites. We pay $130 per month for our offices, on a month-to-month basis. In July 2018, the Company also began renting a shared office space for $175 per month on a month to month basis.

In April 2018, the Company entered into an agreement with a third party for a subscription to its e-commerce platform. The Company paid $3,000 for implementation and pays $2,000 per month, with an initial term of one year. After the initial term, the monthly fee may increase depending on the Company’s level of sales through the platform.

The Company has entered into three independent contractor agreements whereby the Company will pay each contractor $5,000 per month for a period of one year. These contractors may also receive shares of common stock depending on certain performance targets as discussed in Note 6.

NOTE 5 – CONVERTIBLE NOTES PAYABLE

On January 10, 2019, the Company entered into an unsecured convertible promissory note, with a principal amount of $126,000. The Company received net cash proceeds of $102,000 after an original issue discount of $21,000 and fees of $3,000. The convertible note bears interest at 8% and matures on January 10, 2020, with interest accruing at a rate of 22% if the Company is in default. Beginning six months after the issuance of the note, the holder may convert the note at any time through the maturity date into shares of common stock, to the extent and provided that no holder of these notes was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion. The conversion price is determined based on 85% of the lowest trading price during the 15 trading days prior to the conversion date. Unamortized discount and deferred financing costs were $18,739 as of March 31, 2019 related to this convertible note.

On February 7, 2019, the Company entered into an unsecured convertible promissory note, with a principal amount of $83,000. The Company received net cash proceeds of $80,000 after payment fees of $3,000. The convertible note bears interest at 8% and matures on February 7, 2020, with interest accruing at a rate of 22% if the Company is in default. Beginning six months after the issuance of the note, the holder may convert the note at any time through the maturity date into shares of common stock, to the extent and provided that no holder of these notes was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion. The conversion price is determined based on 65% of the lowest trading price during the 15 trading days prior to the conversion date. Unamortized discount and deferred financing costs were $2,573 as of March 31, 2019 related to this convertible note.

F- 9

NOTE 6 – STOCKHOLDERS’ DEFICIT

Common Stock

In March 2018, the Company issued 200,000 shares of common stock valued at $200,000 to acquire a license from VOTOCAST, INC. as discussed in Note 8. It was determined to be a transaction with an entity under common control and the share issuance was determined to be a deemed distribution to the related party for the value of the shares in excess of the historical carry over basis of the asset.

During the year ended December 31, 2018, the Company issued a total of 1,366,500 shares of common stock to consultants and recorded $1,463,207 of compensation cost. In addition, the Company committed to issue an additional 532,500 of shares that will vest at various dates through June 2019. The Company issued 300,000 of these shares during in February 2019, and there are 112,500 shares remaining that vest upon completion of certain milestones, including sales targets. For those shares that are based on performance targets, no expense was recognized as of December 31, 2018, as the targets being met is not considered probable. Stock-based compensation related to these awards during the three months ended March 31, 2019 was $39,922, and the Company may recognize an additional $528,675 of compensation cost under these agreements.

In January 2019, the Company entered into three agreements with contractors for services. The contractors may earn up to 377,500 shares depending on the completion of certain milestones and sales targets, through August 2019. Two contractors will also each receive $5,000 per month of cash compensation for a term of one year. The Company issued 2,500 shares related to one of these agreements in January 2019. The Company recognized expense of $3,000 related to the shares issued during the quarter, and expects to recognize an additional $506,350 of expense assuming all shares vest.

In February 2019, the Company entered into an agreement for advisory services, and issued 40,000 shares of common stock related to this agreement that vest equally over 12 months. The Company recognized expense of $14,133 related to the shares issued during the quarter, and expects to recognize an additional $70,667 of expense assuming all shares vest.

In February 2019, the Company entered into an agreement for marketing services, and issued 10,000 shares of common stock as compensation under the agreement, with $21,200 of expense recognized upon issuance.

In February 2019, the Company issued 30,000 shares of common stock related to advisory agreements entered into during the year ended December 31, 2018. The Company recognized expense of $37,600 during the three months ended March 31, 2019, and will recognize an additional $34,400 of expense related to these shares in future periods.

In March 2019, the Company entered into an agreement for consulting services, and issued 125,000 shares of common stock under the agreement for services to be provided over a one-year period. The Company recognized expense of $17,396 during the three months ended March 31, 2019, and will recognize an additional $191,354 of expense related to these shares in future periods.

In March 2019, the Company entered into an agreement with a contractor for services. This contractor may earn a total of 1,000,000 shares of common stock and 2,000,000 warrants to purchase common stock. The warrants have an exercise price of $1.50 per share, and an initial term of 3 years from the date of issuance. The contractor can elect to extend the term for an additional year with 90 days’ notice. Of the total awards, 250,000 shares and 334,000 warrants were earned upon execution of the agreement, with the 250,000 shares being issued in April 2019. The Company recognized $362,500 and $234,169 related to the initial shares and warrants vesting. The fair value of the warrants was estimated using the Black-Scholes option pricing model and the following assumptions: expected term of 4 years, risk-free interest rate of 2.22%, dividend yield of 0%, and volatility of 62.7%. The remaining shares and warrants vest upon completion of certain performance-related milestones. As of March 31, 2019, the Company expects to recognize additional compensation cost of $1,087,500 related to the shares and $1,168,041 related to the warrants, assuming all instruments vest.

On December 31, 2018, the Company entered into a business alliance agreement with Bruce Lee Beverage, LLC. (“BLB”). Under the terms of the agreement, the parties will develop a new product utilizing the intellectual property of BLB, with an initial term of five years and automatic five-year renewals thereafter, unless terminated by either party with 120 days’ prior written notice. The Company issued 150,000 shares of common stock to BLB on December 31, 2018, and an additional 350,000 shares in January 2019. The Company recognized expense of $581,000 for the shares issued in January 2019.

F- 10

The Company also issued 1,500,000 warrants in January 2019, with an exercise price of $1.01 per share, with 500,000 vesting upon issuance. BLB can receive up to an additional 1,000,000 shares of common stock, and vest in the remaining 1,000,000 warrants as follows:

500,000 shares of common stock and 500,000 warrants will vest upon approval of co-branded product formula (“New Product”), packaging and marketing strategy; execution of licensing agreement between the two parties; and commencement of a mutually agreed upon marketing campaign.

250,000 shares of common stock and 250,000 warrants will vest upon sale of 10,000 units of the New Product.

250,000 shares of common stock and 250,000 warrants will vest upon sale of 30,000 units of the New Product.

The fair value of the warrants was estimated using the Black-Scholes option pricing model and the following assumptions: expected term of 2 years, risk-free interest rate of 2.55%, dividend yield of 0%, and volatility of 60.1%. The company recognized $175,055 related to the warrants that vested in January 2019.

Additionally, management believes that the first milestone will be met during the second quarter of 2019, and during the three months ended March 31, 2019 recognized $615,583 and $129,833 of stock-based compensation expense for the shares and warrants, respectively, that are expected to vest upon completion of that milestone.

Under this agreement, the Company expects to recognize additional expense of $1,264,694 related to the 1,000,000 shares and 1,000,000 warrants which have not yet been issued or vested as of March 31, 2019, assuming all shares and warrants vest.

The following table summarizes all warrant activity for the three months ended March 31, 2019:

Common Stock Warrants

Weighted Average Exercise Price

Weighted average Remaining Life in years

Outstanding at December 31, 2018

–

Granted

3,500,000

1.29

3.1

Cancelled

–

Expired

–

Exercised

–

Outstanding at March 31, 2019

3,500,000

1.29

3.1

Exercisable at March 31, 2019

834,000

1.29

2.7

As of March 31, 2019, the outstanding and exercisable warrants had an intrinsic value of $660,000 and $220,000, respectively.

NOTE 7 – LOSS PER COMMON SHARE

The basic net loss per common share is calculated by dividing the Company's net loss available to common shareholders by the weighted average number of common shares during the year. The diluted net loss per common share is calculated by dividing the Company's net loss available to common shareholders by the diluted weighted average number of common shares outstanding during the year. The diluted weighted average number of common shares outstanding is the basic weighted number of common shares adjusted for any potentially dilutive debt or equity. Diluted net earnings (loss) per common share excludes any impact from the 3,500,000 warrants outstanding (including 834,000 that are exercisable as of March 31, 2019) as their impact would be antidilutive.

F- 11

	Three Months Ended March 31,
	2019			2018
Numerator:

Net loss	$	(2,448,499	)	$	(745,877	)

Denominator

Denominator for basic and diluted net loss per common share - weighted average of common shares		30,165,622			27,314,589

Basic and diluted net loss per common share attributed to stockholders	$	(0.08	)	$	(0.03	)

NOTE 8 – TRANSACTION WITH RELATED PARTIES

In March 2018, the Company entered into an Agreement with VOTOCAST, INC. dba newkleus, a California corporation formed and owned by Steven Raack, the President, CEO and a Director of the Company. The Company received an exclusive license in the cannabis industry for the state-of-the-art newkleus™ technology to (1) facilitate Vitalibis’ micro-influencer sales model, and (2) enhance and compliment Vitalibis’ social media strategy.

The Agreement grants Vitalibis™ an exclusive license for the newkleus patent-pending, user-generated content (UGC) technology for all applications in the cannabis industry. The integration of the newkleus technology allows Vitalibis to create an interactive digital community, while concurrently acquiring valuable user data and content, all of which Vitalibis anticipates will (1) increase customer acquisition and retention and (2) build direct, meaningful and loyal customer relationships.

The Company paid 200,000 shares upon execution of the agreement and a monthly fee ranging from $0 to $2,000 depending on volume of usage. In addition, newkleus provides operational and business development consulting services.

During the three months ended March 31, 2018, $200 of cash was contributed to the Company by the Chief Financial Officer to open the Company’s bank account.

NOTE 9 – SUBSEQUENT EVENTS

On March 29, 2019, the Company entered into an unsecured convertible promissory note, with a principal amount of $250,000. In April 2019, the Company received net cash proceeds of $200,000 after an original issue discount of $50,000. The convertible note bears interest at 8% and matures on September 30, 2019, with interest accruing at a rate of 22% if the Company is in default. Beginning at the issuance of the note, the holder may convert the note at any time through the maturity date into shares of common stock, to the extent and provided that no holder of these notes was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion. The conversion price is the lesser of $2 or 70% of the lowest trading price during the 30 trading days prior to the conversion date. On April 3, 2019, the Company issued 35,000 shares to this lender.

F- 12

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of

Vitalibis, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Vitalibis, Inc. (collectively, the “Company”) as of December 31, 2018 and 2017, and the related statements of operations, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Going Concern Matter

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provides a reasonable basis for our opinion.

/s/ MaloneBailey, LLP

www.malonebailey.com

We have served as the Company's auditor since 2016.

Houston, Texas

March 28, 2019

F- 13

VITALIBIS, INC.

BALANCE SHEETS

	December 31,			December 31,
	2018			2017

ASSETS
Current assets:
Cash	$	171,979		$	–
Prepaid expenses		60,608			–
Inventory		188,717			–

Total current assets		421,304			–

Long term assets
Website development, net		149,103			–


Total assets	$	570,407		$	–

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable and accrued liabilities	$	63,841		$	6,169
Deferred revenue		105,159			–
Unsecured notes payable		11,389			–
Total current liabilities		180,389			6,169

Total liabilities		180,389			6,169

COMMITMENTS AND CONTINGENCIES

Stockholders' equity (deficit):
Preferred stock; $.001 par value, 5,000,000 shares authorized, none issued and outstanding		–			–
Common stock; $.001 par value, 112,500,000 shares authorized, 29,638,900 shares issued and outstanding and 27,010,000 shares issued outstanding as of December 31, 2018 and 2017, respectively		29,639			27,010
Additional paid-in capital		2,913,903			291,725
Accumulated deficit		(2,553,524	)		(324,904	)
Total stockholders’ equity (deficit)		390,018			(6,169	)

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)	$	570,407		$	–

The accompanying notes are an integral part of these financial statements.

F- 14

VITALIBIS, INC.

STATEMENTS OF OPERATIONS

FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2017

	For the Years Ended
	December 31,
	2018			2017
Revenue	$	51,331		$	–
Cost of Goods Sold		(23,001	)		–

Gross Profit		28,330			–

Operating expenses:
Selling, general and administrative expenses		2,095,787			32,328
Professional fees		160,463			70,537

Loss from operations		(2,227,920	)		(102,865	)

Interest expense		(700	)		–
Other expenses, net		–			(39	)

Loss before provision for income taxes		(2,228,620	)		(102,904	)
Provision for income taxes		–			–

Net loss	$	(2,228,620	)	$	(102,904	)

Net loss per common share – basic and diluted	$	(0.08	)	$	(0.00	)

Weighted average common shares outstanding – basic and diluted		28,643,855			24,398,370

The accompanying notes are an integral part of these financial statements.

F- 15

VITALIBIS, INC.

STATEMENTS OF CHANGE IN SHAREHOLDERS' EQUITY (DEFICIT)

FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2017

	Share Capital						Additional
	Number of						paid-in			Accumulated
	Shares			Amount			capital			deficit			Total

Balance at December 31, 2016		22,635,000		$	22,635		$	199,365		$	(222,000	)	$	–

Shares returned and cancelled from prior management		(18,125,000	)		(18,125	)		18,125			–			–
Debt balance forfeited by prior management		–			–			93,981			–			93,981
Shares issued to new officers related to change of control		22,500,000			22,500			(22,500	)		–			–
Contributed services		–			–			2,754			–			2,754
Net loss		–			–			–			(102,904	)		(102,904	)
Balance at December 31, 2017		27,010,000			27,010			291,725			(324,904	)		(6,169	)

Shares issued for cash		912,400			912			911,488			–			912,400
Shares issued for services		1,516,500			1,517			1,710,690			–			1,712,207
Deemed distribution		200,000			200			(200	)		–			–
Contribution from shareholders		–			–			200			–			200
Net loss		–			–			–			(2,228,620	)		(2,228,620	)
Balance at December 31, 2018		29,638,900		$	29,639		$	2,913,903		$	(2,553,524	)	$	390,018

The accompanying notes are an integral part of the financial statements.

F- 16

VITALIBIS, INC.

STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 2018 AND 2017

	For the Years Ended
	December 31,
	2018			2017
Cash flow from operating activities:
Net loss	$	(2,228,620	)	$	(102,904	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization		27,074			–
Contributed services		–			2,754
Stock based compensation		1,712,207			–
Changes in operating assets and liabilities:
Prepaid expenses		(27,979	)		–
Inventory		(188,717	)		–
Deferred revenue		105,159			–
Accounts payable and accrued liabilities		57,672			6,169
Accounts payable - related parties		–			92,851
Net cash used in operating activities		(543,204	)		(1,130	)

Cash flow from investing activities:
Purchase of assets		(176,177	)		–
Net cash used by investing activities		(176,177	)		–

Cash flow from financing activities:
Contribution of cash by officer		200			–
Repayments on notes payable		(21,240	)		–
Proceeds from equity issuance		912,400			–
Net cash provided by financing activities		891,360			–

NET CHANGE IN CASH		171,979			(1,130	)
CASH AT BEGINNING OF PERIOD		–			1,130
CASH AT END OF PERIOD	$	171,979		$	–

Supplemental disclosure of cash flow information:
Cash paid for interest	$	700		$	–
Cash paid for income taxes	$	–		$	–

Non-cash transactions
Common stock issued to officer for VOTOCAST license	$	200		$	–
Notes payable issued for prepaid expenses	$	32,629		$	–
Debt balance forfeited by prior management	$	–		$	93,981

The accompanying notes are an integral part of these financial statements.

F- 17

VITALIBIS, INC.

NOTES TO FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND GOING CONCERN:

Vitalibis (the “Company”) was formed on April 11, 2014 as a Nevada corporation, under the name of Crowd 4 Seeds, Inc. We plan to focus on the development, sale and distribution of hemp oil-based products that contain naturally occurring cannabinoids, including cannabidiol ("CBD") and other products containing CBD-rich hemp oil (“Legal Hemp”). We leverage our proprietary technology platform to maximize our innovative micro-influencer sales model, which fosters engaged customer connections.

During 2014 the Company issued 9,054,000 shares of its common stock, for a total consideration of $20,000. On December 30, 2016, Tycoon Luck Global Limited acquired 65.72% of the equity interest of the Company from Itzhak Ostashinsky, the major shareholder and sole officer, at a consideration of $220,152 in cash and both parties agreed all the net liabilities of the Company as of the acquisition date are assumed by Itzhak Ostashinsky. On the same day, the new management team was appointed.

On January 9, 2017, the Company filed with Secretary of State of Nevada to change its name to Sheng Ying Entertainment Corp. On April 24, 2017, the Financial Industry Regulatory Authority (“FINRA”) approved the name change. The Company’s common stock symbol was also changed from CWWD to SALL, effective April 25, 2017.

On October 24, 2017, Kok Chee LEE resigned from his positions as CEO and director of the Company, and the Board of Directors of the Company appointed Thomas Raack as a director of the Company. On October 25, 2017, Siew Heok Ong resigned from his positions as director and CFO of the Company, and Sreyneang Jin resigned from her positions as director and COO of the Company. On October 26, 2017, Thomas Raack, the sole remaining director of the Company, appointed himself as the CEO, president and treasurer of the Company, and also terminated David E. Price as secretary and appointed himself as secretary of the Company.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies followed in the preparation of the financial statements are as follows:

Basis of Presentation :

The financial statements are prepared in accordance with accounting principles generally accepted ("GAAP") in the United States of America.

Use of Estimates

The preparation of the financial statements in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.

F- 18

Cash and Cash Equivalents

Cash and cash equivalents include short-term investments with original maturities of 90 days or less. The recorded value of our cash and cash equivalents approximates their fair value.

Inventories

As of December 31, 2018 and 2017, inventory consists of the following components:

	December 31, 2018		December 31, 2017
Raw materials and supplies	$	1,836	$	–
Finished products		186,881		–

Total inventory	$	188,717	$	–

The Company recognized a prepaid expense of $30,431 related to purchases of inventory that had not yet transferred into the control of the Company as of December 31, 2018.

Revenue Recognition

•	Identification of the contract with a customer

•	Identification of the performance obligations in the contract

•	Determination of the transaction price

•	Allocation of the transaction price to the performance obligations in the contract

•	Recognition of revenue when, or as, the Company satisfies a performance obligation

All of the Company’s revenue is currently generated from the sales of similar products. As such no further disaggregation of revenue information is provided.

Performance Obligations

F- 19

Contract Costs

Contract Liabilities

The Company may at times receive payment by credit card at the time customer places an order. Amounts received for undelivered product are considered a contract liability and are recorded as deferred revenue. As of December 31, 2018 and 2017, the Company had deferred revenue of $105,159 and $0, respectively, related to unsatisfied performance obligations. These performance obligations were satisfied during the first quarter of 2019.

Cost of Sales

Selling, General and Administrative Expenses

Advertising and promotional costs are expensed as incurred and totaled $66,563 and $0 in the years ended December 31, 2018 and 2017, respectively. Research and development costs are expensed as incurred and totaled $1,698 and $0 for the years ended December 31, 2018 and 2017, respectively.

Website Development Cost

The Company capitalizes certain development costs associated with internal use software incurred during the application development stage. The Company expenses costs associated with preliminary project phase activities, training, maintenance and any post-implementation period costs as incurred. Capitalization of qualifying application development cost begins when management authorized and commits to funding the project and it is probable that the project will be completed for the function intended. Capitalized internal use software costs are normally amortized over estimated useful lives ranging from 2 to 5 years once the related project has been completed and deployed for customer use. At time the software is considered to have be an indefinite lived asset in which case it is evaluated for impairment at least annually. For the year ending December 31, 2018, the Company capitalized $176,177 related to software under the criteria discussed in this paragraph. These costs are related to the development of our website and customer portal. The Company amortizes capitalized costs over an estimated useful life of three years. Amortization expense for the year ended December 31, 2018 was $27,074. There were no such costs related to the software during the year ended December 31, 2017.

Income Taxes

Deferred taxes are determined utilizing the "asset and liability" method, whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, when it's more likely than not that deferred tax assets will not be realized in the foreseeable future. Deferred tax liabilities and assets are classified as current or non-current based on the underlying asset or liability or if not directly related to and asset or liability based on the expected reversal dates of the specific temporary differences.

F- 20

Fair value of financial instruments

The Company discloses fair value measurements for financial and non-financial assets and liabilities measured at fair value. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but are corroborated by market data.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Stock-based Compensation

The Company measures the total amount of employee stock-based compensation expense for a grant based on the grant date fair value of each award and recognizes the stock-based compensation expense on a straight-line basis over the requisite service period for each separately vesting tranche of an award. Stock-based compensation is based on unvested outstanding awards. The Company has elected to recognize forfeitures when realized.

In the second quarter of 2018 the Company elected to adopt ASU 2018-07 which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. ASU 2018-07 requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year. Upon adoption the Company recorded an adjustment to the first quarter of 2018 of $188,165.

Related Parties

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings and financial position.

Recently Issued Accounting Pronouncements

In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted this standard as of January 1, 2018. The adoption of this standard did not have a significant impact on the Company’s financial statements.

F- 21

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). This ASU applies to all entities that are required to present a statement of cash flows under Topic 230. The amendments provide guidance on eight specific cash flow issues and includes clarification on how these items should be classified in the statement of cash flows and is designed to help eliminate diversity in practice as to where items are classified in the cash flow statement. Furthermore, in November 2016, the FASB issued additional guidance on this Topic that requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with earlier application permitted for all entities. The Company adopted this standard as of January 1, 2018. The adoption of this standard did not have a significant impact on the Company’s financial statements.

NOTE 3 – UNSECURED NOTE PAYABLE

During the year ended December 31, 2018, the Company entered into two insurance financing arrangements. The first agreement was for a value of $6,676, bearing an interest rate of 12.6%. The Company made a down payment of $1,988 and makes monthly payments of $549 through March 2019. The second agreement was for a value of $25,954, bearing an interest rate of 7.75%. The Company made a down payment of $6,676 and makes monthly payments of $1,997 through May 2019. These agreements resulted in prepaid expenses being recognized totaling $32,629.

NOTE 4 – COMMITMENTS AND CONTINGENCIES

NOTE 5 – STOCKHOLDERS’ DEFICIT

Common Stock

The Company effected a 2.5 for 1 forward stock split of our number of authorized shares of the Common Stock and a corresponding increase in the number of issued and outstanding shares of Common Stock held by each stockholder of record as of February 8, 2018, the “Effective Date” of the forward split, as set by the Financial Industry Regulatory Authority ( “FINRA” ). All shares referenced have been respectively adjusted to reflect this stock split.

On the Effective Date, our total authorized shares of Common Stock increased from 45,000,000 to 112,500,000 shares, and our total issued and outstanding shares of Common Stock increased from 10,804,000 to 27,010,000 shares; the par value of $0.001 will remain the same. Any fractional shares resulting from the split will be rounded up to the next whole number. The total authorized shares of our Preferred Shares will not be affected and will remain at 5,000,000.

Pursuant to the Asset Purchase Agreement, on December 18, 2017, we issued 22,500,000 shares of our restricted common stock as consideration for the purchase of assets, pursuant to the closing of an Asset Purchase Agreement. No cash was involved in the transaction. The asset transferred consisted of various intangible assets such as plans and know-how related to the proposed CBD-related products the Company plans to develop. Due to the change of control and related party nature of the transaction a carry-over basis was applied. There is no historical book value for the asset purchased so the Company assigned a value of $0 to the assets.

F- 22

The 22,500,000 shares were the sole consideration paid by the Company for the purchase of assets from the three (3) individual owners, on the basis of 7,500,000 shares each. Prior to issuance, Mr. Larry McNabb assigned all his rights, titles and interest in and to his 7,500,000 shares to B.L.U.E. Stone Ltd. The remaining 15,000,000 shares were issued equally to Steve Raack and Thomas Raack who serve as officers and directors of the Company. At this point, the 22,500,000 shares represented control of 83.3% of the total issued and outstanding shares of the Company and constituted control of the C ompany.

Related to the issuance above, on December 18, 2017, the following four (4) separate shareholders of the Company, in furtherance of a change-of-control transaction, discussed above, voluntarily surrendered to the transfer agent a total of 18,125,000 restricted shares for cancellation:

Shareholder	Number of Shares
Tycoon – Luck Global Ltd.	14,875,000 shares
LWH Biomass Sdn Bhd	1,000,000 shares
Yuping Wang	1,125,000 shares
Yujie Wang	1,125,000 shares

During the year ended December 31, 2018, the Company sold 912,400 shares of its restricted common stock at a price of $1.00 per share, for total net proceeds of $912,400.

During the year ended December 31, 2018, the Company issued a total of 1,366,500 shares of common stock to consultants, and recorded $1,463,207 of compensation cost. In addition, the Company committed to issue an additional 532,500 of shares that will vest at various dates through June 2019. Certain of these shares vest upon completion of certain milestones, including sales targets. For those shares that are based on performance targets, no expense was recognized as of December 31, 2018, as the targets being met is not considered probable. Unrecognized compensation cost related to the share issuances (assuming all shares will vest) was $644,199 as of December 31, 2018.

On December 31, 2018, the Company entered into a business alliance agreement with Bruce Lee Beverage, LLC. (“BLB”). Under the terms of the agreement, the parties will develop a new product utilizing the intellectual property of BLB, with an initial term of five years and automatic five-year renewals thereafter unless terminated by either party with 120 days’ prior written notice. The Company issued 150,000 shares of common stock to BLB on December 31, 2018, and an additional 350,000 shares in January 2019. The Company recognized expense of $249,000 for the shares issued in December 2018.

500,000 shares of common stock and 500,000 warrants will vest upon approval of co branded product formula, packaging and marketing strategy; execution of licensing agreement between the two parties; and commencement of a mutually agreed upon marketing campaign.

250,000 shares of common stock and 250,000 warrants will vest upon sale of 10,000 units of the new product.

250,000 shares of common stock and 250,000 warrants will vest upon sale of 30,000 units of the new product.

Under this agreement, the Company expects to recognize expense of $2,241,000 related to the 1,350,000 shares which have not yet been issued as of December 31, 2018.

F- 23

NOTE 6 – LOSS PER COMMON SHARE

The basic net loss per common share is calculated by dividing the Company's net loss available to common shareholders by the weighted average number of common shares during the year. The diluted net loss per common share is calculated by dividing the Company's net loss available to common shareholders by the diluted weighted average number of common shares outstanding during the year. The diluted weighted average number of common shares outstanding is the basic weighted number of common shares adjusted for any potentially dilutive debt or equity. Diluted net earnings (loss) per common share are the same as basic earnings (loss) per common share due to the lack of dilutive items in the Company.

	Year ended December 31,			Year ended December 31,
	2018			2017
Numerator:

Net loss	$	(2,228,620	)	$	(102,904	)

Denominator

Denominator for basic and diluted net loss per common share - weighted average of common shares		28,643,855			24,398,370

Basic and diluted net loss per common share attributed to stockholders	$	(0.08	)	$	(0.00	)

NOTE 7 – INCOME TAXES

Deferred taxes are determined by applying the provisions of enacted tax laws and rates for the jurisdictions in which the Company operates to the estimated future tax effects of the differences between the tax basis of assets and liabilities and their reported amounts in the Company's financial statements. A valuation allowance is established to reduce deferred tax assets if it is more likely than not that the related tax benefits will not be realized. Significant components of the Company's deferred tax assets are as follows:

	Year ended December 31,			Year ended December 31,
	2018			2017

Net operating loss carry forward	$	(2,228,000	)	$	(264,000	)
Non-deductible expenses		1,712,000			256,000
Net operation loss carry forward		(516,000	)		(8,000	)


		As of December 31, 2018			As of December 31, 2017
Deferred tax asset before valuation allowance		110,000			1,500
Valuation allowance		(110,000	)		(1,500	)
Net deferred tax asset	$	–		$	–

Management currently believes that since the Company has a history of losses it is more likely than not that the deferred tax regarding the loss carry forwards and other temporary differences will not be realized in the foreseeable future. The Company believes that carryforward limitations will be applied to the historical net operating losses due to the recent change of control transition. The Company's cumulative net operating loss carry forward of approximately $524,000 will begin to expire in the year 2038.

F- 24

The Company has recorded no liability for income taxes associated with unrecognized tax benefits at the date of adoption and has not recorded any liability associated with unrecognized tax benefits during 2018 and 2017. Accordingly, the Company has not recorded any interest or penalty in regard to any unrecognized benefit.

The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of the benefits from accumulated net operating losses carryforward due to the uncertainty of the realization of such tax benefits.

On December 22, 2017, the Tax Act was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21%, effective for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017. We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. As a result of the reduction in the U.S. corporate income tax rate from 35% to 21% under the Tax Act, we revalued our ending net deferred tax assets at December 31, 2018 and 2017, which were fully offset by a valuation allowance.

NOTE 8 – TRANSACTION WITH RELATED PARTIES

During the year ended December 31, 2018, $200 of cash was contributed to the Company by the Chief Financial Officer to open the Company’s bank account.

During the year ended December 31, 2017, $2,754 of services were paid for and contributed to the Company by the current officers.

The Company makes borrowings from its related parties from time to time for working capital purposes. As of December 31, 2016, the Company owed $1,130 to Ms. Siew Heok ONG, the former Chief Financial Officer at the time. The amount was due on demand without any interest, but was forgiven on October 25, 2017 and was recorded as a contribution to capital.

During the year ended December 31, 2017 $92,851 of expenses were paid directly by Mr. Kok Chee LEE, the Chief Executive Officer of the Company at the time. On October 25, 2017 Mr. Kok Chee Lee forgave amounts owed to him which were recorded as a contribution to capital. As of December 31, 2018 and 2017, the Company owed $0 to Mr. Kok Chee LEE.

F- 25

NOTE 9 – SUBSEQUENT EVENTS

On January 10, 2019, the Company entered into a convertible promissory note, with a principal amount of $126,000. The Company received net cash proceeds of $102,000 after an original issue discount of $21,000 and fees of $3,000. The convertible note bears interest at 8% and matures on January 10, 2020, with interest accruing at a rate of 22% if the Company is in default. Beginning six months after the issuance of the note, the holder may convert the note at any time through the maturity date into shares of common stock, to the extent and provided that no holder of these notes was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion. The conversion price is determined based on 85% of the lowest trading price during the 15 trading days prior to the conversion date.

On February 7, 2019, the Company entered into a convertible promissory note, with a principal amount of $83,000. The Company received net cash proceeds of $80,000 after payment fees of $3,000. The convertible note bears interest at 8% and matures on February 7, 2020, with interest accruing at a rate of 22% if the Company is in default. Beginning six months after the issuance of the note, the holder may convert the note at any time through the maturity date into shares of common stock, to the extent and provided that no holder of these notes was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion. The conversion price is determined based on 65% of the lowest trading price during the 15 trading days prior to the conversion date.

In February 2019, the Company entered into an agreement for advisory services, and issued 40,000 shares of common stock related to this agreement that vest equally over 12 months.

In February 2019, the Company entered into an agreement for marketing services, and issued 10,000 shares of common stock as compensation under the agreement.

In March 2019, the Company entered into an agreement for consulting services, and issued 125,000 shares of common stock under the agreement.

The Company issued a total of 330,000 shares of common stock for quarterly issuances related to advisory agreements entered into during the year ended December 31, 2018.

F- 26

Vitalibis, Inc.

$5,000,000

Common Stock

5,321,400

Shares of Common Stock

Offered by the Selling Stockholders

3,500,000

Common Stock Purchase Warrants

And

3,500,000

Shares of Common Stock Underlying the Purchase warrants

PROSPECTUS

The date of this prospectus is ________, 2019.

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution

The following is a statement of the estimated expenses (other than underwriting discounts and commissions) to be borne by Vitalibis, Inc. in connection with the issuance and distribution of the securities registered under this registration statement. Except for the SEC registration fee and the FINRA filing fee, all amounts are estimates.


SEC registration fee	$	$2,603.71
Legal fees and expenses (other than Blue Sky)		-
Blue Sky fees and expenses (including counsel fees)		5,000.00
Listing fee		-
Accounting fees and expenses		8,000.00
Printing fees		-
Trustee fees and expenses		-
Miscellaneous		5,000.00
Total	$	20,603.71

_______________________________

The amount of securities and number of offerings are indeterminable and the expenses cannot be estimated at this time. An estimate of the aggregate expenses in connection with the sale and distribution of securities being offered will be included in any applicable prospectus supplement.

Item 14. Indemnification of Directors and Officers

The Company has a provision in its Articles of Incorporation, at Article XI thereof, providing for indemnification of its officers and directors, as follows:

Our Articles of Incorporation at Article X provide for indemnification as follows: "No director or officer of the Corporation shall be personally liable to the Corporation or any of its stockholders for damages for breach of fiduciary duty as a director or officer; provided, however, that the foregoing provision shall not eliminate or limit the liability of a director or officer: (i) for acts or omissions which involve intentional misconduct, fraud or knowing violation of law; or (ii) the payment of dividends in violation of Section 78.300 of the Nevada Revised Statutes. Any repeal or modification of an Article by the stockholders of the Corporation shall be prospective only and shall not adversely affect any limitation of the personal liability of a director or officer of the Corporation for acts or omissions prior to such repeal or modification."

Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable pursuant to Section 14 of the Securities Act.. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any such action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

II- 1

Any agreement that may be entered into in connection with an offering of the securities will contain provisions which indemnify the officers and directors of VCBD in certain circumstances. At this time there are no such agreements, nor are any contemplated.

The Company maintains directors’ and officers’ liability insurance which covers certain liabilities, including liabilities to the Company and its stockholders.

Item 15. Recent Sales of Unregistered Securities.

Each of the below transactions were exempt from the registration requirements of the Securities Act in reliance upon Rule 701 promulgated under the Securities Act, Section 4(a)(2) of the Securities Act or Regulation D promulgated under the Securities Act.

Since the Company’s inception on March 14, 2014 through December 31, 2018, the Company issued and/or sold the following unregistered securities:

The Company sold 912,400 shares of restricted common stock to 39 Accredited Investors during the year ended December 31, 2018, for cash proceeds of $912,400. The 39 purchasers constitute the Selling Stockholders in this prospectus.

Except as noted, none of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering, and the Registrant believes each transaction was exempt from the registration requirements of the Securities Act as stated above. All recipients of the foregoing transactions either received adequate information about the Registrant or had access, through their relationships with the Registrant, to such information. Furthermore, the Registrant affixed appropriate legends to the share certificates and instruments issued in each foregoing transaction setting forth that the securities had not been registered and the applicable restrictions on transfer.

Item 16. Exhibits and Financial Statement Schedules.

A list of exhibits filed with this registration statement on Form S-1 is set forth in the Exhibit Index below and is incorporated into this Item 16 by reference.

Exhibits required by Item 601 of Regulation S-K

The following exhibits are filed with this registration statement:

II- 2

EXHIBIT INDEX


Exhibit No.		Description
3.1		Articles of Organization (Incorporated by reference to the Company’s Form S-1 filed on March 5, 2015)
3.1.1		Amendment to the Articles of Incorporation (Incorporated by reference to the Company’s Form 8-K filed February 14, 2018)
3.2		By-Laws (Incorporated by reference to the Company’s Form S-1 filed on March 5, 2015)
10.12		Agreement with Bruce Lee Beverage, LLC, dated December 31, 2018
10.13		Agreement with Johnnie B. Baker, Jr., dated March 29, 2019
4.4*		Form of Warrant Agreement with Bruce Lee Beverage, LLC
5.1*		Opinion of Counsel
23.1**		Consent of MaloneBailey, LLP, Independent Registered Public Accounting Firm
23.2**		Consent of Michael J. Morrison, Chtd. (included in Exhibit 5.1)
24.1**		Power of Attorney (included on applicable signature pages to this registration statement)

_______________________

To be filed as an amendment or as an exhibit to a document filed under the Exchange Act and incorporated by reference into this registration statement.

Filed herewith.

Item 17. Undertakings

(a) The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

provided, however , that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

II- 3

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4) That, for the purpose of determining liability under the Securities Act to any purchaser:

(i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

(5) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

II- 4

(c) The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act (the “Act”) in accordance with the rules and regulations prescribed by the Commission under Section 305(b)(2) of the Act.

(d) The undersigned registrant hereby undertakes to supplement the prospectus, after the expiration of the subscription period, to set forth the results of the subscription offer, the transactions by the underwriters during the subscription period, the amount of unsubscribed securities to be purchased by the underwriters, and the terms of any subsequent re-offering thereof. If any public offering by the underwriters is to be made on terms differing from those set forth on the cover page of the prospectus, a post-effective amendment will be filed to set forth the terms of such offering.

(e) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

II- 5

SIGNATURES

Pursuant to the requirements of the Securities Act, Vitalibis, Inc. has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Las Vegas, State of Nevada, on the 16th day of May, 2019.


	VITALIBIS, INC.

	By:	/s/ Steven Raack
		Steven Raack
		Chief Executive Officer

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the 16th day of May, 2019.


	By:	/s/ Steven Raack
		Steven Raack
		Principal Executive Officer and Director
		Chairman of the Board of Directors


	By:	/s/ Thomas Raack
		Thomas Raack
		Principal Financial and Accounting Officer
		and Director

II- 6

Exhibit 4.4

THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED.

Warrant No.:

Void After ____________________

VITALIBIS, INC.

WARRANT TO PURCHASE SHARES

This Warrant is issued to Bruce Lee Beverage LLC ("Holder") by VITALIBIS, INC., a Nevada corporation (the "Company"), in connection with consideration received from Holder, pursuant to the terms of an Alliance Agreement between the parties, the receipt and sufficiency of which is hereby expressly acknowledged by the Company.

1. Purchase of Shares. Subject to the terms and conditions hereinafter set forth, the Holder of this Warrant is entitled, upon surrender of this Warrant at the principal office of the Company (or at such other place as the Company shall notify the Holder hereof in writing), to purchase from the Company, pursuant to the terms of the Alliance Agreement, up to 1,500,000 fully paid and nonassessable shares of the Company's Common Stock (each a "Share" and collectively the "Shares") at an exercise price of $ 1.01 per Share (such price, as adjusted from time to time, is herein referred to as the "Exercise Price").

2. Exercise Period. This Warrant shall be exercisable, in whole or in part, during the term commencing on the issuance date of this Warrant and ending at 5 p.m. Nevada time on 2 years from issuance and vesting (the "Exercise Period").

3. Method of Exercise. While this Warrant remains outstanding and exercisable in accordance with Section 2 above, the Holder may exercise from time to time, in whole or in part, the purchase rights evidenced hereby. Such exercise shall be effected by:

(i) the surrender of the Warrant, together with a written notice of exercise to the Secretary of the Company at its principal offices; and

(ii) the payment to the Company of an amount equal to the aggregate Exercise Price for the number of Shares being purchased.

4. Certificates for Shares; Amendments of Warrants. Upon the exercise of the purchase rights evidenced by this Warrant, one or more certificates for the number of Shares so purchased shall be issued as soon as practicable thereafter, and in any event within thirty (30) days of the delivery of the subscription notice. Upon partial exercise, the Company shall promptly issue an amended Warrant representing the remaining number of Shares purchasable thereunder. All other terms and conditions of such amended Warrant shall be identical to those contained herein.

5. Issuance of Shares. The Company covenants that (i) the Shares, when issued pursuant to the exercise of this Warrant, will be duly and validly issued, fully paid and nonassessable and free from all taxes, liens, and charges with respect to the issuance thereof, (ii) during the Exercise Period the Company will reserve from its authorized and unissued Common Stock sufficient Shares in order to perform its obligations under this Warrant.

6. Adjustment of Exercise Price and Number of Shares. The number of and kind of securities purchasable upon exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time as follows:

(a) Subdivisions, Combinations and Other Issuances. If the Company shall at any time before the expiration of this Warrant subdivide the Shares, by split-up or otherwise, or combine its Shares, or issue additional shares of its Shares as a dividend, the number of Shares issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the purchase price payable per share, but the aggregate purchase price payable for the total number of Shares purchasable under this Warrant (as adjusted) shall remain the same. Any adjustment under this Section 6(a) shall become effective at the close of business on the date the subdivision or combination becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the making of such dividend.

(b) Reclassification, Reorganization and Consolidation. In case of any reclassification, capital reorganization, or change in the capital stock (including because of a change of control) of the Company (other than as a result of a subdivision, combination, or stock dividend provided for in Section 6(a) above), then the Company shall make appropriate provision so that the Holder of this Warrant shall have the right at any time before the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares of stock and other securities and property receivable in connection with such reclassification, reorganization, or change by a holder of the same number of Shares as were purchasable by the Holder of this Warrant immediately before such reclassification, reorganization, or change. In any such case appropriate provisions shall be made with respect to the rights and interest of the Holder of this Warrant so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities and property deliverable upon exercise hereof, and appropriate adjustments shall be made to the purchase price per share payable hereunder, provided the aggregate purchase price shall remain the same.

(c) Notice of Adjustment. When any adjustment is required to be made in the number or kind of shares purchasable upon exercise of the Warrant, or in the Exercise Price, the Company shall promptly notify the Holder of such event and of the number of Shares or other securities or property thereafter purchasable upon exercise of this Warrant.

7. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of the Exercise Price then in effect.

8. Representations of the Company. The Company represents that all required corporate actions on the part of the Company, its officers, directors and stockholders necessary for the sale and issuance of this Warrant have been taken.

9. Representations and Warranties by the Holder. The Holder represents and warrants to the Company as follows:

(a) This Warrant and the Shares issuable upon exercise thereof are being acquired for its own account, for investment and not with a view to, or for resale in connection with, any distribution or public offering thereof within the meaning of the Securities Act of 1933, as amended (the "Act"). Upon exercise of this Warrant, the Holder shall, if so requested by the Company, confirm in writing, in a form satisfactory to the Company, that the securities issuable upon exercise of this Warrant are being acquired for investment and not with a view toward distribution or resale.

(b) The Holder understands that the Warrant and the Shares have not been registered under the Act by reason of their issuance in a transaction exempt from the registration and prospectus delivery requirements of the Act pursuant to Section 4(2) thereof, and that they must be held by the Holder indefinitely, and that the Holder must therefore bear the economic risk of such investment indefinitely, unless a subsequent disposition thereof is registered under the Act or is exempted from such registration. The Holder further understands that the Warrant Shares have not been qualified under the California Securities Law of 1968 (the "California Law") by reason of their issuance in a transaction exempt from the qualification requirements of the California Law pursuant to Section 25102(f) thereof, which exemption depends upon, among other things, the bona fide nature of the Holder's investment intent expressed above.

(c) The Holder has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the purchase of this Warrant and the Shares purchasable pursuant to the terms of this Warrant and of protecting its interests in connection therewith.

(d) The Holder is able to bear the economic risk of the purchase of the Shares pursuant to the terms of this Warrant.

(e) The Holder is an "accredited investor" as such term is defined in Rule 501 of Regulation D promulgated under the

Act.

10. Restrictive Legend.

The Shares (unless registered under the Act) shall be stamped or imprinted with a legend in substantially the following

form:

(i) THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"). SUCH SECURITIES MAY NOT BE TRANSFERRED UNLESS A REGISTRATION STATEMENT UNDER THE ACT IS IN EFFECT AS TO SUCH TRANSFER OR SUCH TRANSFER MAY BE MADE PURSUANT TO RULE 144 OR IN THE OPINION OF COUNSEL FOR THE COMPANY, REGISTRATION UNDER THE ACT IS UNNECESSARY IN ORDER FOR SUCH TRANSFER TO COMPLY WITH THE ACT.

(ii) "THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ISSUED UNDER THE LIMITED OFFERING EXEMPTION PROVIDED BY SEC. 25102(F) OF THE CALIFORNIA CORPORATIONS CODE."

11. Warrants Transferable. Subject to compliance with the terms and conditions of this Section 11, this Warrant and all rights hereunder are transferable, without charge to the Holder hereof (except for transfer taxes), upon surrender of this Warrant properly endorsed or accompanied by written instructions of transfer. With respect to any offer, sale or other disposition of this Warrant or any Shares acquired pursuant to the exercise of this Warrant before registration of such Warrant or Shares, the Holder hereof agrees to give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of such Holder's counsel, or other evidence, if requested by the Company, to the effect that such offer, sale or other disposition may be effected without registration or qualification (under the Act as then in effect or any federal or state securities law then in effect) of this Warrant or the Shares and indicating whether or not under the Act certificates for this Warrant or the Shares to be sold or otherwise disposed of require any restrictive legend as to applicable restrictions on transferability in order to ensure compliance with such law. Upon receiving such written notice and reasonably satisfactory opinion or other evidence, if so requested, the Company, as promptly as practicable, shall notify such Holder that such Holder may sell or otherwise dispose of this Warrant or such Shares, all in accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant to this Section 11 that the opinion of counsel for the Holder or other evidence is not reasonably satisfactory to the Company, the Company shall so notify the Holder promptly with details thereof after such determination has been made. Each certificate representing this Warrant or the Shares transferred in accordance with this Section 11 shall bear a legend as to the applicable restrictions on transferability in order to ensure compliance with such laws, unless in the aforesaid opinion of counsel for the Holder, such legend is not required. In order to ensure compliance with such laws, the Company may issue stop transfer instructions to its transfer agent in connection with such restrictions.

12. Rights of Stockholders. No Holder of this Warrant shall be entitled, as a Holder, to vote or receive dividends or be deemed the holder of the Shares or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the Holder of this Warrant, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of stock, reclassification of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until the Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein.

13. Notices. All notices and other communications required or permitted hereunder shall be in writing, shall be effective when given, and shall in any event be deemed to be given upon receipt or, if earlier, (a) five (5) days after deposit with the U.S. Postal Service or other applicable postal service, if delivered by first class mail, postage prepaid, (b) upon delivery, if delivered by hand, (c) one business day after the business day of deposit with Federal Express or similar overnight courier, freight prepaid or (d) one business day after the business day of facsimile transmission, if delivered by facsimile transmission with copy by first class mail, postage prepaid, and shall be addressed (i) if to the Holder, at 4221 Don Jose Dr, Los Angeles, CA 90008_ and (ii) if to the Company, at the address of its principal corporate offices 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169 (attention: President), with a copy to Michael J. Morrison, Chtd., 1495 Ridgeview Drive, Ste. 220, Reno, NV 89519, Attn: Michael J. Morrison, Esq. (which copy shall not be deemed to constitute

notice to the Company) or at such other address as a party may designate by ten days advance written notice to the other party pursuant to the provisions above.

14. Governing Law. This Warrant and all actions arising out of or in connection with this Agreement shall be governed by and construed in accordance with the laws of Nevada, without regard to the conflicts of law provisions of Nevada or of any other state.

15. Rights and Obligations Survive Exercise of Warrant. Unless otherwise provided herein, the rights and obligations of the Company, of the Holder of this Warrant and of the holder of the Shares issued upon exercise of this Warrant, shall survive the exercise of this Warrant.

	VITALIBIS, INC.


	By: /s/ Steven P. Raack

	Steven P. Raack

	Its: CEO

EXHIBIT A

NOTICE OF EXERCISE

VITALIBIS, INC.

3960 Howard Hughes Parkway, Suite 500

Las Vegas, NV 89169

Attention: President

1. The undersigned hereby elects to purchase_________________ shares of Common Stock of VITALIBIS, INC. (the "Shares") pursuant to the terms of the attached Warrant.

2. The undersigned elects to exercise the attached Warrant by means of a cash payment, and tenders herewith payment in full for the purchase price of the shares being purchased, together with all applicable transfer taxes, if any.

3. Please issue a certificate or certificates representing said Shares in the name of the undersigned or in such other name as is specified below:


	(Name)


	(Address)


	(Address)

4. The undersigned hereby represents and warrants that the aforesaid Shares are being acquired for the account of the undersigned for investment and not with a view to, or for resale, in connection with the distribution thereof, and that the undersigned has no present intention of distributing or reselling such shares and all representations and warranties of the undersigned set forth in Section 9 of the attached Warrant (including Section 9(e) thereof) are true and correct as of the date hereof.


		(Signature)


		(Name)



(Date)		(Title)

EXHIBIT B

FORM OF TRANSFER

(To be signed only upon transfer of Warrant)

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto_______________________________________ the right represented by the attached Warrant to purchase_____ shares of Common Stock of VITALIBIS, INC. to which the attached Warrant relates, and appoints_________ Attorney to transfer such right on the books of VITALIBIS, INC., with full power of substitution in the premises.

Dated:________________


	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)

	Address: _____________________

	______________________

	______________________

	_______________________

Signed in the presence of:

_______________________

Dated: ____________________

Exhibit 5.1

Michael J. Morrison, Esq.

1495 Ridgeview Drive #220

Reno, NV 89519

May 16, 2019

Vitalibis, Inc.

3960 Howard Hughes Parkway, Suite 500

Las Vegas, NV 89169

Ladies and Gentlemen:

You have requested my opinion, as counsel, with respect to certain matters in connection with the filing by Vitalibis, Inc., a Nevada corporation (the “Registrant”) of a Registration Statement on Form S-1 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933 , as amended (the “1933 Act”) including a related prospectus filed with the Registration Statement (the “prospectus”) covering the resale by selling stockholders (the “Selling Stockholders”) of 21,482,771 shares of the Company’s Common Stock and Warrants (the “Shares”) to be sold by the Selling Stockholders.

I have assumed the genuineness of all signatures, the conformity to authentic original documents of the copies of all such documents submitted to me as certified, conformed and photocopied, including the quoted, extracted, excerpted, and reprocessed text of such documents. I have not been engaged to examine, nor have I examined, the Registration Statement for the purpose of determining the accuracy and completeness of the information contained therein or the compliance and conformity thereof with the rules and regulations of the SEC or the requirements of Form S-1 and I express no opinion with respect thereto.

My opinion is limited to matters of the Nevada Business Corporations Code and I do not express an opinion on the federal law of the United States of America or the law of any jurisdiction therein other than the State of Nevada, as specified herein.

On the basis of the foregoing and in reliance thereon, I am of the opinion that the Shares subject to resale by the Selling Stockholders pursuant to the Registration Statement and the related Prospectus are validly issued, fully paid, and non-assessable Shares.

I consent to the use of my opinion as an exhibit to the registration statement and to the reference thereto under the heading “Interests of Named Experts and Counsel” in the prospectus contained in the registration statement.

In giving the foregoing consents, I do not thereby admit that my firm comes within the category of persons or entities whose consent is required under Section 7 of the 1933 Act or the rules and regulations of the SEC promulgated thereunder.

Very truly yours,

By: /s/ Michael J. Morrison, Esq.

Michael J. Morrison, Esq.

Exhibit 10.12

BUSINESS ALLIANCE AGREEMENT

This BUSINESS ALLIANCE AGREEMENT ("Agreement") is made, deemed entered into in Las Vegas, Nevada, and deemed binding and effective for all purposes this 31st day of December, 2018 ("Effective Date"), by and between Vitalibis, Inc., a Nevada corporation, whose principal place of business is located at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169 ("VITALIBIS" or the "Company"), and Bruce Lee Beverage, LLC, a California limited liability company , whose principal place of business is located at 4221 Don Jose Drive, Los Angeles, CA 90008 ("BLB"). Both VITALIBIS and BLB may be referred to variously as a "Party" and/or, together, as "Parties."

RECITALS:

WHEREAS, VITALIBIS currently markets and sells proprietary ingredients and products, including but not limited to hemp oil products, skincare products, nutritional products and private label products.

WHEREAS, BLB currently designs, formulates, develops, markets and sells a proprietary blend of adaptogens and super herbs in liquid and powder forms.

WHEREAS, VITALIBIS wishes to enter into a business alliance with BLB to develop, market and sell a full-spectrum oil produced by Vitalibis which incorporates certain Bruce Lee related intellectual property licensed by BLB (the "Co-Branded Product") and which will be sold on the VITALIBIS website.

NOW, THEREFORE, in consideration of the foregoing and the mutual promises hereinafter set forth, the Parties agree as follows:

The Parties hereby specifically incorporate by reference herein the Recitals set forth above.

1. Engagement

This Agreement is entered into for the purpose of establishing a business alliance relationship between the Parties, based on good faith efforts to promote and expand each Party's respective business by VITALIBIS selling Co-Branded Product(s) on the VITALIBIS website (the "Project").

Co-Branded Products

(a) BLB and VITALIBIS will jointly define and agree upon, in writing, which Co-Branded Product(s) will be sold via the VITALIBIS website and which content will be used to highlight the Co-Branded Products sold on the website, on social media and in any marketing initiatives. The Parties understand and agree that the Parties shall work together to prepare a mutually approved propriety formulation to be used in the Co-Branded Product.

(b) The Parties understand and agree that, in furtherance of this Agreement and prior to the development of the Co-Branded Product, it will be necessary for BLB to grant VITALIBIS a non-exclusive license to use certain intellectual property owned by BLB in connection with the development, marketing and sales of the Co-Branded Product. The Parties shall enter into a written license agreement on terms and conditions mutually agreed to by the Parties, including tetras of compensation for such license.

Publicity

Upon launch of VITALIBIS' efforts to sell and market the Co-Branded Product on the VITALIBIS website, VITALIBIS may publish a Press Release. Such Press Release will be completed in collaboration between VITALIBIS and BLB, with written / email approval by each respective Party prior to release. Neither Party will unreasonably withhold a written / email approval. VITALIBIS and BLB may collaborate on additional communications prior to the launch of the Co-Branded Product (including without limitation in connection with public offerings and / or other financing activities), each of which will receive prior written / email approval from both Parties before release. The Parties expressly acknowledge that VITALIBIS is a publicly traded corporation and subject to various state and federal securities laws, rules and regulations, and any publicity will have to be consistent with such laws, rules and regulations.

2. Compensation

As consideration for the cobranding of products included in this Project, VITALIBIS agrees to compensate BLB as specified in Exhibit A.

3. Expenses

All website-related and Co-Branded Product expenses required per this Agreement shall be paid by VITALIBIS.

4. Term; Termination

(a) This Agreement is effective, binding and enforceable as of the Effective Date and will continue for a period of five (5) years (the "Initial Term"). The Initial Term shall automatically renew for subsequent five terms (each a "Renewal Term"), unless otherwise terminated in writing by VITALIBIS or BLB. The Initial Term and any Renewal Term may be terminated earlier than the expiration of such Initial Term or Renewal Term, as applicable, in accordance with Section 4(b) below.

(b) This Agreement may be terminated by either Party at any time for any reason, or for no reason, upon 120 calendar days prior written notice to the other Party. Upon such termination, each Party will pay all undisputed outstanding expenses incurred by the other Party in good faith. If termination is requested by BLB, VITALIBIS will have the opportunity for a mutually agreed period of time to sell off the remaining previously bottled Co-Branded Product inventory. Any post termination sales of the Co-Branded Product by VITALIBIS (regardless of which Party exercises its termination right) shall be subject to and in accordance with the terms and obligations set forth herein (including, without limitation, the possibility of such post termination sales triggering the Milestones set forth in Exhibit A). In addition, as additional consideration hereunder, both Parties shall, respectively, from and after the date of termination, remain bound by the terms and conditions of Sections 5 through 12, and 18 hereof, inclusive, and Sections 5 through 12, and 18, inclusive, shall not terminate, but rather, shall perpetually remain in full force and effect. Each Party expressly and unconditionally acknowledges and agrees that the terms and conditions, as well as the restrictions, set forth in Sections 5 through 12, and 18, inclusive, are fair, just and reasonable, and this acknowledgment and agreement was discussed and negotiated by and between the Parties.

5. Independent Businesses

(a) Both Parties are solely and exclusively limited to that of independent businesses, and nothing in this Agreement is intended to, or should be construed to, create an agency, joint venture, employee relationship, partnership or any other type of relationship. Except as specifically provided herein, neither Party will not be entitled to any of the benefits that the other Party may make available to its employees, including, but not limited to, group health or life insurance, profit sharing or retirement benefits. Each Party, respectively, is solely responsible for and will file, if applicable, on a timely basis: (a) all tax returns and payments required to be filed with, or made to, any federal, state or local tax authority with respect to the performance of its obligations and duties and receipt of compensation under this Agreement, as well as, (b) any and all required reports and forms; and (c) shall comply with all other regulatory, licensing and compliance requirements of state, federal and/or local regulatory agencies. Each Party is solely responsible for their own and must maintain adequate written records of their own respective expenses incurred in the course of performing obligations and duties under this Agreement. No part of BLB's Compensation hereunder will be subject to payroll tax withholding and payment by VITALIBIS, including, but not limited to, federal income tax, state income tax, federal and state employment taxes, federal social security tax, and federal Medicare tax (collectively, the "Taxes").

(b) Neither Party is authorized to make any representation, contract or commitment on behalf of the other Party unless specifically requested or authorized in writing to do so by an authorized officer of such Party.

(c) Both Parties are solely responsible for their own respective business operations, and will timely file and pay, all tax returns and personal income tax payments required to be filed with, or made to, any federal, state or local tax authority (each a "Tax Authority") with respect to the performance of its obligations and duties and receipt of fees under this Agreement.

6. Nondisclosure of Confidential Information, Intellectual Property and

Company Property

(a) Agreement Not to Disclose - BLB. BLB agrees not to, directly or indirectly, use any Confidential Information (as defined below) disclosed to BLB by VITALIBIS for BLB's own use or for any purpose other than to carry out discussions concerning, and the undertaking of, the obligations and duties of BLB hereunder. BLB shall not, directly or indirectly, disclose or peiiiiit disclosure of any Confidential Information of VITALIBIS to third parties. BLB expressly and unconditionally agrees to take all reasonable measures to protect the secrecy of and avoid disclosure or use of Confidential Information of VITALIBIS in order to prevent it from falling into the public domain or the possession of persons other than those persons specifically authorized under this Agreement to have any such information. BLB further agrees to notify VITALIBIS in writing of any actual or suspected misuse, misappropriation or unauthorized disclosure of VITALIBIS' Confidential Information.

(b) Agreement Not to Disclose - VITALIBIS. VITALIBIS agrees not to, directly or indirectly, use any Confidential Information (as defined below) disclosed to VITALIBIS by BLB for VITALIBIS' own use or for any purpose other than to carry out discussions concerning, and the undertaking of, the obligations and duties of VITALIBIS hereunder. VITALIBIS shall not, directly or indirectly, disclose or permit disclosure of any Confidential Information of BLB to third parties. VITALIBIS expressly and unconditionally agrees to take all reasonable measures to protect the secrecy of and avoid disclosure or use of Confidential Information of BLB in order to prevent it from falling into the public domain or the possession of persons other than those persons specifically authorized under this Agreement to have any such information. VITALIBIS further agrees to notify BLB in writing of any actual or suspected misuse, misappropriation or unauthorized disclosure of BLB's Confidential Information.

(c) Definition of Confidential Information. "Confidential Information" means data or information possessed by either Party, or its affiliates, about itself, its business activities, its intellectual property, and/or its relationships and activities with third-parties that is competitively sensitive material and not generally known to the public. Confidential Information shall include, without limitation, any and all proprietary information, trade secrets, or materials belonging to either party or its affiliates, either patentable or non-patentable, including, without limitation, the following: (a) drawings, photographs, charts, patent applications, and prototypes: (b) equipment or apparatuses; (c) data, memorandum or reports; (d) patent status, business plans, research and/or marketing developments, product samples, technical and non-technical information, and know-how; (e) data concerning ingredients, concentrates, special processes, formulas, specifications, chemical ingredients, constituents or molecules; (f) analytical data, engineering information, and manufacturing information communicated to, learned of, developed or otherwise acquired by either Party; (g) existing, previous, and potential suppliers and customers; (h) sensory methodologies and protocols and consumer insight information and (i) in the case of BLB any private and/or personal data and/or information related to Linda Lee Cadwell, Shannon Lee, Bruce Lee, Brandon Lee and their respective family members and businesses that is not generally known by or readily available to competitors and/or to the public including, but not limited to, information relating to intellectual property (e.g., literary materials, development materials, proposals, pitches, formats, drawings, designs, animation, photographs, film footage, interviews, trademarks, copyrights, patents, inventions, ideas, trade secrets, know how, computer software, computer databases and/or files, customer lists, manuals, etc.), contact information, personal data, financial information, contractual arrangements and negotiations, style guides, manuals and forms, customer, contractor, supplier, vendor and licensee/distributor information, employee and consultant information, investor information, past and present business strategies and plans, claims and litigation information, and other sensitive or proprietary materials pertaining to any business, finances, relationships and/or affairs.

Confidential Information may be disclosed in writing or other tangible form, verbally or visually, and includes any Confidential Information inadvertently learned by either Party from the other Party or a third party. In addition, any information disclosed or acquired in connection with the Project that is marked as "Confidential" or "Secret" or words to that effect shall be treated by the acquiring Party as "Confidential Information".

Confidential Information does not include information, technical data or know-how which: (a) is in the respective possession of BLB or VITALIBIS, as applicable, at the time of disclosure, as shown by BLB's or VITALIBIS' files and records immediately prior to the time of disclosure; or (b) becomes part of the public knowledge or literature, not as a direct or indirect result of any improper inaction or action of BLB or VITALIBIS, as applicable.

(d) Exceptions. Notwithstanding the above, neither Party shall not have liability to the other Party or any of its subsidiaries with regard to any Confidential Information of said Party can prove (a) is disclosed with the prior written approval of such Party, or (b) is disclosed pursuant to the order or requirement of a court, administrative agency, or other governmental body; provided, however, that a Party shall provide prompt notice of such court order or requirement to the other Party to enable that Party or its appropriate subsidiary to seek a protective order or otherwise prevent or restrict such disclosure.

7. No Duplication; Return of Materials

Each. Party agrees, except as otherwise expressly authorized by the other Party, in writing, not to make any copies or duplicates of any Confidential Information. Any materials or documents that have been furnished by either Party in connection with the Project shall be promptly returned by the other Party, accompanied by all copies of such documentation, within five (5) calendar days after (a) the Project has been concluded or (b) the written request of the other Party or (c) this Agreement has been terminated by either Party.

8. No Rights Granted

Nothing in this Agreement shall be construed as granting any rights in or to, or liens or encumbrances upon, any patent, copyright, trademark or other intellectual property right of one Party to the other, nor shall this Agreement grant one Party any rights in or to the other Party's Confidential Information, except the limited right to use the Confidential Information in connection with the Project.

9. Representations and Warranties

(a) VITALIBIS' Representations and Warranties. VITALIBIS expressly and unconditionally represents and warrants that, in addition to its other obligations specified herein, VITALIBIS makes the below representations and warranties as of the Effective Date:

(i). Authority. VITALIBIS has the full, absolute and unrestricted right, power and authority to execute and deliver this Agreement and to perform VITALIBIS' obligations and duties pursuant to this Agreement.

(ii). Organization. VITALIBIS is duly organized corporation validly existing, and in good standing under the laws of the state of Nevada.

(iii) No Conflicts. VITALIBIS represents, warrants and covenants to BLB that its execution of this Agreement does not conflict with any other agreements to which VITALIBIS is a party.

(b) BLB's Representations and Warranties. BLB expressly and unconditionally represents and warrants that, in addition to its other obligations specified herein, VITALIBIS makes the below representations and warranties as of the Effective Date:

(i). Authority. BLB has the full, absolute and unrestricted right, power and authority to execute and deliver this Agreement and to perform BLB's obligations and duties pursuant to this Agreement.

(ii). Organization. BLB is duly organized limited liability company validly existing, and in good standing under the laws of the state of California.

(iii) No Conflicts. BLB represents, warrants and covenants to VITALIBIS that its execution of this Agreement does not conflict with any other agreements to which BLB is a party.

NEITHER PARTY MAKES ANY OTHER WARRANTY TO THE OTHER PARTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY OR SUCH FITNESS OF THE PRODUCTS FOR ANY PARTICULAR PURPOSES.

10. Noninterference with Business

During the term of this Agreement, and for a period of one (1) year immediately following its termination, each Party expressly and unconditionally agrees not to interfere directly or indirectly, with the business of the other Party, in any manner. By way of example, and not in limitation, each Party expressly and unconditionally agrees not to directly or indirectly, attempt to or actually solicit or induce any employee, consultant, customer, independent contractor or other entity of the other Party to terminate or breach any contractual (either written or verbal) or other relationship with the other Party.

11. Limited Liability

In no event shall either Party be liable to the other or any third party in contract, tort or otherwise for incidental or consequential damages of any kind, including, without limitation, punitive or economic damages or lost profits, regardless of whether either Party shall be advised, shall have other reason to know or, in fact, shall know of the possibility of any such damages.

12. Notices

Any notices, requests, demands or other communications provided for by this Agreement shall be solely and exclusively in writing and shall be sufficiently given when and if sent by personal delivery or overnight courier to the Party entitled thereto at the address stated below or at such other address as the parties may have given by similar notice:

Vitalibis, Inc.

3960 Howard Hughes Parkway Suite 500

Las Vegas, NV 89169

Attn: Steve Raack

Phone: 702-944-9620

Email: sraack@vitalibis.com

Bruce Lee Beverage, LLC

4221 Don Jose Drive

Los Angeles, CA 90008

Attn: Eugene Tsai

(310) 592-7478

Email: gene@bruceleebeverage.corn

Notice hereunder shall be deemed given and effective hereunder on the date of personal delivery or delivery by overnight courier to a Party, as documented in writing.

13. Entire Agreement

This Agreement contains the entire agreement between the Parties hereto with respect to matters herein and supersedes all prior agreements and understandings, oral or written, between the Parties hereto relating to any such matters.

14. Headings

The headings contained in this Agreement are not to be used for interpretation of this Agreement, but rather, have been placed herein solely for the convenience of the Parties.

15. Severability

In the event that any provision or portion of this Agreement shall be determined to be invalid or unenforceable for any reason, the remaining provisions and portions of this Agreement shall be unaffected thereby and shall remain in full force and effect, to the fullest extent permitted by law.

16. Applicable Law and Venue

(a) Governing Law. This Agreement shall be governed solely and exclusively by the laws of the State of Nevada (excepting any conflict of laws or provisions which would serve to defeat application of Nevada substantive law). Each of the Parties to this Agreement hereby irrevocably and unconditionally: (a) consents to submit to the exclusive jurisdiction of the courts of Clark County, Nevada, for enforcement of any dispute resolution decision ("Decision") arising in connection with this Agreement, and each such Party agrees not to commence any proceeding of any nature, in any court, anywhere, except a proceeding in the courts of Clark County, Nevada, to enforce such Decision, and (b) waives any objection to the laying of venue of any such proceeding in the courts of Clark County, Nevada.

17. Amendment or Modification; Waiver

(a) No provision of this Agreement may be amended unless such amendment is in a writing signed by both Parties.

(b) The failure by VITALIBIS or BLB to enforce at any time or for any period of time any one or more of the terms or conditions of this Agreement shall not constitute a waiver of such terms or conditions or of VITALIBIS' or BLB's right thereafter to enforce each and every term and condition of this Agreement.

18. Restrictions.

The Parties expressly and unconditionally agree that the restrictions contained in this entire Agreement are fair and reasonable and necessary for the protection of the legitimate business interests of each Party, and each Party intends that such restrictions be enforceable, and enforced, to their fullest extent.

19. Counterparts.

This Agreement may be executed in multiple counterparts, each of which shall be

deemed an original, but all of which, together, shall constitute one and the same instrument. This Agreement may be executed on signature pages exchanged by facsimile or other electronic means, in which event each Party shall promptly deliver to the other Party an original executed copy.

[SIGNATURE PAGE TO FOLLOW]

	BRUCE LEE BEVERAGE, LLC


	By: /s/ Eugene Tsai
	EUGENE TSAI

	Its: MANAGING MEMBER


	VITALIBIS, INC.


	By: /s/ Steve Raack
	STEVE RAACK

	Its: PRESIDENT AND C.E.O.

Exhibit A

COMPENSATION

CO-BRANDED PRODUCTS

As total consideration for this Agreement, VITALIBIS shall issue to BLB a total of 1,500,000 shares of VITALIBIS restricted Common Stock, par value $.001 per share, and shall issue 1,500,000 warrants to purchase a total of 1,500,000 shares of VITALIBIS restricted Common Stock (that is, 1 warrant entitles the holder to purchase 1 share of Common Stock). The warrants will expire at 5:00 P.M. (Nevada Time), two (2) years from the date of vesting to BLB. The Common Stock and warrants shall vest pursuant to the following schedule:

MILESTONE 1

Upon Execution of this Business Alliance Agreement:

500,000 restricted shares of VCBD Common Stock with piggy-back registration rights in VITALIBIS Registration Statement (currently being prepared) and per an installment schedule agreed to in writing by the Parties

500,000 warrants with piggy-back registration rights in VITALIBIS Registration Statement (currently being prepared) and per an installment schedule agreed to in writing by the Parties. The Registration Statement will also include the 500,000 shares underlying the warrants.

MILESTONE 2

Upon completion of the following:

(a)

Written Approval of BLB Formula, Packaging Design and Marketing Plan Strategy for Co-Branded Product;

(b)

BLB licensing agreement executed by both Parties;

(c)

Begin Co-Branded Product Marketing Campaigns

Execution of BLB Marketing Plan Strategy to share how to purchase the Co-Branded Product via a variety of marketing channels, including but not limited to social media, Podcast, email distribution, etc.

There will be a minimum of one full marketing campaign per quarter for the first 4 quarters after the launch of the Co-Branded Product,

Then:

500,000 warrants with piggy-back registration rights in the VITALIBIS Registration Statement (currently being prepared) and per an installment schedule agreed to in writing by the Parties. The Registration Statement will also include the 500,000 shares underlying the warrants.

MILESTONE 3

After 10,000 units in Co-Branded Product are sold to end users:

250,000 restricted shares of VCBD Common Stock with piggy-back registration rights in the VITALIBIS Registration Statement (currently being prepared) and per an installment schedule agreed to in writing by the Parties.

250,000 warrants with piggy-back registration rights in the VITALIBIS Registration Statement (currently being prepared) and per an installment schedule agreed to in writing by the Parties. The Registration Statement will also include the 250,000 shares underlying the warrants

MILESTONE 4

After 30,000 units in Co-Branded Product are sold to end users:

250,000 restricted shares of VCBD Common Stock with piggy-back registration rights in the VITALIBIS Registration Statement (currently being prepared) per an installment schedule agreed to in writing by the Parties.

250,000 warrants with piggy-back registration rights in the VITALIBIS Registration Statement (currently being prepared) per an installment schedule agreed to in writing by the Parties. The Registration Statement will also include the 250,000 shares underlying the warrants.

NOTE: In connection with the VCBD Common Stock and warrants hereunder, and to insure compliance with applicable state and federal securities laws, rules and regulations, the Parties will enter into a Stock Subscription Agreement and Warrant Agreement.

Business Alliance Agreement
Attachment for Exhibit A
Installment Schedule

Milestone 1:

Stock Shares	12/31/2018	1/16/2019
Vesting Shares	150,000	350,000	Shares

Warrants	12/31/2018	1/16/2019
Grant		1,500,000	Warrants
Exercise Price		$ 1.01

Vesting Warrants		500,000	Warrants

Bruce Lee Beverage, LLC

By: /s/ Eugene Tsai

Eugene Tsai

Its: Managing Member

Vitablis, Inc.

By: /s/ Steve Raack

Steve Raack

Its: President andCEO

STOCK SUBSCRIPTION OFFER
VITALIBIS, INC.

TO: THE BOARD OF DIRECTORS

1. Stock Subscription Offer ("Agreement"): Bruce Lee Beverage, LLC , (the "Undersigned"), whose address is 4221 Don Jose Dr, Los Angeles, CA 90008 , hereby offers to subscribe for Five Hundred Thousand (500,000) Shares of Common Stock, par value $.001 per share (the "Stock"), of VITALIBIS, INC., a Nevada corporation (the "Company"), whose address is: 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169. The Undersigned agrees to accept such Stock as agreed-upon consideration under the terms of an Alliance Agreement entered into by and between the parties ("Consideration"). Ownership of the Stock will vest upon the Company's (a) acceptance of this Offer and Agreement and (b) receipt of the Consideration provided in Milestone 1 of the Alliance Agreement and (c) Installment schedule(s).

2. Representations and Warranties of the Undersigned: The Undersigned hereby represents and warrants that:

A. The Undersigned is financially responsible, able to meet his/her/its obligations hereunder and acknowledges this investment may be long term and is by its nature speculative; further, the Undersigned acknowledges he/she/it is financially capable of bearing the risk of this investment.

B. The Undersigned has had substantial prior investment experience, including investment in non-listed and non-registered securities, as well as experience in business or investments in one or more of the following:

(i) knowledge of and investment experience with securities, such as stocks and bonds;

(ii) ownership of interests in new ventures and/or start-up companies;

(iii) experience in business and financial dealings and parlance, and the Undersigned can protect his/her/its own interests in an investment of this nature and does not have a "Purchaser Representative," as that term is defined in Regulation D of the Securities Act of 1933, as amended, (the "Securities Act") and does not need such a Representative.

C. The Undersigned is capable of bearing the high degree of economic risks and burdens of this investment, including, but not limited to, the possibility of complete loss of all his/her investment capital and the lack of a liquid public market, such that he/she/it may not be able to readily liquidate the investment whenever desired or at the then current asking price of the Stock.

D. The Undersigned has had access to the information set forth in Paragraph 4 hereof and was able to request, in writing, copies of such infoiiiiation from the Company regarding such written information he/she/it desired. The Undersigned understands that the Stock has not been registered under the Securities Act and the applicable state securities laws in reliance on the exemption provided by Section 4(2) of the Securities Act and Regulation D, Rule 506 and/or Regulation S, and California B&P Code Sec. 25102(h), relating to transactions not involving a public offering. In this connection, the Undersigned understands that, if the Stock is sold in the United States or to United States residents, it is the position of the SEC that the statutory basis for such exemption would not be present if his/her/its representation merely meant that his/her/its present intention was to hold the Stock for a short period, for a deferred sale, for a market rise, or for any other fixed period. The Undersigned realizes that, in the view of the SEC, a purchase now with an intent to resell would represent a purchase with an intent inconsistent with his/her/its representation to the Company, and the SEC might regard such a sale, transfer or other disposition as a deferred sale for which the exemption is not available.

E The Undersigned further understands that he/she/it is purchasing the Stock without being furnished any offering literature, prospectus or private offering memorandum, other than that supplied with or specifically identified in this Offer.

F. At no time was the Undersigned presented with or solicited by any leaflet, public promotional meeting, circular, newspaper or magazine article, radio or television advertisement, or any other form of general advertising otherwise than in connection and concurrently with this Offer.

G. The Stock which the Undersigned hereby subscribes is being acquired solely for his/her/its own account, for investment, and is not being purchased with a view to or for the resale or distribution thereof and the Undersigned has no present plans to enter into any contract, undertaking, agreement or arrangement for such resale or distribution.

H. The Undersigned is aware of the following:

(i) The Company's financial and operating history;

(ii) The existence of substantial restrictions on the transferability of Stock;

(iii) Except as otherwise provided in the Alliance Agreement, the Stock will not be, and the Undersigned will have no rights to require, that the Company register the Stock under the Securities Act or any state securities laws; and

(iv) The Undersigned may not be able to avail himself/herself/itself of the provisions of Rule 144 adopted by the Securities and Exchange Commission under the Securities Act or any applicable state securities acts with respect to the release of the Stock, and, accordingly, it may not be possible for the Undersigned to liquidate part or all of his/her/its investment in the Company or to liquidate at the then current asking price of the Stock, if any.

I. It has at no time been represented, guaranteed, or warranted to the Undersigned by an officer or director of the Company, or the agents or employees thereof, or any other person, expressly or impliedly, any of the following:

(i) An exact or approximate length of time that the Undersigned will or will not remain as owner of the Stock;

(ii) A percentage of profit and/or amount or type of consideration, profit, loss, credits or deductions to be realized, if any, as a result of the Undersigned's ownership of the Stock; or

(iii) Past performance on the part of any director or officer of the Company, or the agents or employees thereof, that will in any way indicate the predictable results accruing from ownership of the Stock.

J. Except as otherwise provided in the Alliance Agreement, the Company is under no duty to register the Stock or comply with any exemption from registration under the Securities Act or any state securities law, including supplying to the appropriate agency or to the Undersigned any information required in connection with transfers under appropriate rules and regulations.

K. The Undersigned is an "Accredited Investor", as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act. The Undersigned is (check applicable box):

[ x ] An Accredited Investor.

[_] NOT an Accredited Investor.

If the Undersigned is an Accredited Investor, the Undersigned's status is (check applicable box):

(a) [_] a bank as defined in Section 3(a)(2) of the Securities Act, or a savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities Act, acting in either an individual or fiduciary capacity.

(b) [_] an insurance company as defined in Section 2(13) of the Act.

(c) [_] an investment company registered under the Investment Issuer Act of 1940 or a business development company as defined in Section 2(a)(48) of that Act.

(d) [_] a Small Business Investment Issuer licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958.

(e) [_] a plan established and maintained by a state, its political subdivisions or any agency or instrumentality of a state or its political subdivisions for the benefit of its employees, if such plan has total assets in excess of $5,000,000.

(f) [_] an employee benefit plan within the meaning of Title 1 of the Employee Retirement Income Security Act of 1974, and the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, savings and loan association, insurance company or registered investment advisor, or an employee benefit plan having total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons who are Accredited Investors.

(g) [_] a private business development company as defined in Section 202(a(22) of the investment Advisors Act of 1940.

(h) [_] an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, a corporation, Massachusetts or similar business trust, or a partnership not formed for the specific purpose of acquiring the Promissory Note, with total assets in excess of $5,000,000.

(i) [_] any trust with total assets in excess of $5,000,000 not formed for the specific purpose of acquiring the Promissory Note, whose purchase is directed by a sophisticated person who has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment.

(j) [_] a broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, as amended.

(k) [_] an individual (See Section 2.4 below)

(l) [ x ] none of the above

Individual Undersigned . If the Undersigned is an individual who is an Accredited Investor, then the Undersigned has the following status (check an applicable box):

[_] is a director, executive officer or general partner of the Company/issuer of the Stock being offered or sold or a director, executive officer or general partner of a general partner of that issuer.

[_] has an individual net worth, or joint net worth with that person's spouse, at the time of his purchase exceeding $1,000,000, exclusive of the primary residence.

[_] had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person's spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year.

[_] none of the above.

		________
		(Initials)

L. The Undersigned acknowledges and agrees that the Company is relying on the Undersigned's representations contained in this Agreement in determining whether to accept this subscription. The Undersigned agrees that the Company reserves the unrestricted right and sole discretion to accept, reject or limit any subscription, and to close the offer of securities at any time, (i) for any reason, (i) for no reason, or (i) based on applicable federal and/or state laws, rules or regulations, including, but not limited to federal and/or state securities laws, rules or regulations.

M. The foregoing representations and warranties shall be true and accurate as of the date hereof and as of the date of any acceptance of this Offer by the Company and shall survive the date of such acceptance by the Company. The Undersigned represents and warrants that all representations made by the Undersigned hereunder are true and correct in all material respects as of the date of execution hereof, and the Undersigned further agrees that the Undersigned shall inform the Company immediately of any changes in any of the representations provided by the Undersigned hereunder.

3. Indemnification: The Undersigned acknowledges that he/she/it understands the meaning and legal consequence of the representations and warranties contained in Paragraph 2 hereof and the Undersigned hereby expressly and unconditionally agrees to indemnify and hold harmless the Company, together with its officers, directors, controlling persons, shareholders, agents, representatives, employees, accountants and attorneys, together with their respective heirs, representatives, successors and assigns, from any and all loss, damage or liability due to or arising out of (i) a breach of any such representation or warranty by the Undersigned, or (ii) a breach of any warranty of the Undersigned contained in this Offer. The Undersigned further agrees to hold the Company and its directors, officers and controlling persons and their respective heirs, representatives, successors and assigns harmless and to indemnify them against all liabilities, costs and expenses incurred by them as a result of any sale, transfer or other disposition of the Securities by the Undersigned in violation of any Securities Laws or any misrepresentation herein.

4. Access to and Furnishing Infounation: The Company has provided the Undersigned with a link to the EDGAR Database containing the Company's background, history, corporate governance, financial information and information related to the proposed business of the Company ("Company Information"). The Undersigned hereby acknowledges that he/she/it has had an opportunity to review and understand the Company Information and has, if he/she/it deemed it necessary, consulted with a legal and/or tax advisor.

Most significantly, neither the Company, nor its officers, directors, employees, representatives or agents have made any oral representation of whatsoever nature to the Undersigned relating to the Company and/or Company Information, and the Undersigned is relying exclusively on the Company Information referenced in this Paragraph 4 in making an investment decision.

5. Transferability: The Undersigned agrees not to transfer or assign this Offer, or any of the Undersigned's interest therein, and further agrees that the assignment and transferability of the Stock acquired pursuant hereto shall be made only in accordance with this Offer. The Company shall issue stop transfer instructions to its transfer agent for its common stock with respect to the Stock and shall place the following legend on the certificates representing the Stock:

"The shares represented by this certificate have been acquired pursuant to a transaction effected in reliance upon Section 4(2) of the Securities Act of 1933, as amended, (the "Act") and have not been the subject of a Registration Statement under the Act or any state securities act. These securities may not be sold or otherwise transferred in the absence of such registration or applicable exemption therefrom under the Act or any applicable state securities act."

"The shares represented by this certificate have been issued under the limited offering exemption provided by Sec. 25102(f) of the California Corporations Code."

6. Revocation: The Undersigned expressly and unconditionally agrees that he/she/it shall not cancel, terminate or revoke this Agreement or any provisions hereof or any agreement of the Undersigned made hereunder.

7. Notices: All notices or other communications given or made hereunder shall be in writing and shall be delivered or mailed by registered or certified mail, return receipt requested, postage prepaid, to the Undersigned or to the Company at their respective addresses set forth herein.

8. Governing Law: This Agreement, and any and all transactions contemplated hereunder, shall be construed in accordance with and governed solely and exclusively by the laws of the State of Nevada, as amended, and sole and exclusive jurisdiction and venue regarding any matters relating to this Agreement shall be in Reno, Washoe County, Nevada.

9. Entire Agreement: This Offer constitutes the entire agreement among the parties hereto with respect to the subject matter hereof and may be amended only by a writing executed by all parties.

IN WITNESS WHEREOF, the parties hereto have executed this Offer as of the date and year set forth below.

DATED this _31 day of December, 2018.

	Bruce Lee Beverage, LLC Name of Subscriber (Please Print) /s/ Eugene Tsai Signature EugeneTsai (Managing Member) Name of Signer (Please Print) 4221 Don Jose Dr, Address Los Angeles, CA 90008 City State/Province Postal/Zip Code Gene@BruceLeeBeverage.com E-mail


THIS OFFER IS ACCEPTED BY:	VITALIBIS, INC.

	By: /s/ Steven P. Raack

	Its: Steven P. Raack
	Name of Signer (Please Print)

Warrant No.:

Void After ____________________

VITALIBIS, INC.

WARRANT TO PURCHASE SHARES

(i) the surrender of the Warrant, together with a written notice of exercise to the Secretary of the Company at its principal offices; and

(ii) the payment to the Company of an amount equal to the aggregate Exercise Price for the number of Shares being purchased.

9. Representations and Warranties by the Holder. The Holder represents and warrants to the Company as follows:

(d) The Holder is able to bear the economic risk of the purchase of the Shares pursuant to the terms of this Warrant.

(e) The Holder is an "accredited investor" as such term is defined in Rule 501 of Regulation D promulgated under the

Act.

10. Restrictive Legend.

The Shares (unless registered under the Act) shall be stamped or imprinted with a legend in substantially the following

form:

(ii) "THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ISSUED UNDER THE LIMITED OFFERING EXEMPTION PROVIDED BY SEC. 25102(F) OF THE CALIFORNIA CORPORATIONS CODE."

notice to the Company) or at such other address as a party may designate by ten days advance written notice to the other party pursuant to the provisions above.

	VITALIBIS, INC.


	By: /s/ Steven P. Raack

	Steven P. Raack

	Its: CEO

EXHIBIT A

NOTICE OF EXERCISE

VITALIBIS, INC.

3960 Howard Hughes Parkway, Suite 500

Las Vegas, NV 89169

Attention: President

1. The undersigned hereby elects to purchase_________________ shares of Common Stock of VITALIBIS, INC. (the "Shares") pursuant to the terms of the attached Warrant.

3. Please issue a certificate or certificates representing said Shares in the name of the undersigned or in such other name as is specified below:


	(Name)


	(Address)


	(Address)


		(Signature)


		(Name)



(Date)		(Title)

EXHIBIT B

FORM OF TRANSFER

(To be signed only upon transfer of Warrant)

Dated:________________


	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)

	Address: _____________________

	______________________

	______________________

	_______________________

Signed in the presence of:

_______________________

Dated: ____________________

Exhibit 10.13

INDEPENDENT CONTRACTOR / FOUNDING AMBASSADOR AGREEMENT

This Vitalibis Independent Contractor / Founding Ambassador Agreement, entered into and made effective and binding on the parties hereto as of March 29, 2019 ("Effective Date"), sets forth the terms and conditions of the understanding and agreement for enrolling JOHNNIE B. BAKER, JR. as a Founding Ambassador (referred to as "Ambassador", "Dusty", "r, "me, or "my"), and VITALIBIS, INC., a Nevada corporation, and its subsidiary(ies) and affiliated entities (together referred to collectively as "Vitalibis" or "Company"). The parties expressly and unconditionally understand, acknowledge and agree that, for all purposes, this Agreement is deemed by the parties hereto to have been entered into and executed in the State of California, and is subject to and governed by, in any and all respects whatsoever, by the laws of the State of California.

1. Agreement. The term "Agreement" shall collectively refer to this Vitalibis Independent Contractor / Founding Ambassador Agreement, and any addendum executed by the parties hereto, including Addendum 1 attached to this Agreement (together, the "Documents"). These Documents, in their current form, are specifically incorporated and integrated herein by reference, and constitute the entire agreement between Ambassador and Vitalibis. ¹

2. Independent Contractor. I expressly and unconditionally understand, acknowledge and agree that, as an Ambassador, I am solely and exclusively an independent contractor, under the employment laws of the state in which the Ambassador resides and/or operates, and I am not an employee, agent, partner, legal representative or franchisee of Vitalibis. I understand and agree that I am not, and will not be treated as, an employee of Vitalibis for any purpose whatsoever, including, but not limited to federal or state tax purpose(s) and/or purpose(s) of any direct or indirect employee benefit(s) of any nature or kind whatsoever. Other than my status as an independent contractor, I do not have any other relationship of whatsoever nature, directly or indirectly, with Vitalibis. I expressly and unconditionally understand and agree that Vitalibis is not responsible for my withholding, or any other kind or form of taxes, and shall not withhold or deduct any taxes from any compensation, unless such withholding becomes required by an applicable law, rule or regulation.

3. Publicity Rights. Unless expressly agreed in a writing executed by Ambassador and Vitalibis, Ambassador does not consent to the use of his voice, likeness, image, name, signature, photograph or any other thing as determined by California law in which Ambassador has a Right of Publicity. However, Vitalibis may use Ambassador's name, photograph, and likeness as necessary to fulfill the terms of this Agreement, and in connection with Ambassador's role as stated herein. Any use by Vitalibis of Ambassador's name, voice, signature, photograph, likeness, or any other thing in which Ambassador has a Right of Publicity as determined by California law shall cease immediately upon termination of this Agreement. Vitalibis expressly agrees to strictly comply with the terms of this paragraph.

____________________

¹ The parties hereby acknowledge that use of the Vitalibis website, whether as customer or ambassador requires reference and compliance with the Vitalibis Privacy Policy and Terms of Use.

4. Cooperation and Good Faith. The parties hereto hereby agree to cooperate with the other and to act in good faith and to fairly deal with each other in all respects. This covenant of cooperation and good faith extends to the conduct and efforts described in Addendum 1, "Description of Services and Compensation." Nothing herein, however, shall serve to require or otherwise mandate Ambassador to achieve any of the goals set forth in Milestones set forth in Addendum 1 by a date certain, or at all; although any efforts toward this end will be subject to the Parties' obligations to cooperate fairly and to act in good faith in all respects.

5. Compliance with the Law. Ambassador shall comply with any and all applicable laws, rules and regulations, and shall not engage in any act or omission that constitutes a violation of any applicable laws, rules or regulations.

6. Term. The term of this Agreement commences on the date Vitalibis signs and accepts my application and continues until terminated ("Term").

7. Termination. Ambassador expressly and unconditionally understands and acknowledges that he/she may terminate this Agreement for any reason, or for no reason, at any time by giving Vitalibis written or email ( CustomerCare@vitalibis.com ) notice. Ambassador also expressly and unconditionally understands and acknowledges that, in the event Ambassador breaches any of the terms or conditions of this Agreement, or any New Agreement, and does not cure such breach(es) within thirty (30) calendar days after Vitalibis gives written notice to Ambassador and to Ambassador's counsel, Huguenin Kahn, LLP of such breach(es), Vitalibis may terminate this Agreement, or any New Agreement. The date of termination will be the date Vitalibis gives Ambassador and Ambassador's counsel, Huguenin Kahn, LLP written notice of termination ("Termination Date"). If the Agreement is terminated for any reason, or for no reason, I expressly and unconditionally understand, acknowledge and agree that I will immediately and permanently lose (a) all rights, titles, interests, benefits and privileges available to an Ambassador, including, but not limited to, rights to commissions, bonuses and other compensation, other than those rights, titles, interests, benefits and privileges which have become earned and acquired and/or due and payable prior to or on the Date of Termination, and (b) any and all rights and claims relating, directly or indirectly, to my sales organization and rights under this Agreement. The Parties also agree that any portion of the Milestone Incentive Benefits, as defined in Addendum 1, accumulated upon termination of the Agreement, regardless of cause, shall be offered to Ambassador in direct proportion to the Milestone condition(s) satisfied (e.g., if in Milestone 4, Ambassador and his ambassador team secured gross sales in the amount of $800,000 as of the date of termination, Ambassador will be entitled to receive 80% of the Incentive Benefits from Milestone 4).

8. No Guarantee of Income. I fully understand and agree, subject to any earned commissions hereunder or other Incentive Benefits earned or accumulated pursuant to the terms and conditions of Addendum 1, that Vitalibis has not guaranteed, and does not guarantee, that I will earn or be otherwise entitled to receive any amount of income or be profitable in my efforts hereunder, and Vitalibis has never made any representations, directly or indirectly, to the contrary. I fully understand and agree that I shall not represent to others, either directly or indirectly, that an Ambassador is guaranteed an income or will derive profits from his/her efforts hereunder. I fully understand and specifically acknowledge and agree that my income hereunder, if any, is dependent solely and exclusively on my gross sales (commissions) and my efforts in securing the Milestone achievements as set forth in Addendum 1, both of which include my direct sales of products offered by Vitalibis to the end-user / customer ("Products").6

9. General Conduct. Ambassador shall diligently and in good faith safeguard and promote the good will and reputation of (a) Vitalibis, its directors, officers, agents, advisors, attorneys and employees, and (b) the Products. I also expressly and unconditionally agree to refrain from and avoid all deceptive, misleading, unethical or immoral conduct or practices that would otherwise serve to detrimentally impact my ability to serve as an Ambassador and to represent the Vitalibis product line and values for which it stands. The foregoing obligations, conduct and practices shall, together, constitute the policy of Vitalibis as regards minimum standards of acceptable conduct by Ambassador ("Policy"). Ambassador shall not engage in any conduct that may, damage or cast a negative light on either (a) the goodwill, reputation, brand, management personnel or business of Vitalibis, or (b) the Product(s). While it is impossible to specify all misconduct that would be contrary to our Policy, Ambassador expressly and unconditionally acknowledges and agrees that the following list of conduct and standards specifically apply to and govern Ambassador's activities hereunder:

AT NO TIME SHALL AMBASSADOR MAKE ANY REPRESENTATIONS OR CLAIMS OF ANY NATURE WHATSOEVER, AT ANY TIME, IN ANY FORM OF COMMUNICATION RELATING TO THE VITALIBIS PRODUCTS, OR THE INCOME THAT MAY BE DERIVED FROM HIS/HER POSITION AS AN AMBASSADOR, SAVE AND EXCEPT FOR THE FOLLOWING:

THE REPRESENTATIONS AND CLAIMS PUBLISHED BY VITALIBIS ON ITS COMPANY WEBSITE;

THE REPRESENTATIONS AND CLAIMS PUBLISHED BY VITALIBIS ON THE PRODUCT PACKAGING; and

THE REPRESENTATIONS AND CLAIMS ON THE CONTAINERS IN WHICH THE PRODUCTS ARE SOLD.

Ambassador must conspicuously identify himself/herself as a Vitalibis Independent Contractor / Ambassador in all advertising, telephone directory listings, promotional material, social media postings, and other forms of communication in which Ambasador promotes Vitalibis, the Products, Vitalibis services ("Services ") and/or the Vitalibis business. Ambassador is responsible for the content of all material that he/she produces and/or utilizes in the performance of Services hereunder, specifically including, but not limited to any and all of his/her postings on any social media site, as well as all posting on any social media site that he/she own, operate, manage or control. Nothing herein shall be construed to preclude or otherwise restrict Dusty from marketing Vitalibis products on his various business websites, provided that any and all sales under and through Dusty's Vitalibis website are processed and appropriately credited in and through Dusty's Vitalibis website sales link.

Deceptive conduct is always strictly prohibited — no exceptions. Ambassador must ensure that his/her statements are truthful, fair, accurate, and are not misleading in any fashion. However, and because Ambassador will rely on certain representations and claims made by Vitalibis, Vitalibis expressly warrants that all representations and claims published by Vitalibis on its company website, all representations and claims published by Vitalibis on any and all product packaging, and all representations and claims on any and all containers in which Vitalibis products are sold are truthful, fair, accurate, and are not misleading in any fashion.

Ambassador may not make any social media postings, or link to or from any postings or other material that is sexually explicit, obscene, pornographic, offensive, profane, hateful, threatening, harmful, defamatory, libelous, harassing, or discriminatory (whether based on race, ethnicity, creed, religion, gender, sexual orientation, physical disability, or otherwise), is graphically violent, is solicitous of any unlawful behavior, that engages in personal attacks on any individual, group, or entity, or is in violation of any intellectual property rights of Vitalibis or any third party.

If this Agreement is terminated for any reason, or for no reason, Ambassador must immediately, commencing on the Date of Termination, and forever thereafter, discontinue using the Vitalibis name, trademark and all other Vitalibis intellectual property, and all derivatives of such intellectual property, in postings on any social media, websites, or other promotional material, for the purpose of promoting sales or other related business activity.

Ambassador may not represent or imply that any state or federal government official, agency, or body has approved or endorses Vitalibis, its business, programs, or Products unless any such state or federal governmental official, agency, or body has approved or endorsed Vitalibis, its business, programs, or Products, or Ambassador is given authorization by Vitalibis to make such representations.

Ambassador expressly and unconditionally represents, warrants and agrees that he/she shall not, directly or indirectly, offer the Products for sale or fulfill sales/orders of such Products through any website or other electronic site, without the express prior written consent of Vitalibis, which can be granted solely through execution by Vitalibis of a separate and distinct Vitalibis Authorized Online Seller Agreement. Execution by Vitalibis of the Authorized Online Seller Agreement constitutes the sole and exclusive authorized means of providing its consent to advertise, market or sell the Products online. No Vitalibis employee or agent may authorize online sales through oral statements, other written agreements, or by any other means. Selling on third-party marketplace sites, including Amazon, eBay, Walmart Marketplace, Sears Marketplace, and Jet, or through drop-ship accounts (e.g. Rakuten, Newegg, Overstock), classified sites (e.g. Etsy, Craigslist, Facebook Marketplace), or social media is absolutely and strictly prohibited — no exceptions. Any Ambassador that violates the above prohibitions is subject to immediate and permanent termination of (i) this Agreement, and (ii) all purchasing and selling privileges.

10. Indemnification and Defense. Vitalibis and its directors, officers, shareholders, members, partners, employees, attorneys, agents and assigns (collectively referred to as "Indemnifying Parties") shall defend, indemnify and hold harmless indemnitee Ambassador ² from, against and in respect of any and all losses involving a Third Party products liability claim or action incurred or suffered by the Ambassador, directly or indirectly, or relating to Vitalibis products. Indemnifying Parties shall defend indemnify and hold harmless Ambassador from, against and in respect to any and all claims, suits, actions, proceedings, or other related litigation arising from, or in connection with, any and all representations and claims published by Vitalibis on its company website, all representations and claims published by Vitalibis on any and all product packaging, and all representations and claims on any and all containers in which Vitalibis products, including where Ambassador has repeated or disseminated such material. Ambassador and Vitalibis expressly agree that Ambassador shall retain the right, at Ambassador's sole discretion, to retain the attorney of Ambassador's choice in any such suit without waiving any of the defense and indemnity rights stated herein.

In connection with any agreement Vitalibis enters into with any other Ambassador, associate or otherwise, Vitalibis expressly represents and warrants that it shall require and include in any such agreement an indemnity and defense provision of equal dignity with the terms and conditions of this Section 10. The express intent of including this required provision is to insure that Dusty is protected from liability arising, directly or indirectly, from the action and/or inaction hereunder by any and all other Vitalibis Ambassadors.

In turn, Ambassador agrees to indemnify Vitalibis in connection with any conduct of Ambassador (conduct for which Vitalibis does not owe a duty to defend and indemnify Ambassador as determined by the above) for which there has been an adjudication of liability against Vitalibis.

11. Confidential Information. "Confidential Information" includes, but is not limited to, the identities, contact information, and/or sales information relating to Vitalibis Ambassadors and/or Customers: (a) that is contained in or derived from any Ambassador's respective "Behind the Counter" facilities or programs; (b) that is derived from any reports issued by Vitalibis to Ambassadors to assist them in operating and managing his/her respective Vitalibis-related business; and/or (c) to whom/which an Ambassador would not otherwise have access or would not otherwise have acquired, but for his/her independent contractor relationship with Vitalibis. Confidential Information also includes proprietary business trade secrets which belongs exclusively to Vitalibis, but are provided to Ambassador in strict confidence, and subject to prior execution of a Non-competition, Non-disclosure and Non-Circumvention Agreement, consistent with and governed in all respects by Nevada law. Such Agreement shall be expressly and unconditionally deemed by the parties hereto, for all purposes, to have been executed in the State of Nevada. Confidential Information shall not be directly or indirectly disclosed by Ambassador to any third party, nor used for any purpose whatsoever other than Ambassador's use in building and managing his/her Vitalibis-related business described herein.

_______________

² This indemnity provision shall apply and extend to protect indemnitees, Johnnie B. Baker Jr., individually, and as Trustee of the Johnnie B. Baker and Melissa G. Baker, Revocable Trust ("the Trust"), and the Trust, as signatories to this Agreement.

12. Commissions. Vitalibis utilizes a unique compensation plan with three distinct commission areas: 1) Retail Commission, 2) Level 1 Commissions and 3) Level 2 Commissions. Accordingly, in addition to the benefits afforded to Ambassador under Addendum 1, Ambassador shall also be entitled to the commissions from sales as follows:

Retail Commissions are earned by Ambassadors who sell Products to Retail Customers. Retail Customers are those customers who purchase product directly through the Vitalibis website and who are not otherwise defmed as Level 1 or Level 2 Ambassadors. Vitalibis uses a tiered Retail Commission structure as follows: Total Retail Sales between $1-499 in a calendar month will earn a 20% commission; Total Retail Sales between $500-999 in a calendar month will earn a 25% commission; Total Retail Sales of $1,000 or more in a calendar month will earn 30% commission.

Level 1 Commissions earned by Ambassadors whose Level 1 Ambassadors generate sales volume. Level 1 Ambassadors are ambassadors defined in Addendum 1 as members of Dusty's Ambassador Team. Vitalibis uses a tiered Level 1 Commission structure as follows: Total Level 1 Volume between $1-2,499 in a calendar month will earn 5% commission; Total Level 1 Volume between $2,500-$4,999 in a calendar month will earn 7% commission; Total Level 1 Volume of $5,000 or more in a calendar month will earn 10% commission.

Level 2 Commissions are earned by Ambassadors whose Level 2 Ambassadors generate sales volume. Level 2 Ambassadors are ambassadors not otherwise defined as Retail Customers or Level 1 Ambassadors and are those who sign up as ambassadors through the company website. All Level 2 Commissions are paid out at 5%.

Payments for all commissions earned shall be paid to Ambassador on a monthly basis, unless Vitalibis modifies its payment system to enable weekly and/or daily payment of commissions to its entire Ambassador community.

13. Adjustment to Commissions. When a Products is returned to Vitalibis for a refund, is repurchased by the Company, or a chargeback occurs, the commissions earned as a result of the corresponding sale will be deducted from the Ambassador and his/her commissions. A refund of one order may impact the commissions for one or more Ambassadors, but shall not, in any way, affect any of the benefits earned or accumulated under the Milestone provisions set forth in Addendum 1.

14. Order Cancellation and Return Policy. Federal and state law requires that Ambassador notifies his/her retail Customers that the Customers have 3 business days within which to cancel his/her purchase and receive a full refund upon return of the Products in substantially as good condition as when they were delivered. Ambassador shall verbally inform his/her Customers of this right, shall provide them with 2 copies of a retail receipt at the time of the sale, and shall point out this cancellation right stated on the receipt. Vitalibis agrees that it is responsible for keeping Ambassador informed of any changes to the Order Cancellation and Return Policy, and/or any changes in the applicable Federal and state law.

NOTE: The exceptions to the 3-business day rule are as follows: 5 business days for Alaska residents; and 15 business days for residents of North Dakota over the age of 65. For purposes of counting the applicable days, Saturday is a business day, Sundays and legal holidays are not business days.

In addition to the Federal and State laws requiring cancellation notices, Vitalibis offers the following return policy:

Return Procedures: Within 45 calendar days of a Product purchase, you must complete a Return Authorization Form (available on the Company website at www.vitalibis.com ). Return the merchandise along with the fully completed Return Authorization Form to Vitalibis' home office (the return shipping address is on the Return Authorization Form).

15. Governing Law, Jurisdiction and Venue. Jurisdiction and venue of any matter arising hereunder shall reside exclusively in the Superior Court of Placer County, California. The Federal Arbitration Act shall govern all matters relating to any and all disputes of whatsoever nature arising hereunder, and the sole and exclusive method of resolution of such disputes shall be binding, non-appealable arbitration hereunder. This notwithstanding, the laws of the State of Nevada shall solely and exclusively govern all matters relating to or arising, directly or indirectly, from this Agreement.

16. Dispute Resolution.

If a dispute arises relating to any relationship, contractual or otherwise, between or among Vitalibis, its officers, employees, members, agents, attorneys, partners, Ambassadors or vendors ("Party" or "Parties"), or arising out of any Products sold by Vitalibis, the parties agree to attempt in good faith to resolve any such dispute in an amicable and mutually satisfactory manner.

In the event such efforts are unsuccessful for any reason, either Party may serve a written notice of arbitration ("Notice of Arbitration") on the other Party. Notice of Arbitration shall be personally delivered or sent by prepaid registered mail, courier, facsimile transmission, email or by such other means of telecommunication that provides a record of sending the Notice of Arbitration and shall be effective on receipt thereof by the Party to whom it is addressed. The Notice of Arbitration shall be dated, and, without prejudice to any right under the applicable rules permitting subsequent modifications, shall specify the claims or issues which are to be arbitrated. The Parties shall schedule an arbitration to occur in Placer County, California within 45 calendar days of receipt of the Notice of Arbitration.

THE PARTIES SPECIFICALLY AGREE THAT, IN ORDER TO PROMOTE TO THE FULLEST EXTENT REASONABLY POSSIBLE A MUTUALLY AMICABLE

RESOLUTION OF THE DISPUTE IN A TIMELY, EFFICIENT AND COST-EFFECTIVE MANNER, THEY KNOWINGLY AND UNCONDITIONALLY WAIVE HIS/HER RESPECTIVE RIGHTS TO A TRIAL BY JURY AND SHALL SETTLE HIS/HER DISPUTE SOLELY BY SUBMITTING THE CONTROVERSY TO BINDING ARBITRATION IN ACCORDANCE WITH THE COMMERCIAL RULES OF THE AMERICAN ARBITRATION ASSOCIATION ("A.A.A.") THEN IN EFFECT, EXCEPT THAT ALL PARTIES SHALL BE ENTITLED TO ALL DISCOVERY RIGHTS ALLOWED UNDER THE FEDERAL RULES OF CIVIL PROCEDURE. EACH PARTY EXPRESSLY ACKNOWLEDGES THAT HE/SHE HAD THE OPPORTUNITY TO DISCUSS THIS CLAUSE WITH AN ATTORNEY AND/OR A PROFESSIONAL OF THEIR CHOICE.

The Parties shall attempt to select a mutually agreeable arbitrator from A.A.A.'s Panel of Arbitrators. Within fifteen (15) business days of the mailing and/or service date of the Notice of Arbitration, Vitalibis or its related parties shall propose, in writing, a list five arbitrators from the A.A.A. Panel of Arbitrators. Within ten (10) business days of receipt of the proposed list, Ambassador shall select one arbitrator or propose Ambassador's own list of five arbitrators. Vitalibis or its related parties shall have five (5) business days to select one arbitrator from Ambassador's proposed list. If the Parties cannot agree on an arbitrator or an arbitrator is not selected by agreement, an arbitrator shall be selected in accordance with the Commercial Rules of A.A.A.

The Arbitration shall be governed by the Federal Arbitration Act, 9 U.S.C. §1 et. seq.; and the judgment upon the award rendered by the arbitrator may be entered by any California court having jurisdiction to enter the judgement. Either Party may elect to participate in the arbitration telephonically. Any substantive or procedural rights other than the enforceability of this Dispute Resolution Policy shall be governed by solely and exclusively by Nevada law, without regards to Nevada's conflict of laws principles. NOTE: Louisiana resident Ambassadors may choose to arbitrate contract disputes in Louisiana and Louisiana law will govern the contract and dispute.

The Parties agree that any arbitration proceeding will be conducted on an individual, not a class-wide, basis, and that any proceeding between the Parties may not be consolidated with another proceeding between one of the Parties and any other entity or person. THE PARTIES KNOWINGLY AND SPECIFICALLY WAIVE ANY RIGHT TO CLASS-WIDE TREATMENT OF ANY CLAIM COVERED BY THIS AGREEMENT AND DISPUTE RESOLUTION POLICY.

The Parties further expressly agree that (i) the arbitrator shall only reach his/her decision by applying strict rules of law to the facts, (ii) the arbitration shall be conducted in the English language, in Placer County, California (iii) the Party in whose favor the arbitration award is rendered shall be entitled to recover all costs and expenses of the arbitration including, but not limited to, legal fees, expert or other professional fees, and the cost and expense of administration of the arbitration proceedings, and any costs and legal fees incurred in executing on or enforcing the arbitration award, and (iv) the arbitration award shall be issued in Placer County, California.

The Parties, A.A.A., and the arbitrator shall maintain the confidentiality of the entire arbitration process and may not disclose to any other person not directly involved in the arbitration process: (i) the substance of, or basis for, the controversy, dispute, or claim; (ii) the content of any testimony or other evidence presented at an arbitration hearing or obtained through discovery in the arbitration; or (iii) the terms or amount of any arbitration award. A.A.A. and the arbitrator shall have the authority to make appropriate rulings to safeguard confidentiality unless the law provides to the contrary.

Except as provided in the following sentences, no party shall be entitled to commence or maintain any action in a court of law upon any matter in dispute until such matter shall have been submitted and determined as provided herein and then only for the enforcement of such arbitration award. Provided that, notwithstanding this Dispute Resolution Policy, either party may apply to a court of competent jurisdiction in Placer County, California to seek injunctive relief before or after the pendency of any arbitration proceeding. The institution of any action for injunctive relief shall not constitute a waiver of the right or obligation of any party to submit any claim seeking relief other than injunctive relief to arbitration. Judgment upon the award may be entered by the Superior Court of Placer County, California, or application may be made to such court for the judicial acceptance of the award and order of enforcement, as the case may be, if the Arbitrator's award or decision is not complied with within 7 calendar days of the date the Arbitrator's decision is issued.

Arbitration in accordance with the terms of this Dispute Resolution Policy shall be the sole and exclusive procedure for resolution of disputes between the Parties, including any disputes that might arise after termination of this Agreement.

Notwithstanding the foregoing, any revision, modification, amendment to, or termination of the Dispute Resolution protocol contained in this Agreement shall not apply to a dispute of which Vitalibis has actual notice prior to the effective date of such revision, modification, amendment or termination. The effective date of any such revision, modification, amendment or termination shall be 30 calendar days after the revision, modification, amendment or termination is posted on the Company website at www. vitalibis.com .

17. Handling Personal Information. As an Ambassador, you may receive Personal Information from and about prospective Ambassadors, Customers and other individuals. Keeping such Personal Information secure not only helps to ensure your compliance with the law, but it also helps you to maintain current Customers' and potential Customers' trust, which is a highly important factor in your activities hereunder. Personal Information is information that identifies, or permits you to contact, an individual. It includes a Customer's, potential Customer's or other individual's name, address, email address, phone number, credit card information, and other information associated with these details, such as purchases of Product(s).

18. Survival Rights. The parties' respective rights and obligations shall survive the death and/or incapacitation of Dusty Baker, and will continue for a period of 18 months, and thereafter for any period of time that Company and Trustee of the Trust shall mutually agree. Any and all such rights and obligations shall bind and inure to the benefit of his Trust, and Ambassador's respective successors, heirs, executors, administrators and permitted assigns.

19. Miscellaneous. In addition to those rights and obligations afforded above in Paragraph 18, the parties likewise agree that their respective rights and obligations under this contract will bind and inure to the benefit of their respective successors, heirs, executors and administrators and permitted assigns.

Independent Ambassador — Founding Ambassador

Name Johnnie B. Baker Jr., as Trustee of the Johnnie B. Baker Jr. and Melissa G. Baker Revocable Trust

Signature /s/ Jonnes B. Baker Jr.

Date 4/1/19

Vitalibis, Inc.

Name Steve Raack

Signature /s/ Steve Raack

Title CEO

Date March 29, 2019

Addendum 1

DESCRIPTION OF SERVICES AND COMPENSATION

This Addendum 1 is specifically incorporated into the fully executed INDEPENDENT CONTRACTOR / FOUNDING AMBASSADOR AGREEMENT entered into and made effective on March 2019 by and between Johnnie B. Baker Jr.. as Trustee of the Johnnie B. Baker Jr. and Melissa G. Baker Revocable Trust ("Founding Ambassador", "Dusty", "Independent Contractor" or "IC") and VITALIBIS INC. ("Vitalibis"). The parties expressly and unconditionally understand, acknowledge and agree that, for all purposes, this Addendum is deemed by the parties hereto to have been entered into and to be performed by the parties in the State of Nevada. If, upon Termination, as set forth in paragraph 5 "Termination" to the Ambassador Agreement, Ambassador has purchased or otherwise acquired warrants for the purchase of any stock or shares, including Vitalibis equity or VCBD common stock or shares, related to Vitalibis, Vitalibis and Ambassador expressly agree that Ambassador has the right to exercise the rights secured by the warrants, pursuant to the terms and conditions of such warrants.

A. Terms and Definitions.

1. Milestone Conditions: Milestone Conditions refer to the specific conditions under which any Milestone Benefit Incentive may be earned. Upon termination, regardless of cause, any Milestone Benefit Incentive not fully earned shall be offered to Ambassador in direct proportion to the Milestone Condition accumulated (either by reference to the amount of Associate Ambassadors signed and approved, or the amount of gross sales, calculated on the effective date of termination, including all sales that are pending as of said date, but excluding those that are later cancelled.

2. Gross Sales: Gross Sales are defined as any sales that are secured, reported and processed through www.vitalibis.com/dusty, and any sales processed through this link shall be credited to Ambassador, and all Associate Ambassadors, including all Level 1 and Level 2 Ambassadors on Dusty's team, shall be linked to that Account by Company. Vitalibis shall make any and all reports regarding Gross Sales available periodically for inspection by Ambassador upon request. Gross Sales for any one Milestone below are cumulative of other prior Milestone sales and thus, are not independent and separate goals for each Milestone. In other words, Gross Sales conditions for Milestones 1-4, collectively, are $2 million in total.

3. Dusty's Ambassador Team. Dusty and all of his recruited Associate Ambassadors, including all Level 1 and 2 Ambassadors, are referred to herein collectively as "Dusty's Ambassador Team." Any Ambassador that Dusty recommends/refers, the Company approves and for whom an Ambassador contract is secured, shall count toward the satisfaction of the below Milestone Conditions. All Gross Sales secured by Dusty's Ambassador Team shall count toward Dusty's total Gross Sales for purposes of the Milestone Conditions and the Incentive Benefits below. Vitalibis' approval and consent of Dusty's prospective Ambassador team members shall not be withheld unreasonably. Dusty shall not be restricted in recruiting and/or referring more Ambassadors beyond the 10 Associate Ambassadors needed for satisfaction of the Milestone Conditions referenced below. Dusty shall retain the right, in his discretion, to remove any Ambassador from his team during the term of this Agreement (understanding as well that Company may, in its sole discretion, continue to work with said Ambassador separately).

4. Milestone Benefits and Incentives. Incentives and Benefits are defined in terms of grants of restricted common stock in Vitalibis and the right to acquire Warrants, in amounts as more fully set forth below. All such stock and warrants will be issued in the name of and owned solely and exclusively by the Johnnie B. Baker Jr. and Melissa G. Baker Res ()cable Crust.

5. Performance of Obligations. Notwithstanding the fact that the Johnnie B. Baker Jr. and Melissa G. Baker Revocable Trust shall be the owner of all of the benefits and incentives of this Agreement, the individual responsible for performing all obligations of and as an Ambassador hereunder shall be

Johnnie B. Baker Jr.

B. Milestones.

MILESTONE 1

1. Milestone 1 Conditions:

Execution of Independent Contractor Founding Ambassador Agreement.

Enter into Advisory Board Agreement.

2. Milestone 1 Incentives and Benefits:

Inclusion of Dusty Baker's Vitalibis ("VCBD") equity in the Vitalibis Registration Statement (currently being prepared).

250,000 restricted shares of VCBD Common Stock with piggy-back registration rights in the Vitalibis Registration Statement (currently being prepared) and issued per a written installment schedule.

–

334,000 warrants, with piggy-back registration rights in the Vitalibis Registration Statement (currently being prepared) , which warrants expire three (3) years from date of issuance ("Warrant Exercise Date"). The Warrant Exercise Date may be extended by successive 12-month periods upon Ambassador providing 90 days' written notice of his request for same (with a maximum of one 12-month extension, which does not require Vitaibis consent). Each warrant entitles the holder to purchase one (1) share of Vitalibis restricted common stock, at the exercise/strike price of US$1.50, per share. Any warrant not exercised on or before the Warrant Exercise Date, or any extensions allowed hereunder, shall be null, void and worthless.

MILESTONE 2

1. Milestone 2 Conditions:

–

Begin Founding Ambassador Campaign

–

Dusty secures 5 associate Ambassadors for his team that are approved and signed by Dusty Baker and Vitalibis and/or Dusty's Ambassador Team collectively secures $500,000 in gross sales.

2. Milestone 2 Incentive and Benefits

–

250,000 shares of Vitalibis common stock issued with 6-month restriction.

–

333,000 warrants which shall be subject to all of the same terms and conditions as set forth in Milestone 1.

MILESTONE 3

1. Milestone Conditions:

Continue Founding Ambassador Campaign

–

Dusty secures 5 additional associate Ambassadors for his team, approved and signed by Dusty Baker and Vitalibis; and/or Dusty's Ambassador Team secures a total cumulative $1,000,000 in gross sales

2. Milestone 3 Incentives and Benefits:

250,000 shares issued with 6-month restriction.

–

333,000 warrants which shall be subject to all of the same terms and conditions as set forth in Milestone 1.

MILESTONE 4

1. Milestone Condition:

Focus on Product Sales Volume. Dusty's Ambassador Team generates at least a cumulative $2 million in total gross sales.

2. Milestone 4 Incentives and Benefits

1,000,000 warrants, which shall be subject to all of the same terms and conditions as set forth in Milestone 1.

C. Services

1. IC will personally assist Vitalibis in brand awareness and Product sales by diligently engaging in e-mail campaigns, phone calls, in-person meetings and social media campaigns ("Personal Services").

IC will perform such Personal Services utilizing the highest ethics and professionalism.

IC will not discuss any Product performance claims or income claims at any time, save and except for such claims approved in advance, in writing, by Vitalibis.

IC will not communicate any Confidential Information to anyone at any time.

D. Compensation

1. All purchases of Product(s) by Retail Customers will be allocated, per Section 11 (Commissions) of the Agreement, to the IC's Founding Ambassador account, contained in and described in the standard Vitalibis Compensation Plan.

2. All Ambassadors enrolled in and through the Founding Ambassador's account and that comprise Dusty's Ambassador Team will be designated as a Level 1 Ambassador and included in the Founding Ambassador's account within the standard Vitalibis Compensation Plan.

3. All Ambassadors enrolled in and through the Level 1 Ambassador's account will be designated as a Level 2 Ambassador and included in the Level 1 Ambassador's account within the standard Vitalibis Compensation Plan.

E. Compliance with Securities Laws

Any issuance of Common Stock as compensation hereunder will be accompanied by documentation, as approved by Securities Counsel for VITALIBIS.

The parties shall work together with such Securities Counsel to take any and all actions and execute any and all documents deemed necessary and appropriate, to comply with all applicable state and federal securities laws, rules and regulations, regarding each such issuance. Dusty's execution of such documentation will be required prior to issuance of such securities.

END OF ADDENDUM 1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the inclusion in this Registration Statement on Form S-1 of our report dated March 28, 2019 with respect to the audited financial statements of Vitalibis, Inc for the years ended December 31, 2018 and 2017. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

We also consent to the references to us under the heading “Experts” in such Registration Statement.

/s/ MaloneBailey, LLP

www.malonebailey.com

Houston, Texas

May 16, 2019